

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : A61K 39/00, 39/395, 38/18, C07K 14/475	A1	(11) International Publication Number: WO 00/27426 (43) International Publication Date: 18 May 2000 (18.05.00)
(21) International Application Number: PCT/US99/25744 (22) International Filing Date: 28 October 1999 (28.10.99) (30) Priority Data: 60/107,522 7 November 1998 (07.11.98) US (71) Applicant (for all designated States except US): GENENTECH, INC. [US/US]; 1 DNA Way, South San Francisco, CA 94080-4990 (US). (72) Inventor; and (75) Inventor/Applicant (for US only): GAO, Wei-Qiang [CN/US]; 641 Pilgrim Drive, Foster City, CA 94404 (US). (74) Agent: DREGER, Ginger; Knobbe, Martens, Olson & Bear, LLP, Sixteenth Floor, 620 Newport Center Drive, Newport Beach, CA 92660-8016 (US).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: METHOD FOR ENHANCING PROLIFERATION OF INNER EAR HAIR CELLS USING LIGANDS FOR HER2 AND/OR HER3 RECEPTORS (57) Abstract Ligands which bind to the HER2 and/or HER3 receptors are useful as inner-ear-supporting cell growth factors to enhance proliferation-mediated generation of new hair cells.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

METHOD FOR ENHANCING PROLIFERATION OF INNER EAR HAIR CELLS USING LIGANDS FOR HER2 AND/OR HER3 RECEPTORS

BACKGROUND OF THE INVENTION

Field of the Invention

This application relates to inducing, promoting, or enhancing the growth, proliferation, repair, generation, or regeneration of inner ear tissue, particularly inner ear epithelial hair cells and supporting cells. More particularly, this application relates to potentially stimulating supporting cell proliferation and enhancing proliferation-mediated generation of new hair cells. In addition, this application provides methods, compositions and devices for prophylactic and therapeutic treatment of inner ear disorders and conditions, particularly sensorineural hearing and balance impairments. This invention relates to the use of HER2 ligands, in particular heregulin polypeptides, as inner-ear-supporting cell growth factors.

Description of Background

Hearing and balance impairments are serious handicaps which affect millions of people. Hearing impairments can be attributed to a wide variety of causes, including infections, mechanical injury, loud sounds, aging, and chemical-induced ototoxicity that damages neurons and/or hair cells of the peripheral auditory system. The peripheral auditory system consists of auditory receptors, hair cells in the organ of Corti, and primary auditory neurons, the spiral ganglion neurons in the cochlea. Spiral ganglion neurons ("SGN") are primary afferent auditory neurons that deliver signals from the peripheral auditory receptors, the hair cells in the organ of Corti, to the brain through the cochlear nerve. The eighth nerve connects the primary auditory neurons in the spiral ganglia to the brain stem. The eighth nerve also connects vestibular ganglion neurons ("VGN"), which are primary afferent sensory neurons responsible for balance and which deliver signals from the utricle, saccule and ampullae of the inner ear to the brain, to the brainstem. Destruction of primary afferent neurons in the spiral ganglia and hair cells has been attributed as a major cause of hearing impairments. Damage to the peripheral auditory system is responsible for a majority of hearing deficits (Dublin, 1976; Rybak, 1986; Lim, 1986; Pryor, 1994).

Hearing loss or impairment is a common occurrence for mammals. Impairment anywhere along the auditory pathway from the external auditory canal to the central nervous system may result in hearing loss or balance impairment. Auditory apparatus can be divided into the external and middle ear, inner ear and auditory nerve and central auditory pathways. While having some variations from species to species, the general characterization is common for all mammals. Auditory stimuli are mechanically transmitted through the external auditory canal, tympanic membrane, and ossicular chain to the inner ear. The middle ear and mastoid process are normally filled with air. Disorders of the external and middle ear usually produce a conductive hearing loss by interfering with this mechanical transmission. Common causes of a conductive hearing loss include obstruction of the external auditory canal, as can be caused by aural atresia or cerumen; thickening or perforation of the tympanic membrane, as can be caused by trauma or infection; fixation or resorption of the components of the ossicular chain; and obstruction of the Eustachian tube, resulting in a fluid-filled middle-ear space. Auditory information is transduced from a mechanical signal to a neurally conducted electrical impulse by the action of neuro-epithelial cells (hair cells) and SGN in the inner ear. All central fibers of SGN form synapses in the cochlear nucleus of the pontine brain stem. The auditory projections from the

cochlear nucleus are bilateral, with major nuclei located in the inferior colliculus, medial geniculate body of the thalamus, and auditory cortex of the temporal lobe. The number of neurons involved in hearing increases dramatically from the cochlea to the auditory brain stem and the auditory cortex. All auditory information is transduced by a limited number of hair cells, which are the sensory receptors of the inner ear, of which the so-called inner hair cells, numbering a comparative few, are critically important, since they form synapses with approximately 90 percent of the primary auditory neurons. By comparison, at the level of the cochlear nucleus, the number of neural elements involved is measured in the hundreds of thousands. Thus, damage to a relatively few cells in the auditory periphery can lead to substantial hearing loss or balance impairment. Hence, many causes of sensorineural loss can be ascribed to lesions in the inner ear. This hearing loss and balance impairment can be progressive. In addition, the hearing becomes significantly less acute because of changes in the anatomy of the ear as the animal ages.

During embryogenesis, the vestibular ganglion, spiral ganglion, and the otic vesicle are derived from the same neurogenic ectoderm, the otic placode. The vestibular and auditory systems thus share many characteristics including peripheral neuronal innervations of hair cells and central projections to the brainstem nuclei. Both of these systems are sensitive to ototoxins that include therapeutic drugs, antineoplastic agents, contaminants in foods or medicines, and environmental and industrial pollutants. Ototoxic drugs include the widely used chemotherapeutic agent cisplatin and its analogs (Fleischman et al., 1975; Stadnicki et al., 1975; Nakai et al., 1982; Berggren et al., 1990; Dublin, 1976; Hood and Berlin, 1986), commonly used aminoglycoside antibiotics, e.g. gentamicin, for the treatment of infections caused by Gram-negative bacteria, (Sera et al., 1987; Hinojosa and Lerner, 1987; Bareggi et al., 1990), quinine and its analogs, salicylate and its analogs, and loop-diuretics.

The toxic effects of these drugs on auditory cells and spiral ganglion neurons are often the limiting factor for their therapeutic usefulness. For example, antibacterial aminoglycosides such as gentamicins, streptomycins, kanamycins, tobramycins, and the like are known to have serious toxicity, particularly ototoxicity and nephrotoxicity, which reduce the usefulness of such antimicrobial agents (see Goodman and Gilman's *The Pharmacological Basis of Therapeutics*, 6th ed., A. Goodman Gilman et al., eds; Macmillan Publishing Co., Inc., New York, pp. 1169-71 (1980) or most recent edition). Aminoglycoside antibiotics are generally utilized as broad spectrum antimicrobials effective against, for example, gram-positive, gram-negative and acid-fast bacteria. Susceptible microorganisms include *Escherichia* spp., *Hemophilus* spp., *Listeria* spp., *Pseudomonas* spp., *Nocardia* spp., *Yersinia* spp., *Klebsiella* spp., *Enterobacter* spp., *Salmonella* spp., *Staphylococcus* spp., *Streptococcus* spp., *Mycobacteria* spp., *Shigella* spp., and *Serratia* spp. Nonetheless, the aminoglycosides are used primarily to treat infections caused by gram-negative bacteria and, for instance, in combination with penicillins for the synergistic effects. As implied by the generic name for the family, all the aminoglycoside antibiotics contain aminosugars in glycosidic linkage. Otitis media is a term used to describe infections of the middle ear, which infections are very common, particularly in children. Typically antibiotics are systemically administered for infections of the middle ear, e.g., in a responsive or prophylactic manner. Systemic administration of antibiotics to combat middle ear infection generally results in a prolonged lag time to achieve therapeutic levels in the middle ear, and requires high initial doses in order to achieve such levels. These drawbacks complicate the ability to obtain therapeutic

levels and may preclude the use of some antibiotics altogether. Systemic administration is most often effective when the infection has reached advanced stages, but at this point permanent damage may already have been done to the middle and inner ear structure. Clearly, ototoxicity is a dose-limiting side-effect of antibiotic administration. For example, nearly 75% of patients given 2 grams of streptomycin daily for 60 to 120 days displayed some vestibular impairment, whereas at 1 gram per day, the incidence decreased to 25% (U.S. Patent 5,059,591). Auditory impairment was observed: from 4 to 15% of patients receiving 1 gram per day for greater than 1 week develop measurable hearing loss, which slowly becomes worse and can lead to complete permanent deafness if treatment continues.

Ototoxicity is also a serious dose-limiting side-effect for cisplatin, a platinum coordination complex, that has proven effective on a variety of human cancers including testicular, ovarian, bladder, and head and neck cancer. Cisplatin damages auditory and vestibular systems (Fleischman et al., 1975; Stadnicki et al., 1975; Nakai et al., 1982; Carenza et al., 1986; Sera et al., 1987; Bareggi et al., 1990). Salicylates, such as aspirin, are the most commonly used therapeutic drugs for their anti-inflammatory, analgesic, anti-pyretic and anti-thrombotic effects. Unfortunately, they have ototoxic side effects. They often lead to tinnitus ("ringing in the ears") and temporary hearing loss (Myers and Bernstein, 1965). However, if the drug is used at high doses for a prolonged time, the hearing impairment can become persistent and irreversible, as reported clinically (Jarvis, 1966).

Accordingly, there exists a need for means to prevent, reduce or treat the incidence and/or severity of inner ear disorders and hearing impairments involving inner ear tissue, particularly inner ear hair cells, and optionally, the associated auditory nerves. Of particular interest are those conditions arising as an unwanted side-effect of ototoxic therapeutic drugs including cisplatin and its analogs, aminoglycoside antibiotics, salicylate and its analogs, or loop diuretics. In addition, there exists a need for methods which will allow higher and thus more effective dosing with these ototoxicity-inducing pharmaceutical drugs, while concomitantly preventing or reducing ototoxic effects caused by these drugs. What is needed is a method that provides a safe, effective, and prolonged means for prophylactic or curative treatment of hearing impairments related to inner ear tissue damage, loss, or degeneration, particularly ototoxin-induced, and particularly involving inner ear hair cells. The present invention provides compositions and methods to achieve these goals and others as well.

A need continues to exist for a method of treatment hearing and balance impairments and other conditions associated with damage to hair cells or their supporting cells.

SUMMARY OF THE INVENTION

In general an object of the invention is to provide a method of inducing, promoting, or enhancing the growth, proliferation, repair, or regeneration of inner ear tissue, particularly inner ear hair cells and their supporting cells for the purpose of promoting repair and healing of inner tissue damage or injury.

Accordingly, one object of this invention is to provide a method of treating inner ear disorders and conditions in patients, primarily human patients, in need of such treatment. A further object is to provide a method of inducing inner-ear-supporting cell growth, generation, and development, which leads to generation of new hair cells.

In one aspect of this invention, it has now been discovered that these objects and the broader objective of treating conditions associated with hair cell or inner-ear-supporting cell damage and injury

are achieved by administering to a patient in need of such treatment an effective amount of a heregulin ligand, preferably a polypeptide or fragment thereof. These heregulin polypeptides, include HRG- α , HRG- β 1, HRG- β 2, HRG- β 3 and other heregulin polypeptides which cross-react with antibodies directed against these family members and/or which are substantially homologous as defined below and
5 includes heregulin variants such as N-terminal and C-terminal fragments thereof. A preferred heregulin is the ligand disclosed in Fig. 1A - 1D and further designated HRG- α . Other preferred heregulins are the ligands disclosed in Figure 2A - 2E, and designated HRG- β 1; disclosed in Figure 3A - 3E designated HRG- β 2; and disclosed in Figure 4A - 4C designated HRG- β 3.

In another aspect, the invention provides a method in which heregulin agonist antibodies are
10 administered to achieve the objects of the invention. In this embodiment, HER2/HER3 or fragments thereof (which also may be synthesized by *in vitro* methods) are fused (by recombinant expression or an *in vitro* peptidyl bond) to an immunogenic polypeptide and this fusion polypeptide, in turn, is used to raise antibodies against a HER2/HER3 epitope. Agonist antibodies are recovered from the serum of immunized animals. Alternatively, monoclonal antibodies are prepared from *in vitro* cells or *in vivo*
15 immunized animals in conventional fashion. If desired, the agonist antibodies may be obtained by phage display selection from a phage library of antibodies or antibody fragments. Preferred antibodies identified by routine screening will bind to the receptor, but will not substantially cross-react with any other known ligands such as EGF, and will activate the HER receptors HER2 or HER3, preferably Her2. In addition, antibodies may be selected that are capable of binding specifically to individual family
20 members of heregulin family, e.g. HRG- α , HRG- β 1, HRG- β 2, HRG- β 3, and which are agonists thereof.

In general, the invention is a method of regenerating and/or repairing hair cell or inner-ear-supporting cell injury by stimulating growth and proliferation of inner-ear-supporting cells to enhance generation of new hair cells. The hair cells may be injured by many types of insults, for example, injury due to surgical incision or resection, chemical or smoke inhalation or aspiration, chemical or
25 biochemical ulceration, cell damage due to viral or bacterial infection, etc. The inner-ear-supporting cells which may be affected by the method of the invention include any inner-ear-supporting cell which expresses HER2 or HER3, preferably Her3. The method of the invention stimulates growth and proliferation of the inner-ear-supporting cells leading to generation of new hair cells to repair and re-establish the sensorineural contacts in the inner ear to allow the affected tissues to develop normal
30 physiological functions more quickly.

Accordingly, one embodiment of the invention is a method of inducing inner-ear-supporting cell growth by contacting a inner-ear-supporting cell which expresses HER2 receptor with an effective amount of a HER2 activating ligand.

A further embodiment is a method of treating inner ear hair cell injury, caused by ototoxins or
35 acoustic assault for example, by administering to a patient in need thereof an effective amount of a HER2 activating ligand.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1A - 1D show the deduced amino acid sequence (SEQ ID NO:1) for the cDNA sequence (SEQ ID NO:2) contained in a clone obtained according to U.S. 5,367,060. The initiating methionine
40 (Met) of HRG- α is at position 45.

Figure 2A - 2E show the deduced amino acid sequence (SEQ ID NO:3) and cDNA sequence (SEQ ID NO:4) of a potential coding sequence of a clone obtained according to U.S. 5,367,060 for HRG- β 1. The initiating Met is at M31.

Figure 3A - 3E show the deduced amino acid sequence (SEQ ID NO:5) and cDNA sequence (SEQ ID NO:6) of a nucleotide sequence of a clone obtained according to U.S. 5,367,060 for HRG- β 2.

Figure 4A - 4C show the deduced amino acid sequence (SEQ ID NO:7) and cDNA sequence (SEQ ID NO:8) of a nucleotide sequence of a clone obtained according to U.S. 5,367,060 for HRG- β 3.

Figure 5A - 5D show the deduced amino acid sequence (SEQ ID NO:9) and cDNA sequence (SEQ ID NO:10) of a nucleotide sequence of a clone obtained according to U.S. 5,367,060 for HRG- β 2-like protein.

Figure 6A - 6C show a comparison of the amino acid homologies of several known heregulins α , β 1, β 2, β 2-like and β 3 in descending order and illustrates the amino acid insertions, deletions, and substitutions that characterize these forms of heregulin (SEQ ID NOS: 1, 3, 5, 9, and 7).

Figure 7A - 7C show the deduced amino acid sequence (SEQ ID NO:11) and cDNA sequence (SEQ ID NO:12) of -HRG. The hydrophobic region is underlined. The EGF-like domain is shaded, cysteine residues in the EGF-like domain are circled. N-linked glycosylation sites are marked above the nucleic acid sequence with a ().

Figure 8 shows the cDNA sequence (SEQ ID NO:13) and amino acid sequence (SEQ ID NO:14) of SMDF. An EGF-like domain and the apolar and uncharged domains (*i.e.* "apolar I" consisting of residues from about 48-62 and "apolar II" consisting of residues from about 76-100) are underlined. Cysteines in the EGF-like domain and in the "cysteine knot" in the unique N-terminal domain ("NTD-cys knot") are boxed. The stop codon is denoted by the letter "O".

Figure 9 shows the effect of various polypeptide growth factors on the proliferation of cells in the rat utricular sheet hair cell layer, as indicated by the number of BrdU positive cells per sheet compared to control.

Figure 10 shows the dose-dependent proliferation effect of heregulin on cells in the rat utricular sheet hair cell layer, as indicated by the number of BrdU positive cells per sheet compared to control.

Figures 11A-D show autoradiography of tritiated-thymidine labeled cells in supporting cell and hair cell layer in gentamicin-treated utricles in response to heregulin treatment. Figures A-D are views from similarly treated organotypic rat utricular whole mounts.

Figure 12 shows the cell count of tritiated-thymidine labeled cells in supporting cell and hair cell layer in gentamicin-treated utricles (shown in Figures 11A-D) in response to heregulin treatment compared to control.

Figure 13 shows the RNA concentration of heregulin and the receptors Her2, Her3 and Her4 in RAN isolated from the inner ear sensory epithelium layer.

Figure 14 shows localization of Her2, a heregulin receptor, in the inner ear sensory epithelium, as indicated by immunostaining the P0 cochlea and adult utricle with labeled monoclonal antibody to Her2.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

Heregulin ligands, in particular polypeptides and agonist antibodies thereof, have affinity for and stimulate the HER2, and less preferably HER3, receptors or combinations thereof in

autophosphorylation. Included within the definition of heregulin ligands, in addition to HRG- α , HRG- β 1, HRG- β 2, HRG- β 3 and HRG- β 2-like, are other polypeptides binding to the HER2 receptor, which bear substantial amino acid sequence homology to HRG- α or HRG- β 1. Such additional polypeptides fall within the definition of heregulin as a family of polypeptide ligands that bind to the HER2 receptors.

5 Heregulin polypeptides bind with varying affinities to the HER2 receptors. It is also known that heterodimerization of HER2 with HER3 occurs with subsequent receptor cross-phosphorylation as described above. In the present invention, inner-ear-supporting cell growth and/or proliferation is induced when a heregulin protein interacts and binds with an individual receptor molecule or a receptor dimer such that receptor phosphorylation is induced. Binding and activation of HER2 or Her3 or
10 combinations thereof, therefore, is meant to include activation of any form of the receptor necessary for receptor activation and biologic function including monomeric receptor and dimeric receptor forms. Dimeric receptor forms may be referred to below, for example, as HER2/HER3.

The HER (ErbB) family belongs to the subclass I receptor tyrosine kinase superfamily and consists of three distinct receptors, HER2, HER3, and HER4. A ligand for this ErbB family is the
15 protein heregulin (HRG), a multidomain containing protein with at least 15 distinct isoforms.

Transduction of signals that regulate cell growth and differentiation is regulated in part by phosphorylation of various cellular proteins. Protein tyrosine kinases are enzymes that catalyze this process. Receptor protein tyrosine kinases are believed to direct cellular growth via ligand-stimulated tyrosine phosphorylation of intracellular substrates. Growth factor receptor protein tyrosine kinases of
20 the class I subfamily include the 170 kDa epidermal growth factor receptor (EGFR) encoded by the *erbB1* gene. *erbB1* has been causally implicated in human malignancy. In particular, increased expression of this gene has been observed in more aggressive carcinomas of the breast, bladder, lung and stomach.

The second member of the class I subfamily, p185^{neu}, was originally identified as the product of
25 the transforming gene from neuroblastomas of chemically treated rats. The *neu* gene (also called *erbB2* and HER2) encodes a 185 kDa receptor protein tyrosine kinase. Amplification and/or overexpression of the human HER2 gene correlates with a poor prognosis in breast and ovarian cancers (Slamon *et al.*, *Science* 235:177-182 (1987); and Slamon *et al.*, *Science* 244:707-712 (1989)). Overexpression of HER2 has been correlated with other carcinomas including carcinomas of the stomach, endometrium,
30 salivary gland, lung, kidney, colon and bladder. Accordingly, Slamon *et al.* in US Pat No. 4,968,603 describe and claim various diagnostic assays for determining HER2 gene amplification or expression in tumor cells. Slamon *et al.* discovered that the presence of multiple gene copies of HER2 oncogene in tumor cells indicates that the disease is more likely to spread beyond the primary tumor site, and that the disease may therefore require more aggressive treatment than might otherwise be indicated by
35 other diagnostic factors. Slamon *et al.* conclude that the HER2 gene amplification test, together with the determination of lymph node status, provides greatly improved prognostic utility.

A further related gene, called *erbB3* or HER3, has also been described. See US Pat. No. 5,183,884; Kraus *et al.*, *Proc. Natl. Acad. Sci. USA* 86:9193-9197 (1989); EP Pat Appln No 444,961A1; and Kraus *et al.*, *Proc. Natl. Acad. Sci. USA* 90:2900-2904 (1993). Kraus *et al.* (1989) discovered that
40 markedly elevated levels of *erbB3* mRNA were present in certain human mammary tumor cell lines indicating that *erbB3*, like *erbB1* and *erbB2*, may play a role in human malignancies. Also, Kraus *et al.*

(1993) showed that EGF-dependent activation of the ErbB3 catalytic domain of a chimeric EGFR/ErbB3 receptor resulted in a proliferative response in transfected NIH-3T3 cells. This is now believed to be the result of endogenous ErbB1 or ErbB2 in NIH-3T3. Furthermore, these researchers demonstrated that some human mammary tumor cell lines display a significant elevation of steady-state ErbB3 tyrosine phosphorylation further indicating that this receptor may play a role in human malignancies. The role of *erbB3* in cancer has been explored by others. It has been found to be overexpressed in breast (Lemoine *et al.*, *Br. J. Cancer* 66:1116-1121 (1992)), gastrointestinal (Poller *et al.*, *J. Pathol.* 168:275-280 (1992), Rajkumar *et al.*, *J. Pathol.* 170:271-278 (1993), and Sanidas *et al.*, *Int. J. Cancer* 54:935-940 (1993)), and pancreatic cancers (Lemoine *et al.*, *J. Pathol.* 168:269-273 (1992), and Friess *et al.*, *Clinical Cancer Research* 1:1413-1420 (1995)).

The class I subfamily of growth factor receptor protein tyrosine kinases has been further extended to include the HER4/Erb4 receptor. See EP Pat Appln No 599,274; Plowman *et al.*, *Proc. Natl. Acad. Sci. USA* 90:1746-1750 (1993); and Plowman *et al.*, *Nature* 366:473-475 (1993). Plowman *et al.* found that increased HER4 expression closely correlated with certain carcinomas of epithelial origin, including breast adenocarcinomas. Diagnostic methods for detection of human neoplastic conditions (especially breast cancers) which evaluate HER4 expression are described in EP Pat Appln No. 599,274.

The quest for the activator of the HER2 oncogene has lead to the discovery of a family of heregulin polypeptides. These proteins appear to result from alternate splicing of a single gene which was mapped to the short arm of human chromosome 8 by Orr-Urtreger *et al.*, *Proc. Natl. Acad. Sci. USA* 90:1867-1871(1993). See also Lee and Wood, *Genomics*, 16:790-791 (1993).

Holmes *et al.* isolated and cloned a family of polypeptide activators for the HER2 receptor which they called heregulin- α (HRG- α), heregulin- β 1 (HRG- β 1), heregulin- β 2 (HRG- β 2), heregulin- β 2-like (HRG- β 2-like), and heregulin- β 3 (HRG- β 3). See Holmes *et al.*, *Science* 256:1205-1210 (1992); WO 92/20798; and U.S. Patent 5,367,060. The 45 kDa polypeptide, HRG- α , was purified from the conditioned medium of the MDA-MB-231 human breast cancer cell line. These researchers demonstrated the ability of the purified heregulin polypeptides to activate tyrosine phosphorylation of the HER2 receptor in MCF7 breast tumor cells. Furthermore, the mitogenic activity of the heregulin polypeptides on SK-BR-3 cells (which express high levels of the HER2 receptor) was illustrated. Like other growth factors which belong to the EGF family, soluble HRG polypeptides appear to be derived from a membrane bound precursor (called pro-HRG) which is proteolytically processed to release the 45kDa soluble form. These pro-HRGs lack a N-terminal signal peptide.

While heregulins are substantially identical in the first 213 amino acid residues, they are classified into two major types, α and β , based on two variant EGF-like domains which differ in their C-terminal portions. Nevertheless, these EGF-like domains are identical in the spacing of six cysteine residues contained therein. Based on an amino acid sequence comparison, Holmes *et al.* found that between the first and sixth cysteines in the EGF-like domain, HRGs were 45% similar to heparin-binding EGF-like growth factor (HB-EGF), 35% identical to amphiregulin (AR), 32% identical to TGF- α , and 27% identical to EGF. The 44 kDa *neu* differentiation factor (NDF), which is the rat equivalent of human HRG, was first described by Peles *et al.*, *C II*, 69:205-216 (1992); and Wen *et al.*, *Cell*, 69:559-572 (1992). Like the HRG polypeptides, NDF has an immunoglobulin (Ig) homology domain followed by

an EGF-like domain and lacks a N-terminal signal peptide. Subsequently, Wen *et al.*, *Mol. Cell. Biol.*, 14(3):1909-1919 (1994) carried out "exhaustive cloning" to extend the family of NDFs. This work revealed six distinct fibroblastic pro-NDFs. Adopting the nomenclature of Holmes *et al.*, the NDFs are classified as either α or β polypeptides based on the sequences of the EGF-like domains. Isoforms 1 to 4 are characterized on the basis of the variable justamembrane stretch (between the EGF-like domain and transmembrane domain). Also, isoforms a, b and c are described which have variable length cytoplasmic domains. These researchers conclude that different NDF isoforms are generated by alternative splicing and perform distinct tissue-specific functions. See also EP 505 148; WO 93/22424; and WO 94/28133 concerning NDF.

10 Falls *et al.*, *Cell*, 72:801-815 (1993) describe another member of the heregulin family which they call acetylcholine receptor inducing activity (ARIA) polypeptide. The chicken-derived ARIA polypeptide stimulates synthesis of muscle acetylcholine receptors. See also WO 94/08007. ARIA is a β -type heregulin and lacks the entire spacer region rich in glycosylation sites between the Ig-like domain and EGF-like domain of HRG α , and HRG β 1- β 3.

15 Marchionni *et al.*, *Nature*, 362:312-318 (1993) identified several bovine-derived proteins which they call glial growth factors (GGFs). These GGFs share the Ig-like domain and EGF-like domain with the other heregulin proteins described above, but also have an amino-terminal kringle domain. GGFs generally do not have the complete glycosylated spacer region between the Ig-like domain and EGF-like domain. Only one of the GGFs, GGFII, possessed a N-terminal signal peptide. See also WO 92/18627; WO 94/00140; WO 94/04560; WO 94/26298; and WO 95/32724 which refer to GGFs and uses thereof.

20 Ho *et al.* in *J. Biol. Chem.* 270(4):14523-14532 (1995) describe another member of the heregulin family called sensory and motor neuron-derived factor (SMDF). This protein has an EGF-like domain characteristic of all other heregulin polypeptides but a distinct N-terminal domain. The major structural difference between SMDF and the other heregulin polypeptides is the lack in SMDF of the Ig-like domain and the "glyco" spacer characteristic of all the other heregulin polypeptides. Another feature of SMDF is the presence of two stretches of hydrophobic amino acids near the N-terminus.

25 While the heregulin polypeptides were first identified based on their ability to activate the HER2 receptor (see Holmes *et al.*, *supra*), it was discovered that certain ovarian cells expressing *neu* and *neu*-transfected fibroblasts did not bind or crosslink to NDF, nor did they respond to NDF to undergo tyrosine phosphorylation (Peles *et al.*, *EMBO J.* 12:961-971 (1993)). This indicated another cellular component was necessary for conferring full heregulin responsiveness. Carraway *et al.* subsequently demonstrated that 125 I-HRG β 1₁₇₇₋₂₄₄ bound to NIH-3T3 fibroblasts stably transfected with bovine *erbB3* but not to non-transfected parental cells. Accordingly, they conclude that ErbB3 is a receptor for HRG and mediates phosphorylation of intrinsic tyrosine residues as well as phosphorylation of ErbB2 receptor in cells which express both receptors. Carraway *et al.*, *J. Biol. Chem.* 269(19):14303-14306 (1994). Sliwkowski *et al.*, *J. Biol. Chem.* 269(20):14661-14665 (1994) found that cells transfected with HER3 alone show low affinities for heregulin, whereas cells transfected with both HER2 and HER3 show higher affinities.

35 40 This observation correlates with the "receptor cross-talking" described previously by Kokai *et al.*, *Cell* 58:287-292 (1989); Stern *et al.*, *EMBO J.* 7:995-1001 (1988); and King *et al.*, 4:13-18 (1989).

These researchers found that binding of EGF to the EGFR resulted in activation of the EGFR kinase domain and cross-phosphorylation of p185^{HER2}. This is believed to be a result of ligand-induced receptor heterodimerization and the concomitant cross-phosphorylation of the receptors within the heterodimer (Wada *et al.*, *Cell* 61:1339-1347 (1990)).

5 Plowman and his colleagues have similarly studied p185^{HER4}/p185^{HER2} activation. They expressed p185^{HER2} alone, p185^{HER4} alone, or the two receptors together in human T lymphocytes and demonstrated that heregulin is capable of stimulating tyrosine phosphorylation of p185^{HER4}, but could only stimulate p185^{HER2} phosphorylation in cells expressing both receptors. Plowman *et al.*, *Nature* 336:473-475 (1993).

10 The biological role of heregulin has been investigated by several groups. For example, Falls *et al.*, (discussed above) found that ARIA plays a role in myotube differentiation, namely affecting the synthesis and concentration of neurotransmitter receptors in the postsynaptic muscle cells of motor neurons. Corfas and Fischbach demonstrated that ARIA also increases the number of sodium channels in chick muscle. Corfas and Fischbach, *J. Neuroscience*, 13(5): 2118-2125 (1993). It has also been
15 shown that GGFII is mitogenic for subconfluent quiescent human myoblasts and that differentiation of clonal human myoblasts in the continuous presence of GGFII results in greater numbers of myotubes after six days of differentiation (Sklar *et al.*, *J. Cell Biochem.*, Abst. W462, 18D, 540 (1994)). See also WO 94/26298 published November 24, 1994.

Holmes *et al.*, *supra*, found that HRG exerted a mitogenic effect on mammary cell lines (such
20 as SK-BR-3 and MCF-7). The mitogenic activity of GGFs on Schwann cells has also been reported. See, e.g., Brockes *et al.*, *J. Biol. Chem.* 255(18):8374-8377 (1980); Lemke and Brockes, *J. Neurosci.* 4:75-83 (1984); Brockes *et al.*, *J. Neuroscience* 4(1):75-83 (1984); Brockes *et al.*, *Ann. Neurol.* 20(3):317-322 (1986); Brockes, J., *Methods in Enzym.*, 147: 217-225 (1987) and Marchionni *et al.*, *supra*. Schwann cells constitute important glial cells which provide myelin sheathing around the axons
25 of neurons, thereby forming individual nerve fibers. Thus, it is apparent that Schwann cells play an important role in the development, function and regeneration of peripheral nerves. The implications of this from a therapeutic standpoint have been addressed by Levi *et al.*, *J. Neuroscience* 14(3):1309-1319 (1994). Levi *et al.* discuss the potential for construction of a cellular prosthesis comprising human Schwann cells which could be transplanted into areas of damaged spinal cord. Methods for culturing
30 Schwann cells *ex vivo* have been described. See WO 94/00140 and Li *et al.*, *J. Neuroscience* 16(6):2012-2019 (1996).

Pinkas-Kramarski *et al.* found that NDF seems to be expressed in neurons and glial cells in embryonic and adult rat brain and primary cultures of rat brain cells, and suggested that it may act as a survival and maturation factor for astrocytes (Pinkas-Kramarski *et al.*, *PNAS, USA* 91:9387-9391
35 (1994)). Meyer and Birchmeier, *PNAS, USA* 91:1064-1068 (1994) analyzed expression of heregulin during mouse embryogenesis and in the perinatal animal using in situ hybridization and RNase protection experiments. See also Meyer *et al.*, *Development* 124(18):3575-3586 (1997). These authors conclude that, based on expression of this molecule, heregulin plays a role *in vivo* as a mesenchymal and neuronal factor. Similarly, Danilenko *et al.*, Abstract 3101, *FASEB* 8(4-5):A535 (1994); Danilenko
40 *et al.*, *Journal of Clinical Investigation* 95(2): 842-851 (1995), found that the interaction of NDF and the HER2 receptor is important in directing epidermal migration and differentiation during wound repair.

Ram *et al.*, *Journal of Cellular Physiology* 163:589-596 (1995) evaluated the mitogenic activity of NDF on the immortalized human mammary epithelial cell line MCF-10A. Danilenko *et al.*, *J. Clin. Invest.* 95:842-851 (1995) investigated whether NDF would influence epidermal migration in an *in vivo* model of excisional deep partial-thickness wound repair. It is reported that there were no statistically significant differences in proliferating basal and suprabasal keratinocytes in control wounds vs. wounds treated with rhNDF- α_2 . Marikovsky *et al.*, *Oncogene* 10:1403-1411 (1995), studied the proliferative responses of an aneuploid BALB/MK continuous keratinocyte cell line and evaluated the effects of α - and β -isoforms of NDF on epidermal keratinocytes.

The relationship between the structure and function of new proteins can be investigated using any of a variety of available mutational analysis techniques. Examples of such techniques include alanine scanning mutagenesis and phagemid display. Alanine scanning can be used to identify active residues (i.e., residues that have a significant effect on protein function) in a protein or protein domain. For example, Cunningham and Wells used alanine scanning to identify residues in human growth hormone that were important for binding its receptor. Cunningham and Wells, *Science* 244:1081-1085 (1989). In alanine scanning, a gene encoding the protein or domain to be scanned is inserted into an expression vector, and mutagenesis is carried out to generate a series of vectors that encode proteins or domains in which sequential residues are converted to alanine. The encoded proteins or domain are expressed from these vectors, and the activities of the alanine-substituted variants are then tested to identify those with altered activity. An alteration in activity indicates that the residue at the alanine-substituted position is an active residue.

Phagemid display was developed to allow the screening of a large number of variant polypeptides for a particular binding activity. Smith and Parmley demonstrated that foreign peptides can be "displayed" efficiently on the surface of filamentous phage by inserting short gene fragments into gene III of the fd phage. Smith, *Science* 228:1315-1317 (1985); Parmley and Smith, *Gene* 73:305-318 (1985). The gene III coat protein is present in about five copies at one end of the phage particle. The modified phage were termed "fusion phage" because they displayed the foreign peptides fused to the gene III coat protein. As each fusion phage particle displayed approximately five copies of the fusion protein, this mode of phage display was termed "polyvalent display."

Scott *et al.* and Cwirla *et al.* showed that fusion phage libraries could be screened by sequential affinity selections known as "panning." Scott *et al.*, *Science* 249:386-390 (1990); Cwirla *et al.*, *PNAS USA* 87:6378-6382 (1990). However, early efforts to select high affinity fusion phage failed, presumably due to the polyvalence of the phage particles. This problem was solved with the development of a "monovalent" phage display system in which the fusion protein is expressed at a low level from a phagemid and a helper phage provides a large excess of wild-type coat protein. Bass *et al.*, *Proteins* 8:309-314 (1990); Lowman *et al.*, *Biochem.* 30:10832-10838 (1991). Monovalent phage display can be used to generate and screen a large number of variant polypeptides to isolate those that bind with high affinity to a target of interest.

I. Definitions

In general, the following words or phrases have the indicated definition when used in the description, examples, and claims.

"Heregulin" ligand is defined herein to be any isolated ligand, preferably a polypeptide sequence which possesses a biological property of a naturally occurring heregulin polypeptide that binds and activates Her2. Ligands within the scope of this invention include the heregulin polypeptides discussed in detail herein. Heregulin includes the polypeptides shown in Figs. 1A-1D, 2A-2E, 3A-3E, 4A-4C, 5A-5D, 6A-6C, and 7A-7C and mammalian analogues thereof. Variants can be prepared by the methods described below, optionally together with alanine scanning and phage display techniques known in the art. Cunningham and Wells, Science 244:1081-85 (1989); Bass et al., Proteins 8:309-14 (1990); Lowman et al., Biochem. 30:10832-38 (1991).

The term a "normal" hair cell or inner-ear-supporting cell means an hair cell or inner-ear-supporting cell which is not transformed, i.e., is non-cancerous and/or non-immortalized. Further, the normal hair cell or inner-ear-supporting cell is preferably not aneuploid. Aneuploidy exists when the nucleus of a cell does not contain an exact multiple of the haploid number of chromosomes, one or more chromosomes being present in greater or lesser number than the rest. Typical properties of transformed cells which fall outside the scope of this invention include the ability to form tumors when implanted into immune-deprived mice (nude mice), the ability to grow in suspension or in semi-solid media such as agar, a loss of contact inhibition allowing piling up of cells into colonies or foci, a loss of dependence on growth factors or serum, cell death if cells are inhibited from growing, and disorganization of actin filaments. Specifically included within the invention are normal cells which will not form tumors in mice, grow attached to plastic or glass (are anchorage dependent), exhibit contact inhibition, require serum-containing hormones and growth factors, remain viable if growth is arrested by lack of serum, and contain well-organized actin filaments. Although the normal inner-ear-supporting cells are preferably not cultured cells, also suitable for the invention are non-transformed, non-immortalized epithelial cells isolated from mammalian tissue. These isolated cells may be cultured for several generations (up to about 10 or even 50 generations) in the presence of a heregulin in order to induce growth and/or proliferation of the isolated inner ear supporting cell sample, that is, to expand the sample. The expanded sample can then be reintroduced into the mammal for the purpose of repopulating the hair cell or inner-ear-supporting cell tissue (re-epithelialization). This is particularly useful for repairing tissue injury or damage.

"Biological property" for the purposes herein means an *in vivo* biologic or antigenic function or activity that is directly or indirectly performed by an heregulin sequence (whether in its native or denatured conformation), or by any subsequence thereof. Biologic functions include receptor binding, any enzyme activity or enzyme modulatory activity, any carrier binding activity, any hormonal activity, any activity in promoting or inhibiting adhesion of cells to extracellular matrix or cell surface molecules, or any structural role. However, biologic functions do not include antigenic functions, i.e. possession of an epitope or antigenic site that is capable of cross-reacting with antibodies raised against a naturally occurring heregulin polypeptide.

"Biologically active" heregulin is defined herein as a polypeptide sharing a biologic function of an heregulin sequence which may (but need not) in addition possess an antigenic function. A principal known effect or function of heregulin is as a ligand polypeptide having a qualitative biological activity of binding to HER2 resulting in the activation of the receptor tyrosine kinase (an "activating ligand"). One test for activating ligands is the heregulin tyrosine autophosphorylation assay described below.

Included within the scope of heregulin as that term is used herein are heregulin having translated mature amino acid sequences of the complete human heregulin as set forth herein; deglycosylated or unglycosylated derivatives of heregulin, amino acid sequence variants of heregulin sequence, and derivatives of heregulin, which are capable of exhibiting a biological property in common with heregulin.

5 While native heregulin is a membrane-bound polypeptide, soluble forms, such as those forms lacking a functional transmembrane domain, are also included within this definition. In particular, included are polypeptide fragments of heregulin sequence which have an N-terminus at any residue from about S216 to about A227, and its C-terminus at any residue from about K268 to about R286, and the homologous sequences shown in Fig. 6A-C, hereinafter referred to collectively for all heregulins as the
10 growth factor domain (GFD).

"Antigenically active" heregulin is defined as a polypeptide that possesses an antigenic function of an heregulin and which may (but need not) in addition possess a biologic function.

In preferred embodiments, antigenically active heregulin is a polypeptide that binds with an affinity of at least about 10^{-9} l/mole to an antibody raised against a naturally occurring heregulin
15 sequence. Ordinarily the polypeptide binds with an affinity of at least about 10^{-8} l/mole. Most preferably, the antigenically active heregulin is a polypeptide that binds to an antibody raised against one of heregulins in its native conformation. Heregulin in its native conformation generally is heregulin as found in nature which has not been denatured by chaotropic agents, heat or other treatment that substantially modifies the three dimensional structure of heregulin as determined, for example, by
20 migration on nonreducing, nondenaturing sizing gels. Antibody used in this determination may be rabbit polyclonal antibody raised by formulating native heregulin from a non-rabbit species in Freund's complete adjuvant, subcutaneously injecting the formulation, and boosting the immune response by intraperitoneal injection of the formulation until the titer of anti-heregulin antibody plateaus.

Ordinarily, biologically or antigenically active heregulin will have an amino acid sequence
25 having at least 75% amino acid sequence identity with a given heregulin sequence, more preferably at least 80%, even more preferably at least 90%, and most preferably at least 95%. Identity or homology with respect to an heregulin sequence is defined herein as the percentage of amino acid residues in the candidate sequence that are identical with heregulin residues in the heregulin of Fig. 6A-6C, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent homology, and not considering any conservative substitutions as part of the sequence identity. None of N-
30 terminal, C-terminal or internal extensions, deletions, or insertions into heregulin sequence shall be construed as affecting homology.

Thus, the biologically active and antigenically active heregulin polypeptides that are the subject of this invention include each entire heregulin sequence; fragments thereof having a consecutive
35 sequence of at least 5, 10, 15, 20, 25, 30 or 40 amino acid residues from heregulin sequence; amino acid sequence variants of heregulin sequence wherein an amino acid residue has been inserted N- or C-terminal to, or within, heregulin sequence or its fragment as defined above; amino acid sequence variants of heregulin sequence or its fragment as defined above has been substituted by another residue. heregulin polypeptides include those containing predetermined mutations by, e.g., site-
40 directed or PCR mutagenesis, and other animal species of heregulin polypeptides such as rabbit, rat,

porcine, non-human primate, equine, murine, and ovine heregulin and alleles or other naturally occurring variants of the foregoing and human sequences; derivatives of heregulin or its fragments as defined above wherein heregulin or its fragments have been covalently modified by substitution, chemical, enzymatic, or other appropriate means with a moiety other than a naturally occurring amino acid (for example a detectable moiety such as an enzyme or radioisotope); glycosylation variants of heregulin (insertion of a glycosylation site or deletion of any glycosylation site by deletion, insertion or substitution of appropriate amino acid); and soluble forms of heregulin, such as HRG-GFD or those that lack a functional transmembrane domain.

"Isolated" means a ligand, such as heregulin, which has been identified and separated and/or recovered from a component of its natural environment. Contaminant components of its natural environment are materials which would interfere with diagnostic or therapeutic uses for heregulin, and may include proteins, hormones, and other substances. In preferred embodiments, heregulin will be purified (1) to greater than 95% by weight of protein as determined by the Lowry method or other validated protein determination method, and most preferably more than 99% by weight, (2) to a degree sufficient to obtain at least 15 residues of N-terminal or internal amino acid sequence by use of the best commercially available amino acid sequenator marketed on the filing date hereof, or (3) to homogeneity by SDS-PAGE using Coomassie blue or, preferably, silver stain. Isolated heregulin includes heregulin in situ within recombinant cells since at least one component of heregulin natural environment will not be present. Isolated heregulin includes heregulin from one species in a recombinant cell culture of another species since heregulin in such circumstances will be devoid of source polypeptides. Ordinarily, however, isolated heregulin will be prepared by at least one purification step.

In accordance with this invention, heregulin nucleic acid is RNA or DNA containing greater than ten bases that encodes a biologically or antigenically active heregulin, is complementary to nucleic acid sequence encoding such heregulin, or hybridizes to nucleic acid sequence encoding such heregulin and remains stably bound to it under stringent conditions.

Preferably, heregulin nucleic acid encodes a polypeptide sharing at least 75% sequence identity, more preferably at least 80%, still more preferably at least 85%, even more preferably at 90%, and most preferably 95%, with an heregulin sequence. Preferably, the heregulin nucleic acid that hybridizes contains at least 20, more preferably at least about 40, and most preferably at least about 90 bases.

Isolated heregulin nucleic acid includes a nucleic acid that is identified and separated from at least one containment nucleic acid with which it is ordinarily associated in the natural source of heregulin nucleic acid. Isolated heregulin nucleic acid thus is present in other than in the form or setting in which it is found in nature. However, isolated heregulin encoding nucleic acid includes heregulin nucleic acid in ordinarily heregulin-expressing cells where the nucleic acid is in a chromosomal location different from that of natural cells or is otherwise flanked by a different DNA sequence than that found in nature. Nucleic acid encoding heregulin may be used in specific hybridization assays, particularly those portions of heregulin encoding sequence that do not hybridize with other known DNA sequences. "Stringent conditions" are those that (1) employ low ionic strength and high temperature for washing, for example, 0.015 M NaCl/0.0015 M sodium citrate/0.1% NaDodSO₄ at 50° C; (2) employ during

hybridization a denaturing agent such as formamide, for example, 50% (vol/vol) formamide with 0.1% bovine serum albumin, 0.1% Ficoll, 0.1% polyvinylpyrrolidone, 50 mM sodium phosphate buffer at pH 6.5 with 750 mM NaCl, 75 mM sodium citrate at 42° C; or (3) employ 50% formamide, 5 x SSC (0.75 M NaCl, 0.075 M sodium citrate), 50 mM sodium phosphate (pH 6.8), 0.1% sodium pyrophosphate, 5 x Denhardt's solution, sonicated salmon sperm DNA (50 g/ml), 0.1% SDS, and 10% dextran sulfate at 42° C, with washes at 42° C in 0.2 x SSC and 0.1% SDS.

The term "control sequences" refers to DNA sequences necessary for the expression of an operably linked coding sequence in a particular host organism. The control sequences that are suitable for prokaryotes, for example, include a promoter, optionally an operator sequence, a ribosome binding site, and possibly, other as yet poorly understood sequences. Eukaryotic cells are known to utilize promoters, polyadenylation signals, and enhancers.

Nucleic acid is "operably linked" when it is placed into a functional relationship with another nucleic acid sequence. For example, DNA for a presequence or secretory leader is operably linked to DNA for a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide; a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence; or a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation. Generally, "operably linked" means that the DNA sequences being linked are contiguous and, in the case of a secretory leader, contiguous and in reading phase. However enhancers do not have to be contiguous. Linking is accomplished by ligation at convenient restriction sites. If such sites do not exist, then synthetic oligonucleotide adaptors or linkers are used in accord with conventional practice.

An "exogenous" element is defined herein to mean nucleic acid sequence that is foreign to the cell, or homologous to the cell but in a position within the host cell nucleic acid in which the element is ordinarily not found.

As used herein, the expressions "cell", "cell line", and "cell culture" are used interchangeably, and all such designations include progeny. Thus, the words "transformants" and "transformed cells" include the primary subject cell and cultures derived therefrom without regard for the number of transfers. It is also understood that all progeny may not be precisely identical in DNA content, due to deliberate or inadvertent mutations. Mutant progeny that have the same function or biological activity as screened for in the originally transformed cell are included. It will be clear from the context where distinct designations are intended.

"Plasmids" are designated by a lower case "p" preceded and/or followed by capital letters and/or numbers. The starting plasmids herein are commercially available, are publicly available on an unrestricted basis, or can be constructed from such available plasmids in accord with published procedures. In addition, other equivalent plasmids are known in the art and will be apparent to the ordinary artisan.

"Restriction enzyme digestion" of DNA refers to catalytic cleavage of the DNA with an enzyme that acts only at certain locations in the DNA. Such enzymes are called restriction endonucleases, and the sites for which each is specific is called a restriction site. The various restriction enzymes used herein are commercially available and their reaction conditions, cofactors, and other requirements as established by the enzyme suppliers are used. Restriction enzymes commonly are designated by

abbreviations composed of a capital letter followed by other letters representing the microorganism from which each restriction enzyme originally was obtained, and then a number designating the particular enzyme. In general, about 1 mg of plasmid or DNA fragment is used with about 1-2 units of enzyme in about 20 ml of buffer solution. Appropriate buffers and substrate amounts for particular restriction enzymes are specified by the manufacturer. Incubation of about 1 hour at 37°C is ordinarily used, but may vary in accordance with the supplier's instructions. After incubation, protein or polypeptide is removed by extraction with phenol and chloroform, and the digested nucleic acid is recovered from the aqueous fraction by precipitation with ethanol. Digestion with a restriction enzyme may be followed with bacterial alkaline phosphatase hydrolysis of the terminal 5' phosphates to prevent the two restriction cleaved ends of a DNA fragment from "circularizing" or forming a closed loop that would impede insertion of another DNA fragment at the restriction site. Unless otherwise stated, digestion of plasmids is not followed by 5' terminal dephosphorylation. Procedures and reagents for dephosphorylation are conventional as described in sections 1.56-1.61 of Sambrook *et al.*, (*Molecular Cloning: A Laboratory Manual* New York: Cold Spring Harbor Laboratory Press, 1989).

"Recovery" or "isolation" of a given fragment of DNA from a restriction digest means separation of the digest on polyacrylamide or agarose gel by electrophoresis, identification of the fragment of interest by comparison of its mobility versus that of marker DNA fragments of known molecular weight, removal of the gel section containing the desired fragment, and separation of the gel from DNA. This procedure is known generally. For example, see Lawn *et al.*, *Nucleic Acids Res.* 9:6103-6114 (1981), and Goeddel *et al.*, *Nucleic Acids Res.* 8:4057 1980).

"Northern analysis" is a method used to identify RNA sequences that hybridize to a known probe such as an oligonucleotide, DNA fragment, cDNA or fragment thereof, or RNA fragment. The probe is labeled with a radioisotope such as ³²P, or by biotinylation, or with an enzyme. The RNA to be analyzed is usually electrophoretically separated on an agarose or polyacrylamide gel, transferred to nitrocellulose, nylon, or other suitable membrane, and hybridized with the probe, using standard techniques well known in the art such as those described in sections 7.39-7.52 of Sambrook *et al.*, *supra*.

"Ligation" refers to the process of forming phosphodiester bonds between two nucleic acid fragments. To ligate the DNA fragments together, the ends of the DNA fragments must be compatible with each other. In some cases, the ends will be directly compatible after endonuclease digestion. However, it may be necessary to first convert the staggered ends commonly produced after endonuclease digestion to blunt ends to make them compatible for ligation. To blunt the ends, the DNA is treated in a suitable buffer for at least 15 minutes at 15°C with about 10 units of the Klenow fragment of DNA polymerase I or T4 DNA polymerase in the presence of the four deoxyribonucleotide triphosphates. The DNA is then purified by phenol-chloroform extraction and ethanol precipitation. The DNA fragments that are to be ligated together are put in solution in about equimolar amounts. The solution will also contain ATP, ligase buffer, and a ligase such as T4 DNA ligase at about 10 units per 0.5 mg of DNA. If the DNA is to be ligated into a vector, the vector is first linearized by digestion with the appropriate restriction endonuclease(s). The linearized fragment is then treated with bacterial alkaline phosphatase, or calf intestinal phosphatase to prevent self-ligation during the ligation step.

"Preparation" of DNA from cells means isolating the plasmid DNA from a culture of the host cells. Commonly used methods for DNA preparation are the large and small-scale plasmid preparations described in sections 1.25-1.33 of Sambrook *et al.*, *supra*. After preparation of the DNA, it can be purified by methods well known in the art such as that described in section 1.40 of Sambrook *et al.*, *supra*.

"Oligonucleotides" are short-length, single- or double-stranded polydeoxynucleotides that are chemically synthesized by known methods (such as phosphotriester, phosphite, or phosphoramidite chemistry, using solid phase techniques such as described in EP 266,032, published 4 May 1988, or via deoxynucleoside H-phosphonate intermediates as described by Froehler *et al.*, *Nud. Acids Res.* 14:5399-5407, 1986. They are then purified on polyacrylamide gels.

The technique of "polymerase chain reaction," or "PCR," as used herein generally refers to a procedure wherein minute amounts of a specific piece of nucleic acid, RNA and/or DNA, are amplified as described in U.S. Pat. No. 4,683,195, issued 28 July 1987. Generally, sequence information from the ends of the region of interest or beyond needs to be available, such that oligonucleotide primers can be designed; these primers will be identical or similar in sequence to opposite strands of the template to be amplified. The 5' terminal nucleotides of the two primers may coincide with the ends of the amplified material. PCR can be used to amplify specific RNA sequences, specific DNA sequences from total genomic DNA, and cDNA transcribed from total cellular RNA, bacteriophage or plasmid sequences, etc. See generally Mullis *et al.*, *Cold Spring Harbor Symp. Quant. Biol.* 51: 263 (1987); Erlich, ed., *PCR Technology*, (Stockton Press, NY, 1989). As used herein, PCR is considered to be one, but not the only, example of a nucleic acid polymerase reaction method for amplifying a nucleic acid test sample, comprising the use of a known nucleic acid (DNA or RNA) as a primer, and utilizes a nucleic acid polymerase to amplify or generate a specific piece of nucleic acid or to amplify or generate a specific piece of nucleic acid which is complementary to a particular nucleic acid.

The "heregulin tyrosine autophosphorylation assay" to detect the presence or bioactivity of heregulin ligands can be used to monitor the purification of a ligand for the HER2 receptors. This assay is based on the assumption that a specific ligand for the receptor will stimulate autophosphorylation of the receptor, in analogy with EGF and its stimulation of EGF receptor autophosphorylation. See *Sadich et al.*, *Anal. Biochem.* 235:207-214 (1996). MDA-MB-453 cells or MCF7 cells which contain high levels of p185^{HER2} receptors but negligible levels of human EGF receptors, were obtained from the American Type Culture Collection, Rockville, Md. (ATCC No HTB-131) and maintained in tissue culture with 10% fetal calf serum in DMEM/Hams F12 (1:1) media. For assay, the cells were trypsinized and plated at 150,000 cells/well in 24 well dishes (Costar). After incubation with serum containing media overnight, the cells were placed in serum free media for 2-18 hours before assay. Test samples of 100 uL aliquots were added to each well. The cells were incubated for 5-30 minutes (typically 30 min) at 37°C and the media removed. The cells in each well were treated with 100 uL SDS gel denaturing buffer (SEPROSOL, Enpotech, Inc.) and the plates heated at 100°C for 5 minutes to dissolve the cells and denature the proteins. Aliquots from each well were electrophoresed on 5-20% gradient SDS gels (NOVEX, Encinitas, CA) according to the manufacturer's directions. After the dye front reached the bottom of the gel, the electrophoresis was terminated and a sheet of PVDF membrane (PROBLOTT,

ABI) was placed on the gel and the proteins transferred from the gel to the membrane in a blotting chamber (BioRad) at 200 mAmps for 30-60 min. After blotting, the membranes were incubated with TRIS buffered saline containing 0.1% TWEEN 20 detergent buffer with 5% BSA for 2-18 hrs to block nonspecific binding, and then treated with a mouse anti-phosphotyrosine antibody (Upstate Biological Inc., N.Y.). Subsequently, the membrane blots were treated with goat anti-mouse antibody conjugated to alkaline phosphatase. The gels were developed using the PROTOBLOT System from Promega. After drying the membranes, the density of the bands corresponding to p185^{HER2} in each sample lane was quantitated with a Hewlett Packard SCANJET Plus Scanner attached to a Macintosh computer. The number of receptors per cell in the MDA-MB-453 cells is such that under these experimental conditions the p185^{HER2} receptor protein is the major protein which is labeled.

"Protein microsequencing" was accomplished based upon the following procedures. Proteins from the final HPLC step were either sequenced directly by automated Edman degradation with a model 470A Applied Biosystems gas phase sequencer equipped with a 120A PTH amino acid analyzer or sequenced after digestion with various chemicals or enzymes. PTH amino acids were integrated using the CHROMPERFECT data system (Justice Innovations, Palo Alto, CA). Sequence interpretation was performed on a VAX 11/785 Digital Equipment Corporation computer as described (Henzel *et al.*, *J. Chromatography* 404:41-52 (1987)). In some cases, aliquots of the HPLC fractions were electrophoresed on 5-20% SDS polyacrylamide gels, electrotransferred to a PVDF membrane (PROBLOTT, ABI, Foster City, CA) and stained with Coomassie Brilliant Blue (Matsudaira, P., *J. Biol. Chem.* 262:10035-10038, 1987). The specific protein was excised from the blot for N terminal sequencing. To determine internal protein sequences, HPLC fractions were dried under vacuum (SPEEDVAC), resuspended in appropriate buffers, and digested with cyanogen bromide, the lysine-specific enzyme Lys-C (Wako Chemicals, Richmond, VA) or Asp-N (Boehringer Mannheim, Indianapolis, Ind.). After digestion, the resultant peptides were sequenced as a mixture or were resolved by HPLC on a C4 column developed with a propanol gradient in 0.1% TFA before sequencing as described above.

"Antibodies" (Abs) and "immunoglobulins" (Igs) are glycoproteins having the same structural characteristics. While antibodies exhibit binding specificity to a specific antigen, immunoglobulins include both antibodies and other antibody-like molecules which lack antigen specificity. Polypeptides of the latter kind are, for example, produced at low levels by the lymph system and at increased levels by myelomas.

Papain digestion of antibodies produces two identical antigen-binding fragments, called "Fab" fragments, each with a single antigen-binding site, and a residual "Fc" fragment, whose name reflects its ability to crystallize readily. Pepsin treatment yields an F(ab')₂ fragment that has two antigen-combining sites and is still capable of cross-linking antigen.

"Fv" is the minimum antibody fragment which contains a complete antigen-recognition and -binding site. This region consists of a dimer of one heavy chain and one light chain variable domain in tight, non-covalent association. It is in this configuration that the three hypervariable regions of each variable domain interact to define an antigen-binding site on the surface of the V_H-V_L dimer. Collectively, the six hypervariable regions confer antigen-binding specificity to the antibody. However, even a single

variable domain (or half of an Fv comprising only three hypervariable regions specific for an antigen) has the ability to recognize and bind antigen, although at a lower affinity than the entire binding site.

The Fab fragment also contains the constant domain of the light chain and the first constant domain (CH1) of the heavy chain. Also included are Fab fragments having the addition of a few residues at the carboxyl terminus of the heavy chain CH1 domain including one or more cysteine(s) from the antibody hinge region. Fab'-SH is the designation herein for Fab' in which the cysteine residue(s) of the constant domains bear a free thiol group. F(ab')₂ antibody fragments originally were produced as pairs of Fab' fragments which have hinge cysteines between them. Other chemical couplings of antibody fragments are also known.

10 The "light chains" of antibodies (immunoglobulins) from any vertebrate species can be assigned to one of two clearly distinct types, called kappa (κ) and lambda (λ), based on the amino acid sequences of their constant domains.

Depending on the amino acid sequence of the constant domain of their heavy chains, immunoglobulins can be assigned to different classes. There are five major classes of immunoglobulins: IgA, IgD, IgE, IgG, and IgM, and several of these may be further divided into subclasses (isotypes), e.g., IgG1, IgG2, IgG3, IgG4, IgA, and IgA2. The subunit structures and three-dimensional configurations of different classes of immunoglobulins are well known.

15 The term "antibody" herein is used in the broadest sense and specifically covers monoclonal antibodies (including full length monoclonal antibodies), polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), and antibody fragments so long as they exhibit the desired biological activity.

"Antibody fragments" comprise a portion of a full length antibody, generally the antigen binding or variable domain thereof. Examples of antibody fragments include Fab, Fab', F(ab')₂, and Fv fragments; diabodies; linear antibodies; single-chain antibody molecules; and multispecific antibodies formed from antibody fragments.

25 The term "monoclonal antibody" as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present in minor amounts. Monoclonal antibodies are highly specific, being directed against a single antigenic site. Furthermore, in contrast to conventional (polyclonal) antibody preparations which typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen. The modifier "monoclonal" indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method. For example, the monoclonal antibodies to be used in accordance with the present invention may be made by the hybridoma method first described by Kohler *et al.*, *Nature* 256:495 (1975), or may be made by recombinant DNA methods (see, e.g., U.S. Patent No. 4,816,567). The "monoclonal antibodies" may also be isolated from phage antibody libraries using the techniques described in Clackson *et al.*, *Nature* 352:624-628 (1991) and Marks *et al.*, *J. Mol. Biol.* 222:581-597 (1991), for example.

40 The monoclonal antibodies herein specifically include "chimeric" antibodies (immunoglobulins) in which a portion of the heavy and/or light chain is identical with or homologous to corresponding

sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical with or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, so long as they exhibit the desired biological activity (U.S. Patent No. 4,816,567; and Morrison *et al.*, *Proc. Natl. Acad. Sci. USA* 81:6851-6855 (1984)).

"Humanized" forms of non-human (e.g., murine) antibodies are chimeric antibodies which contain minimal sequence derived from non-human immunoglobulin. For the most part, humanized antibodies are human immunoglobulins (recipient antibody) in which hypervariable region residues of the recipient are replaced by hypervariable region residues from a non-human species (donor antibody) such as mouse, rat, rabbit or nonhuman primate having the desired specificity, affinity, and capacity. In some instances, framework region (FR) residues of the human immunoglobulin are replaced by corresponding non-human residues. Furthermore, humanized antibodies may comprise residues which are not found in the recipient antibody or in the donor antibody. These modifications are made to further refine antibody performance. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the hypervariable regions correspond to those of a non-human immunoglobulin and all or substantially all of the FRs are those of a human immunoglobulin sequence. The humanized antibody optionally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin. For further details, see Jones *et al.*, *Nature* 321:522-525 (1986); Reichmann *et al.*, *Nature* 332:323-329 (1988); and Presta, *Curr. Op. Struct. Biol.* 2:593-596 (1992).

"Single-chain Fv" or "sFv" antibody fragments comprise the V_H and V_L domains of antibody, wherein these domains are present in a single polypeptide chain. Generally, the Fv polypeptide further comprises a polypeptide linker between the V_H and V_L domains which enables the sFv to form the desired structure for antigen binding. For a review of sFv see Pluckthun in *The Pharmacology of Monoclonal Antibodies*, vol. 113, Rosenberg and Moore eds. Springer-Verlag, New York, pp. 269-315 (1994).

The term "diabodies" refers to small antibody fragments with two antigen-binding sites, which fragments comprise a heavy chain variable domain (V_H) connected to a light chain variable domain (V_L) in the same polypeptide chain ($V_H - V_L$). By using a linker that is too short to allow pairing between the two domains on the same chain, the domains are forced to pair with the complementary domains of another chain and create two antigen-binding sites. Diabodies are described more fully in, for example, EP 404,097; WO 93/11161; and Hollinger *et al.*, *Proc. Natl. Acad. Sci. USA* 90:6444-6448 (1993).

The expression "linear antibodies" when used throughout this application refers to the antibodies described in Zapata *et al.* *Protein Eng.* 8(10):1057-1062 (1995). Briefly, these antibodies comprise a pair of tandem Fd segments ($V_H - C_H1 - V_H - C_H1$) which form a pair of antigen binding regions. Linear antibodies can be bispecific or monospecific.

II. USE AND PREPARATION OF Heregulin SEQUENCES

H. PREPARATION OF Heregulin SEQUENCES, INCLUDING VARIANTS

The system to be employed in preparing heregulin sequence will depend upon the particular heregulin sequence selected. If the sequence is sufficiently small heregulin may be prepared by *in vitro* polypeptide synthetic methods. Most commonly, however, heregulin will be prepared in recombinant

cell culture using the host-vector systems described below. Suitable heregulin includes any biologically active and antigenetically active heregulin.

In general, mammalian host cells will be employed, and such hosts may or may not contain post-translational systems for processing heregulin preprosequences in the normal fashion. If the host cells contain such systems then it will be possible to recover natural subdomain fragments from the cultures. If not, then the proper processing can be accomplished by transforming the hosts with the required enzyme(s) or by supplying them in an *in vitro* method. However, it is not necessary to transform cells with the complete prepro or structural genes for a selected heregulin when it is desired to only produce fragments of heregulin sequences. For example, a start codon is ligated to the 5' end of DNA encoding an HRG-GFD, this DNA is used to transform host cells and the product expressed directly as the Met N-terminal form (if desired, the extraneous Met may be removed *in vitro* or by endogenous N-terminal demethionylases). Alternatively, HRG-GFD is expressed as a fusion with a signal sequence recognized by the host cell, which will process and secrete the mature HRG-GFD as is further described below. Amino acid sequence variants of native HRG-GFD sequences are produced in the same way.

Heregulin sequences located between the first N-terminal mature residue and the first N-terminal residue of HRG-GFD sequence, termed HRG-NTD, may function at least in part as an unconventional signal sequence or as a normally circulating carrier/precursor for HRG-GFD having unique biological activity. HRG-NTD is produced in the same fashion as the full length molecule but from expression of DNA in which a stop codon is located at the C-terminus of HRG-NTD. In addition, heregulin variants are expressed from DNA encoding protein in which both the GFD and NTD domains are in their proper orientation but which contain an amino acid insertion, deletion or substitution at the GFD-NTD cleavage site (located within the sequence VKC) which inhibits or prevents proteolytic cleavage of the NTD-GFD joining site *in vivo*, and wherein a stop codon is positioned at the 3' end of the GFD- encoding sequence. In an example of this group of variants (termed HRG-NTDXGFD), (1) the lysine residue found in the NTD-GFD joining sequence VKC is deleted or (preferably) substituted by another residue other than arginyl such as histidyl, alanyl, threonyl or seryl and (2) a stop codon is introduced in the sequence RCT or RCQ in place of cysteinyl, or threonyl (for HRG- α) or glutaminyl (for HRG- β).

A preferred HRG- α ligand with binding affinity to p185^{HER2} comprises amino acids 226-265 of figure 1A-D. This HRG- α ligand further may comprise up to an additional 1-20 amino acids preceding amino acid 226 and 1-20 amino acids following amino acid 265. A preferred HRG- β ligand with binding affinity to p185^{HER2} comprises amino acids 226-265 of figure 2A-E. This HRG- β ligand may comprise up to an additional 1-20 amino acids preceding amino acid 226 and 1-20 amino acids following amino acid 265.

As noted above, other heregulin sequences to be prepared in accordance with this invention are those of the GFD. These are synthesized *in vitro* or are produced in recombinant cell culture. These are produced most inexpensively in yeast or *E.coli* by secretion under the control of a heregulin-heterologous signal as described *infra*, although preparation in mammalian cells is also contemplated using a mammalian protein signal such as that of tPA, UK or a secreted viral protein. The GFD can be

the sequence of a native heregulin or may be a variant thereof as described below. GFD sequences include those in which one or more residues from a member of the EGF family are substituted into or onto the GFD sequence.

5 An additional heregulin is one which contains the GFD and the sequence between the C-terminus of GFD and the N-terminus of the transmembrane domain (the later being termed the C-terminal cleavage domain or CTC). In this variant (HRG-GFD-CTC) the DNA start codon is present at the 5' end of heregulin-heterologous signal sequence or adjacent the 5' end of the GFD-encoding region, and a stop codon is found in place of one of the first about 1 to 3 extra-cellular domain (ECD) residues or first about 1-2 transmembrane region residues. In addition, in some HRG-GFD-CTC
10 variants the codons are modified in the GFD-CTC proteolysis site by substitution, insertion or deletion. The GFD-CTC proteolysis site is the domain that contains the GFD C-terminal residue and about 5 residues N- and 5 residues C-terminal from this residue. It is known that Met-227 terminal and Val-229 terminal HRG- α -GFD are biologically active. The C-terminus for HRG- α -GFD may be Met-227, Lys-228, Val-229, Gln-230, Asn-231 or Gln-232, and for HRG- β -GFD may be Met-226, Ala-227, Ser-228,
15 Phe-229, Trp-230, or Lys231/Ser231. The native C-terminus is determined readily by C- terminal sequencing, although it is not critical that HRG-GFD have the native terminus so long as the GFD sequence possesses the desired activity. In some embodiments of HRG-GFD-CTC variants, the amino acid change(s) in the CTC are screened for their ability to resist proteolysis *in vitro* and inhibit the protease responsible for generation of HRG-GFD.

20 HRG-ECD variants are made by providing a stop codon at the same location as for HRG-GFD-CTC variants. HRG-ECD may comprise any one or more of the variants described above in connection with its subfragments, e.g. the GFD-CTC variants containing CTC-proteolysis site modifications.

If it is desired to prepare the longer heregulin polypeptides and the 5' or 3' ends of the given heregulin are not described herein, it may be necessary to prepare nucleic acids in which the missing
25 domains are supplied by homologous regions from more complete heregulin nucleic acids. Alternatively, the missing domains can be obtained by probing libraries using the DNAs disclosed in the Figures or fragments thereof.

A. Isolation of DNA Encoding Heregulin

The DNA encoding heregulin may be obtained from any cDNA library prepared from tissue
30 believed to possess heregulin mRNA and to express it at a detectable level. HRG- α gene thus may be obtained from a genomic library. Similar procedures may be used for the isolation of other heregulin, such as HRG- β 1, HRG- β 2, or HRG- β 3 encoding genes.

Libraries are screened with probes designed to identify the gene of interest or the protein encoded by it. For cDNA expression libraries, suitable probes include monoclonal or polyclonal
35 antibodies that recognize and specifically bind to HRG- α ; oligonucleotides of about 20-80 bases in length that encode known or suspected portions of HRG- α cDNA from the same or different species; and/or complementary or homologous cDNAs or fragments thereof that encode the same or a similar gene. Appropriate probes for screening genomic DNA libraries include, but are not limited to, oligonucleotides; cDNAs or fragments thereof that encode the same or a similar gene; and/or
40 homologous genomic DNAs or fragments thereof. Screening the cDNA or genomic library with the

selected probe may be conducted using standard procedures as described in chapters 10-12 of Sambrook *et al.*, *supra*.

5 An alternative means to isolate the gene encoding HRG- α is to use polymerase chain reaction (PCR) methodology as described in section 14 of Sambrook *et al.*, *supra*. This method requires the use of oligonucleotide probes that will hybridize to HRG- α . Strategies for selection of oligonucleotides are described below.

10 Another alternative method for obtaining the gene of interest is to chemically synthesize it using one of the methods described in Engels *et al.* (*Agnew. Chem. Int. Ed. Engl.*, 28: 716-734, 1989), specifically incorporated by reference. These methods include triester, phosphite, phosphoramidite and H-Phosphonate methods, PCR and other autoprimers methods, and oligonucleotide syntheses on solid supports. These methods may be used if the entire nucleic acid sequence of the gene is known, or the sequence of the nucleic acid complementary to the coding strand is available, or alternatively, if the target amino acid sequence is known, one may infer potential nucleic acid sequences using known and preferred coding residues for each amino acid residue.

15 A preferred method of practicing this invention is to use carefully selected oligonucleotide sequences to screen cDNA libraries from various tissues, preferably human breast, colon, salivary gland, placental, fetal, brain, and carcinoma cell lines. Other biological sources of DNA encoding an heregulin-like ligand include other mammals and birds. Among the preferred mammals are members of the following orders: bovine, ovine, equine, murine, and rodentia.

20 The oligonucleotide sequences selected as probes should be of sufficient length and sufficiently unambiguous that false positives are minimized. The actual nucleotide sequence(s) may, for example, be based on conserved or highly homologous nucleotide sequences or regions of HRG- α . The oligonucleotides may be degenerate at one or more positions. The use of degenerate oligonucleotides may be of particular importance where a library is screened from a species in which preferential codon usage in that species is not known. The oligonucleotide must be labeled such that it can be detected upon hybridization to DNA in the library being screened. The preferred method of labeling is to use ³²P-labeled ATP with polynucleotide kinase, as is well known in the art, to radiolabel the oligonucleotide. However, other methods may be used to label the oligonucleotide, including, but not limited to, biotinylation or enzyme labeling.

30 Of particular interest is HRG- α nucleic acid that encodes a full-length polypeptide. In some preferred embodiments, the nucleic acid sequence includes the native HRG- α signal sequence. Nucleic acid having all the protein coding sequence is obtained by screening selected cDNA or genomic libraries, and, if necessary, using conventional primer extension procedures as described in section 7.79 of Sambrook *et al.*, *supra*, to detect precursors and processing intermediates of mRNA that may not have been reverse-transcribed into cDNA.

35 HRG- α encoding DNA of Figures 1A-1D may be used to isolate DNA encoding the analogous ligand from other animal species via hybridization employing the methods discussed above. The preferred animals are mammals, particularly bovine, ovine, equine, feline, canine and rodentia, and more specifically rats, mice and rabbits.

The EGF-like domain fragment HRG- β 1 177-244 was amplified from vector pHL89 (which is described in Holmes et al., *Science* 256:1205-1210 (1992)) by PCR with primers having NsiI/XbaI-containing overhangs. The fragment was inserted into phagemid display vector pam-g3 by restriction digest-ligation at the same sites to generate construct pHRG2-g3 (177-244). pam-g3 was a derivative of phGHam-g3, which was designed for phage display of human growth hormone (hGH) and was described in Lowman et al., *Biochemistry* 30:10832-10838 (1991). pam-g3 was produced by removing the hGH gene present in phGHam-g3 and replacing this gene with a stuffer fragment, which provides space for cleavage at the restriction sites used for cloning. The HRG- β 1 fragment was attached to residue 247 of pIII.

The HRG- β 1 EGF-like domain expressed from the above-described construct is designated by removing the "p" and the "-g3" that appear in the name of the construct. Thus, the HRG- β 1 EGF-like domain expressed from the pHRG2-g3 construct is designated "HRG2." The domain was displayed monovalently on phage as a pIII fusion protein, as described by Bass et al., *Proteins* 8:309-314 (1990). Similarly, variants HRG- β 1₁₄₇₋₂₂₇, HRG- β 1₁₄₇₋₂₄₄, and HRG- β 1₁₇₇₋₂₂₇ were prepared and expressed as described above.

B. Amino Acid Sequence Variants of Heregulin

Amino acid sequence variants of heregulin are prepared by introducing appropriate nucleotide changes into heregulin DNA, or by *in vitro* synthesis of the desired heregulin polypeptide. Such variants include, for example, deletions from, or insertions or substitutions of, residues within the amino acid sequence shown for human heregulin sequences. Any combination of deletion, insertion, and substitution can be made to arrive at the final construct, provided that the final construct possesses the desired characteristics. Excluded from the scope of this invention are heregulin variants or polypeptide sequences that are not novel and unobvious over the prior art. The amino acid changes also may alter post-translational processes of HRG- α , such as changing the number or position of glycosylation sites, altering the membrane anchoring characteristics, altering the intra-cellular location of heregulin by inserting, deleting, or otherwise affecting the leader sequence of the native heregulin, or modifying its susceptibility to proteolytic cleavage.

The heregulin sequence may be proteolytically processed to create a number of heregulin fragments. HRG-GFD sequences of HRG- α all contain the amino acid sequence between HRG- α cysteine 226 and cysteine 265. The amino terminus of HRG- α fragment may result from the cleavage of any peptide bond between alanine 1 and cysteine 226, preferably adjacent to an arginine, lysine, valine, or methionine, and most preferably between methionine 45 and serine 46. The carboxy terminus of HRG- α fragment may result from the cleavage of any peptide bond between cysteine 265, preferably adjacent to an arginine, lysine, valine, or methionine, and most preferably between lysine 272 and valine 273, between lysine 278 and alanine 279, or between lysine 285 and arginine 286. The resulting HRG- α ligands resulting from such proteolytic processing are the preferred ligands.

HRG- β -GFD's are analogous to those discussed above for HRG- α -GFD's. Each HRG- β -GFD contains the polypeptide segment from cysteine 212 to cysteine 251 of figure 2A-E. The amino terminus of HRG- β 1 fragment may result from the cleavage of any peptide bond between alanine 1 and cysteine 212, preferably adjacent to an arginine, lysine, valine, or methionine, and most preferably

between methionine 31 and serine 32. The carboxy terminus of HRG- β 1 fragment may result from the cleavage of any peptide bond between cysteine 251 of Fig. 2A-2E, preferably adjacent to an arginine, lysine, valine, or methionine, and most preferably between valine 255 and methionine 256, between lysine 261 and histidine 262, between lysine 276 and alanine 277, or between lysine 301 and threonine 302. The resulting HRG- β 1 ligands resulting from such proteolytic processing are among the preferred ligands. Similarly, processing to produce preferred fragment ligands of HRG- β 2 based upon the Fig. 3A-3E and HRG- β 3 based upon Fig. 4A-4C may be accomplished by cleaving heregulin sequences of Figs. 3A-3E and 4A-4C preferably adjacent to an arginine, lysine, valine or methionine.

In designing amino acid sequence variants of heregulin, the location of the mutation site and the nature of the mutation will depend on heregulin characteristic(s) to be modified. The sites for mutation can be modified individually or in series, e.g., by (1) substituting first with conservative amino acid choices and then with more radical selections depending upon the results achieved, (2) deleting the target residue, or (3) inserting residues of other receptor ligands adjacent to the located site.

A useful method for identification of certain residues or regions of heregulin polypeptide that are preferred locations for mutagenesis is called "alanine scanning mutagenesis" as described by Cunningham and Wells (*Science*, 244: 1081-1085, 1989). Here, a residue or group of target residues are identified (e.g., charged residues such as arg, asp, his, lys, and glu) and replaced by a neutral or negatively charged amino acid (most preferably alanine or polyalanine) to affect the interaction of the amino acids with the surrounding aqueous environment in or outside the cell. Those domains demonstrating functional sensitivity to the substitutions then are refined by introducing further or other variants at or for the sites of substitution. Thus, while the site for introducing an amino acid sequence variation is predetermined, the nature of the mutation *per se* need not be predetermined. For example, to optimize the performance of a mutation at a given site, ala scanning or random mutagenesis may be conducted at the target codon or region and the expressed heregulin variants are screened for the optimal combination of desired activity.

There are two principal variables in the construction of amino acid sequence variants: the location of the mutation site and the nature of the mutation. These are variants from heregulin sequence, and may represent naturally occurring alleles (which will not require manipulation of heregulin DNA) or predetermined mutant forms made by mutating the DNA, either to arrive at an allele or a variant not found in nature. In general, the location and nature of the mutation chosen will depend upon heregulin characteristic to be modified. Obviously, such variations that, for example, convert heregulin into a known receptor ligand, are not included within the scope of this invention, nor are any other heregulin variants or polypeptide sequences that are not novel and unobvious over the prior art.

Amino acid sequence deletions generally range from about 1 to 30 residues, more preferably about 1 to 10 residues, and typically about 1 to 5 are contiguous. Deletions may be introduced into regions of low homology with other EGF family precursors to modify the activity of heregulin. Deletions from heregulin in areas of substantial homology with other EGF family sequences will be more likely to modify the biological activity of heregulin more significantly. The number of consecutive deletions will be selected so as to preserve the tertiary structure of heregulin in the affected domain, e.g., cysteine crosslinking, beta-pleated sheet or alpha helix.

Amino acid sequence insertions include amin - and/or carboxyl-terminal fusions ranging in length from one residue to polypeptides containing a hundred or more residues, as well as intrasequence insertions of single or multiple amino acid residues. Intrasequence insertions (i.e., insertions within heregulin sequence) may range generally from about 1 to 10 residues, more preferably 1 to 5, and most preferably 1 to 3. Examples of terminal insertions include heregulin with an N-terminal methionyl residue (an artifact of the direct expression of heregulin in bacterial recombinant cell culture), and fusion of a heterologous N-terminal signal sequence to the N-terminus of heregulin to facilitate the secretion of mature heregulin from recombinant host cells. Such signal sequences generally will be obtained from, and thus be homologous to, the intended host cell species. Suitable sequences include STII, iPA or lpp for *E. coli*, alpha factor for yeast, and viral signals such as herpes gD for mammalian cells.

Other insertional variants of heregulin include the fusion to the N- or C-terminus of heregulin of an immunogenic polypeptide, e.g., bacterial polypeptides such as beta-lactamase or an enzyme encoded by the *E. coli* *tp* locus, or yeast protein, bovine serum albumin, and chemotactic polypeptides. C-terminal fusions of heregulin-ECD with proteins having a long half-life such as immunoglobulin constant regions (or other immunoglobulin regions), albumin, or ferritin, as described in WO 89/02922, published 6 April 1989 are contemplated.

Another group of variants are amino acid substitution variants. These variants have at least one amino acid residue in heregulin molecule removed and a different residue inserted in its place. The sites of greatest interest for substitutional mutagenesis include sites identified as the active site(s) of heregulin, and sites where the amino acids found in heregulin ligands from various species are substantially different in terms of side-chain bulk, charge, and/or hydrophobicity. A likely sub-domain of HRG-GFD having biological activity as a growth factor is the C-terminal segment, in particular within the sequence about from glycine 218 to valine 226 (HRG- α), and glycine 218 to lysine 228/serine 228 (HRG- β) based upon analogy to the EGF sub-sequence found to have EGF activity.

Other sites of interest are those in which particular residues of heregulin-like ligands obtained from various species are identical. These positions may be important for the biological activity of heregulin. These sites, especially those falling within a sequence of at least three other identically conserved sites, are substituted in a relatively conservative manner. Such conservative substitutions are shown in Table 1 under the heading of "preferred substitutions". If such substitutions result in a change in biological activity, then more substantial changes, denominated exemplary substitutions in Table 1, or as further described below in reference to amino acid classes, are introduced and the products screened.

TABLE 1

Original Residue	Exemplary Substitutions	Preferred Substitutions
Ala (A)	val; leu; ile	val
Arg (R)	lys; gln; asn	lys
Asn (N)	gln; his; lys; arg	gln
Asp (D)	glu	glu
Cys (C)	ser	ser

	Gln (Q)	asn	asn
	Glu (E)	asp	asp
	Gly (G)	pro	pro
	His (H)	asn; gln; lys; arg	arg
5	Ile (I)	leu; val; met; ala; phe; norleucine	leu
	Leu (L)	norleucine; ile; val; met; ala; phe	ile
10	Lys (K)	arg; gln; asn	arg
	Met (M)	leu; phe; ile	leu
	Phe (F)	leu; val; ile; ala	leu
	Pro (P)	gly	gly
	Ser (S)	thr	thr
15	Thr (T)	ser	ser
	Trp (W)	tyr	tyr
	Tyr (Y)	trp; phe; thr; ser	phe
	Val (V)	ile; leu; met; phe; ala; norleucine	leu
20			

Substantial modifications in function or immunological identity of heregulin are accomplished by selecting substitutions that differ significantly in their effect on maintaining (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a sheet or helical conformation, (b) the charge or hydrophobicity of the molecule at the target site, or (c) the bulk of the side chain. Naturally occurring residues are divided into groups based on common side chain properties:

- 1) hydrophobic: norleucine, met, ala, val, leu, ile;
- 2) neutral hydrophilic: cys, ser, thr;
- 3) acidic: asp, glu;
- 30 4) basic: asn, gln, his, lys, arg;
- 5) residues that influence chain orientation: gly, pro; and
- 6) aromatic: trp, tyr, phe.

Non-conservative substitutions will entail exchanging a member of one of these classes for another. Such substituted residues may be introduced into regions of heregulin that are homologous with other receptor ligands, or, more preferably, into the non-homologous regions of the molecule.

In one embodiment of the invention, it is desirable to inactivate one or more protease cleavage sites that are present in the molecule. These sites are identified by inspection of the encoded amino acid sequence. Where protease cleavage sites are identified, they are rendered inactive to proteolytic cleavage by substituting the targeted residue with another residue, preferably a basic residue such as glutamine or a hydrophylic residue such as serine; by deleting the residue; or by inserting a prolyl residue immediately after the residue.

In another embodiment, any methionyl residue other than the starting methionyl residue of the signal sequence, or any residue located within about three residues N- or C-terminal to each such methionyl residue, is substituted by another residue (preferably in accord with Table 1) or deleted. Alternatively, about 1-3 residues are inserted adjacent to such sites.

- 5 Any cysteine residues not involved in maintaining the proper conformation of heregulin also may be substituted, generally with serine, to improve the oxidative stability of the molecule and prevent aberrant crosslinking.

Sites particularly suited for substitutions, deletions or insertions, or use as fragments, include, numbered from the N-terminus of HRG- α of Figure 1A - 1D:

- 10 1) potential glycosaminoglycan addition sites at the serine-glycine dipeptides at 42-43, 64-65, 151-152;
- 2) potential asparagine-linked glycosylation at positions 164, 170, 208 and 437, sites (NDS) 164-166, (NIT) 170-172, (NTS) 208-210, and NTS (609-611);
- 3) potential O-glycosylation in a cluster of serine and threonine at 209-218;
- 15 4) cysteines at 226, 234, 240, 254, 256 and 265;
- 5) transmembrane domain at 287-309;
- 6) loop 1 delineated by cysteines 226 and 240;
- 7) loop 2 delineated by cysteines 234 and 254;
- 8) loop 3 delineated by cysteines 256 and 265; and
- 20 9) potential protease processing sites at 2-3, 8-9, 23-24, 33-34, 36-37, 45-46, 48-49, 62-63, 66-67, 86-87, 110-111, 123-124, 134-135, 142-143, 272-273, 278-279 and 285-286;

Analogous regions in HRG- β 1 may be determined by reference to its' sequence. The analogous HRG- β 1 amino acids may be mutated or modified as discussed above for HRG- α . Analogous regions in HRG- β 2 may also be determined by reference to its' sequence. The analogous
 25 HRG- β 2 amino acids may be mutated or modified as discussed above for HRG- α or HRG- β 1. Analogous regions in HRG- β 3 may be determined by reference to its' sequence. Further, the analogous HRG- β 3 amino acids may be mutated or modified as discussed above for HRG- α , HRG- β 1, or HRG- β 2.

Another heregulin variant is or gamma-heregulin. -HRG is any polypeptide sequence that
 30 possesses at least one biological property of native sequence -HRG having SEQ ID NO:11. The biological property of this variant is the same as for heregulin, noted above. This variant encompasses not only the polypeptide isolated from a native -HRG source such as human MDA-MB-175 cells or from another source, such as another animal species, but also the polypeptide prepared by recombinant or synthetic methods. It also includes variant forms including functional derivatives, allelic
 35 variants, naturally occurring isoforms and analogues thereof. Sometimes the -HRG is "native -HRG" which refers to endogenous -HRG polypeptide which has been isolated from a mammal. The -HRG can also be "native sequence -HRG" insofar as it has the same amino acid sequence as a native -HRG (e.g. human -HRG shown in Fig. 7A-7C). Amino acid sequence variants of the native sequence are prepared by introducing appropriate nucleotide changes into the native sequence DNA, or by *In*
 40 *vitro* synthesis of the desired polypeptide. Such variants include, for example, deletions from, or

insertions or substitutions of, residues within the amino acid sequence shown for the human protein in Fig. 7A-7C as generally described above for other heregulin. Any combination of deletion, insertion, and substitution is made to arrive at the final construct, provided that the final construct possesses the desired characteristics. The amino acid changes also may alter post-translational processes of the native sequence, such as changing the number or position of O-linked glycosylation sites.

Additional variants include polypeptides in which the variant has an amino acid substitution at a selected residue corresponding to a residue of 645-amino acid native human heregulin- β 1 selected from:

S177, H178, L179, V180, K181, E184, E186,
K187, T188, V191, N192, G193, G194, E195,
M198, V199, K200, D201, N204, P205, S206,
R207, Y208, L209, K211, P213, N214, E215,
T217, G218, D219, Q222, N223, Y224, S228, and F229.

In a variation of this embodiment, the amino acid substitution is not a replacement of the selected residue with an epidermal growth factor (EGF) residue corresponding to the selected residue.

Other heregulin- β 1 variants include an amino acid substitution selected from:

S177W; H178S, E, R, or A; V180Q, I or E;
K181P or A; A183G; E184V, W, K, R, G, or N;
K185E, S, Q, or G; E186R; K187E or A; T188Q;
E195Q; F197Y; M198R or K; K200R; D201T or I;
P205T or Y; S206K, H, G, P, or R; R207Y;
Y208R or L; L209M or G; K211R; P213S, T, N, or K;
N214L, K, S, or E; F216M; N223H or W; and M226I.

In a variation of this embodiment, the heregulin variant includes sets of amino acid substitutions selected from this group.

In addition to including one or more of the amino acid substitutions disclosed herein, the heregulin variant can have one or more other modifications, such as an amino acid substitution, an insertion of at least one amino acid, a deletion of at least one amino acid, or a chemical modification. For example, the invention provides a heregulin variant that is a fragment. In a variation of this embodiment, the fragment includes residues corresponding to a portion of human heregulin- β 1 extending from about residue 175 to about residue 230 (i.e., the EGF-like domain). For example, the fragment can extend from residue 177 to residue 244 and may be prepared by recombinant techniques (rHRG β 1-177-244).

DNA encoding amino acid sequence variants of heregulin is prepared by a variety of methods known in the art. These methods include, but are not limited to, isolation from a natural source (in the case of naturally occurring amino acid sequence variants) or preparation by oligonucleotide-mediated (or site-directed) mutagenesis, PCR mutagenesis, and cassette mutagenesis of an earlier prepared variant or a non-variant version of heregulin. These techniques may utilize heregulin nucleic acid (DNA or RNA), or nucleic acid complementary to heregulin nucleic acid.

Oligonucleotide-mediated mutagenesis is a preferred method for preparing substitution, deletion, and insertion variants of heregulin DNA. This technique is well known in the art as described

by Adelman *et al.*, *DNA*, 2: 183 (1983). Briefly, heregulin DNA is altered by hybridizing an oligonucleotide encoding the desired mutation to a DNA template, where the template is the single-stranded form of a plasmid or bacteriophag containing the unaltered or native DNA sequence of heregulin. After hybridization, a DNA polymerase is used to synthesize an entire second
5 complementary strand of the template that will thus incorporate the oligonucleotide primer, and will code for the selected alteration in heregulin DNA.

Generally, oligonucleotides of at least 25 nucleotides in length are used. An optimal oligonucleotide will have 12 to 15 nucleotides that are completely complementary to the template on either side of the nucleotide(s) coding for the mutation. This ensures that the oligonucleotide will
10 hybridize properly to the single-stranded DNA template molecule. The oligonucleotides are readily synthesized using techniques known in the art such as that described by Crea *et al.* (*Proc. Natl. Acad. Sci. USA*, 75: 5765, 1978).

Single-stranded DNA template may also be generated by denaturing double-stranded plasmid (or other) DNA using standard techniques.

15 For alteration of the native DNA sequence (to generate amino acid sequence variants, for example), the oligonucleotide is hybridized to the single-stranded template under suitable hybridization conditions. A DNA polymerizing enzyme, usually the Klenow fragment of DNA polymerase I, is then added to synthesize the complementary strand of the template using the oligonucleotide as a primer for synthesis. A heteroduplex molecule is thus formed such that one strand of DNA encodes the mutated
20 form of heregulin, and the other strand (the original template) encodes the native, unaltered sequence of heregulin. This heteroduplex molecule is then transformed into a suitable host cell, usually a prokaryote such as *E. coli* JM101. After the cells are grown, they are plated onto agarose plates and screened using the oligonucleotide primer radiolabeled with ³²P-phosphate to identify the bacterial colonies that contain the mutated DNA. The mutated region is then removed and placed in an
25 appropriate vector for protein production, generally an expression vector of the type typically employed for transformation of an appropriate host.

The method described immediately above may be modified such that a homoduplex molecule is created wherein both strands of the plasmid contain the mutation(s). The modifications are as follows: the single-stranded oligonucleotide is annealed to the single-stranded template as described
30 above. A mixture of three deoxyribonucleotides, deoxyriboadenosine (dATP), deoxyriboguanosine (dGTP), and deoxyribothymidine (dTTP), is combined with a modified thio-deoxyribocytosine called dCTP-(aS) (which can be obtained from Amersham Corporation). This mixture is added to the template-oligonucleotide complex. Upon addition of DNA polymerase to this mixture, a strand of DNA identical to the template except for the mutated bases is generated. In addition, this new strand of DNA
35 will contain dCTP-(aS) instead of dCTP, which serves to protect it from restriction endonuclease digestion. After the template strand of the double-stranded heteroduplex is nicked with an appropriate restriction enzyme, the template strand can be digested with *ExoIII* nuclease or another appropriate nuclease past the region that contains the site(s) to be mutagenized. The reaction is then stopped to leave a molecule that is only partially single-stranded. A complete double-stranded DNA homoduplex is
40 then formed using DNA polymerase in the presence of all four deoxyribonucleotide triphosphates, ATP,

and DNA ligase. This homoduplex molecule can then be transformed into a suitable host cell such as *E. coli* JM101, as described above.

DNA encoding heregulin mutants with more than one amino acid to be substituted may be generated in one of several ways. If the amino acids are located close together in the polypeptide chain, they may be mutated simultaneously using one oligonucleotide that codes for all of the desired amino acid substitutions. If, however, the amino acids are located some distance from each other (separated by more than about ten amino acids), it is more difficult to generate a single oligonucleotide that encodes all of the desired changes. Instead, one of two alternative methods may be employed.

In the first method, a separate oligonucleotide is generated for each amino acid to be substituted. The oligonucleotides are then annealed to the single-stranded template DNA simultaneously, and the second strand of DNA that is synthesized from the template will encode all of the desired amino acid substitutions.

The alternative method involves two or more rounds of mutagenesis to produce the desired mutant. The first round is as described for the single mutants: wild-type DNA is used for the template, an oligonucleotide encoding the first desired amino acid substitution(s) is annealed to this template, and the heteroduplex DNA molecule is then generated. The second round of mutagenesis utilizes the mutated DNA produced in the first round of mutagenesis as the template. Thus, this template already contains one or more mutations. The oligonucleotide encoding the additional desired amino acid substitution(s) is then annealed to this template, and the resulting strand of DNA now encodes mutations from both the first and second rounds of mutagenesis. This resultant DNA can be used as a template in a third round of mutagenesis, and so on.

PCR mutagenesis is also suitable for making amino acid variants of heregulin. While the following discussion refers to DNA, it is understood that the technique also finds application with RNA. The PCR technique generally refers to the following procedure (see Erlich, *supra*, the chapter by R. Higuchi, p. 61-70). When small amounts of template DNA are used as starting material in a PCR, primers that differ slightly in sequence from the corresponding region in a template DNA can be used to generate relatively large quantities of a specific DNA fragment that differs from the template sequence only at the positions where the primers differ from the template. For introduction of a mutation into a plasmid DNA, one of the primers is designed to overlap the position of the mutation and to contain the mutation; the sequence of the other primer must be identical to a stretch of sequence of the opposite strand of the plasmid, but this sequence can be located anywhere along the plasmid DNA. It is preferred, however, that the sequence of the second primer is located within 200 nucleotides from that of the first, such that in the end the entire amplified region of DNA bounded by the primers can be easily sequenced. PCR amplification using a primer pair like the one just described results in a population of DNA fragments that differ at the position of the mutation specified by the primer, and possibly at other positions, as template copying is somewhat error-prone.

If the ratio of template to product material is extremely low, the vast majority of product DNA fragments incorporate the desired mutation(s). This product material is used to replace the corresponding region in the plasmid that served as PCR template using standard DNA technology. Mutations at separate positions can be introduced simultaneously by either using a mutant second

primer, or performing a second PCR with different mutant primers and ligating the two resulting PCR fragments simultaneously to the vector fragment in a three (or more)-part ligation.

In a specific example of PCR mutagenesis, template plasmid DNA (1mg) is linearized by digestion with a restriction endonuclease that has a unique recognition site in the plasmid DNA outside of the region to be amplified. Of this material, 100 ng is added to a PCR mixture containing PCR buffer, which contains the four deoxynucleotide tri-phosphates and is included in the GENEAMP kits (obtained from Perkin-Elmer Cetus, Norwalk, CT and Emeryville, CA), and 25 pmole of each oligonucleotide primer, to a final volume of 50 µl. The reaction mixture is overlaid with 35 µl mineral oil. The reaction is denatured for 5 minutes at 100°C, placed briefly on ice, and then 1 µl *Thermus aquaticus* (Taq) DNA polymerase (5 units/ml, purchased from Perkin-Elmer Cetus, Norwalk, CT and Emeryville, CA) is added below the mineral oil layer. The reaction mixture is then inserted into a DNA Thermal Cycler (purchased from Perkin-Elmer Cetus) programmed as follows:

2 min. 55°C,
30 sec. 72°C, then 19 cycles of the following:
30 sec. 94°C,
30 sec. 55°C, and
30 sec. 72°C.

At the end of the program, the reaction vial is removed from the thermal cycler and the aqueous phase transferred to a new vial, extracted with phenol/chloroform (50:50:vol), and ethanol precipitated, and the DNA is recovered by standard procedures. This material is subsequently subjected to the appropriate treatments for insertion into a vector.

Another method for preparing variants, cassette mutagenesis, is based on the technique described by Wells *et al.* (*Gene*, 34: 315,1985). The starting material is the plasmid (or other vector) comprising heregulin DNA to be mutated. The codon(s) in heregulin DNA to be mutated are identified. There must be a unique restriction endonuclease site on each side of the identified mutation site(s). If no such restriction sites exist, they may be generated using the above-described oligonucleotide-mediated mutagenesis method to introduce them at appropriate locations in heregulin DNA. After the restriction sites have been introduced into the plasmid, the plasmid is cut at these sites to linearize it. A double-stranded oligonucleotide encoding the sequence of the DNA between the restriction sites but containing the desired mutation(s) is synthesized using standard procedures. The two strands are synthesized separately and then hybridized together using standard techniques. This double-stranded oligonucleotide is referred to as the cassette. This cassette is designed to have 3' and 5' ends that are compatible with the ends of the linearized plasmid, such that it can be directly ligated to the plasmid. This plasmid now contains the mutated heregulin DNA sequence.

C. Insertion of DNA into a Cloning Vehicle

The cDNA or genomic DNA encoding native or variant heregulin is inserted into a replicable vector for further cloning (amplification of the DNA) or for expression. Many vectors are available, and selection of the appropriate vector will depend on 1) whether it is to be used for DNA amplification or for DNA expression, 2) the size of the DNA to be inserted into the vector, and 3) the host cell to be transformed with the vector. Each vector contains various components depending on its function (amplification of DNA or expression of DNA) and the host cell for which it is compatible. The vector

components generally include, but are not limited to, one or more of the following: a signal sequence, an origin of replication, one or more marker genes, an enhancer element, a promoter, and a transcription termination sequence.

(i) Signal Sequence Component

5 In general, the signal sequence may be a component of the vector, or it may be a part of heregulin DNA that is inserted into the vector. The native heregulin DNA is believed to encode a signal sequence at the amino terminus (5' end of the DNA encoding heregulin) of the polypeptide that is cleaved during post-translational processing of the polypeptide to form the mature heregulin polypeptide ligand that binds to the HER2/HER3 receptor, although a conventional signal structure is not apparent.

10 Native heregulin is, secreted from the cell but remains lodged in the membrane because it contains a transmembrane domain and a cytoplasmic region in the carboxyl terminal region of the polypeptide. Thus, in a secreted, soluble version of heregulin the carboxyl terminal domain of the molecule, including the transmembrane domain, is ordinarily deleted. This truncated variant heregulin polypeptide may be secreted from the cell, provided that the DNA encoding the truncated variant encodes a signal

15 sequence recognized by the host.

Heregulin of this invention may be expressed not only directly, but also as a fusion with a heterologous polypeptide, preferably a signal sequence or other polypeptide having a specific cleavage site at the N-and/or C-terminus of the mature protein or polypeptide. In general, the signal sequence may be a component of the vector, or it may be a part of heregulin DNA that is inserted into the vector.

20 Included within the scope of this invention are heregulin with the native signal sequence deleted and replaced with a heterologous signal sequence. The heterologous signal sequence selected should be one that is recognized and processed, i.e., cleaved by a signal peptidase, by the host cell. For prokaryotic host cells that do not recognize and process the native heregulin signal sequence, the signal sequence is substituted by a prokaryotic signal sequence selected, for example, from the group

25 of the alkaline phosphatase, penicillinase, lpp, or heat-stable enterotoxin II leaders. For yeast secretion the native heregulin signal sequence may be substituted by the yeast invertase, alpha factor, or acid phosphatase leaders. In mammalian cell expression the native signal sequence is satisfactory, although other mammalian signal sequences may be suitable.

(ii) Origin of Replication Component

30 Both expression and cloning vectors generally contain a nucleic acid sequence that enables the vector to replicate in one or more selected host cells. Generally, in cloning vectors this sequence is one that enables the vector to replicate independently of the host chromosomal DNA, and includes origins of replication or autonomously replicating sequences. Such sequences are well known for a variety of bacteria, yeast, and viruses. The origin of replication from the plasmid pBR322 is suitable for most

35 Gram-negative bacteria, the 2m plasmid origin is suitable for yeast, and various viral origins (SV40, polyoma, adenovirus, VSV or BPV) are useful for cloning vectors in mammalian cells. Generally, the origin of replication component is not needed for mammalian expression vectors (the SV40 origin may typically be used only because it contains the early promoter).

Most expression vectors are "shuttle" vectors, i.e., they are capable of replication in at least one

40 class of organisms but can be transfected into another organism for expression. For example, a vector

is cloned in *E. coli* and then the same vector is transfected into yeast or mammalian cells for expression even though it is not capable of replicating independently of the host cell chromosome.

DNA may also be amplified by insertion into the host genome. This is readily accomplished using *Bacillus* species as hosts, for example, by including in the vector a DNA sequence that is complementary to a sequence found in *Bacillus* genomic DNA. Transfection of *Bacillus* with this vector results in homologous recombination with the genome and insertion of heregulin DNA. However, the recovery of genomic DNA encoding heregulin is more complex than that of an exogenously replicated vector because restriction enzyme digestion is required to excise heregulin DNA. DNA can be amplified by PCR and directly transfected into the host cells without any replication component.

10 (iii) Selection Gene Component

Expression and cloning vectors should contain a selection gene, also termed a selectable marker. This gene encodes a protein necessary for the survival or growth of transformed host cells grown in a selective culture medium. Host cells not transformed with the vector containing the selection gene will not survive in the culture medium. Typical selection genes encode proteins that (a) confer resistance to antibiotics or other toxins, e.g., ampicillin, neomycin, methotrexate, or tetracycline, (b) complement auxotrophic deficiencies, or (c) supply critical nutrients not available from complex media, e.g., the gene encoding D-alanine racemase for *Bacilli*.

One example of a selection scheme utilizes a drug to arrest growth of a host cell. Those cells that are successfully transformed with a heterologous gene express a protein conferring drug resistance and thus survive the selection regimen. Examples of such dominant selection use the drugs neomycin (Southern *et al.*, *J. Molec. Appl. Genet.* 1: 327, 1982), mycophenolic acid (Mulligan *et al.*, *Science* 209: 1422, 1980) or hygromycin (Sugden *et al.*, *Mol. Cell. Biol.* 5: 410-413, 1985). The three examples given above employ bacterial genes under eukaryotic control to convey resistance to the appropriate drug G418 or neomycin (geneticin), xgpt (mycophenolic acid), or hygromycin, respectively.

Another example of suitable selectable markers for mammalian cells are those that enable the identification of cells competent to take up heregulin nucleic acid, such as dihydrofolate reductase (DHFR) or thymidine kinase. The mammalian cell transformants are placed under selection pressure which only the transformants are uniquely adapted to survive by virtue of having taken up the marker. Selection pressure is imposed by culturing the transformants under conditions in which the concentration of selection agent in the medium is successively changed, thereby leading to amplification of both the selection gene and the DNA that encodes heregulin. Amplification is the process by which genes in greater demand for the production of a protein critical for growth are reiterated in tandem within the chromosomes of successive generations of recombinant cells. Increased quantities of heregulin are synthesized from the amplified DNA.

For example, cells transformed with the DHFR selection gene are first identified by culturing all of the transformants in a culture medium that contains methotrexate (Mtx), a competitive antagonist of DHFR. An appropriate host cell when wild-type DHFR is employed is the Chinese hamster ovary (CHO) cell line deficient in DHFR activity, prepared and propagated as described by Urlaub and Chasin, *Proc. Natl. Acad. Sci. USA*, 77: 4216, 1980. The transformed cells are then exposed to increased levels of methotrexate. This leads to the synthesis of multiple copies of the DHFR gene, and, concomitantly, multiple copies of other DNA comprising the expression vectors, such as the DNA

encoding heregulin. This amplification technique can be used with any otherwise suitable host, e.g., ATCC No. CCL61 CHO-K1, notwithstanding the presence of endogenous DHFR if, for example, a mutant DHFR gene that is highly resistant to Mtx is employed (EP 117,060). Alternatively, host cells (particularly wild-type hosts that contain endogenous DHFR) transformed or co-transformed with DNA sequences encoding heregulin, wild-type DHFR protein, and another selectable marker such as aminoglycoside 3' phosphotransferase (APH) can be selected by cell growth in medium containing a selection agent for the selectable marker such as an aminoglycosidic antibiotic, e.g., kanamycin, neomycin, or G418 (see U.S. Pat. No. 4,965,199).

A suitable selection gene for use in yeast is the *trp1* gene present in the yeast plasmid YRp7 (Stinchcomb *et al.*, *Nature*, 282: 39, 1979; Kingsman *et al.*, *Gene*, 7: 141, 1979; or Tschemper *et al.*, *Gene*, 10: 157, 1980). The *trp1* gene provides a selection marker for a mutant strain of yeast lacking the ability to grow in tryptophan, for example, ATCC No. 44076 or PEP4-1 (Jones, *Genetics*, 85: 12, 1977). The presence of the *trp1* lesion in the yeast host cell genome then provides an effective environment for detecting transformation by growth in the absence of tryptophan. Similarly, *Leu2*-deficient yeast strains (ATCC 20,622 or 38,626) are complemented by known plasmids bearing the *Leu2* gene.

(iv) Promoter Component

Expression and cloning vectors usually contain a promoter that is recognized by the host organism and is operably linked to heregulin nucleic acid. Promoters are untranslated sequences located upstream (5') to the start codon of a structural gene (generally within about 100 to 1000 bp) that control the transcription and translation of a particular nucleic acid sequence, such as heregulin to which they are operably linked. Such promoters typically fall into two classes, inducible and constitutive. Inducible promoters are promoters that initiate increased levels of transcription from DNA under their control in response to some change in culture conditions, e.g., the presence or absence of a nutrient or a change in temperature. At this time a large number of promoters recognized by a variety of potential host cells are well known. These promoters are operably linked to DNA encoding heregulin by removing the promoter from the source DNA by restriction enzyme digestion and inserting the isolated promoter sequence into the vector. Both the native heregulin promoter sequence and many heterologous promoters may be used to direct amplification and/or expression of heregulin DNA. However, heterologous promoters are preferred, as they generally permit greater transcription and higher yields of expressed heregulin as compared to the native heregulin promoter.

Promoters suitable for use with prokaryotic hosts include the b-lactamase and lactose promoter systems (Chang *et al.*, *Nature*, 275: 615, 1978; and Goeddel *et al.*, *Nature* 281: 544, 1979), alkaline phosphatase, a tryptophan (*trp*) promoter system (Goeddel, *Nucleic Acids Res.*, 8: 4057, 1980 and EP 36,776), tPA (U.S. 5,641,655) and hybrid promoters such as the tac promoter (deBoer *et al.*, *Proc. Natl. Acad. Sci. USA* 80: 21-25, 1983). However, other known bacterial promoters are suitable. Their nucleotide sequences have been published, thereby enabling a skilled worker operably to ligate them to DNA encoding heregulin (Siebenlist *et al.*, *Cell* 20: 269, 1980) using linkers or adaptors to supply any required restriction sites. Promoters for use in bacterial systems also generally will contain a Shine-Dalgarno (S.D.) sequence operably linked to the DNA encoding heregulin.

Suitable promoting sequences for use with yeast hosts include the promoters for 3-phosphoglycerate kinase (Hitzeman *et al.*, *J. Biol. Chem.*, 255: 2073, 1980) or other glycolytic enzymes (Hess *et al.*, *J. Adv. Enzyme Reg* 7: 149, 1968; and Holland, *Biochemistry* 17: 4900, 1978), such as enolase, glyceraldehyde-3-phosphate dehydrogenase, hexokinase, pyruvate decarboxylase, phosphofructokinase, glucose-6-phosphate isomerase, 3-phosphoglycerate mutase, pyruvate kinase, triosephosphate isomerase, phosphoglucose isomerase, and glucokinase.

Other yeast promoters, which are inducible promoters having the additional advantage of transcription controlled by growth conditions, are the promoter regions for alcohol dehydrogenase 2, isocytochrome C, acid phosphatase, degradative enzymes associated with nitrogen metabolism, metallothionein, glyceraldehyde-3-phosphate dehydrogenase, and enzymes responsible for maltose and galactose utilization. Suitable vectors and promoters for use in yeast expression are further described in Hitzeman *et al.*, EP 73,657A. Yeast enhancers also are advantageously used with yeast promoters.

Promoter sequences are known for eukaryotes. Virtually all eukaryotic genes have an AT-rich region located approximately 25 to 30 bases upstream from the site where transcription is initiated. Another sequence found 70 to 80 bases upstream from the start of transcription of many genes is a CXCAAT region where X may be any nucleotide. At the 3' end of most eukaryotic genes is an AATAAA sequence that may be the signal for addition of the poly A tail to the 3' end of the coding sequence. All of these sequences are suitably inserted into mammalian expression vectors.

Heregulin gene transcription from vectors in mammalian host cells may be controlled by promoters obtained from the genomes of viruses such as polyoma virus, fowlpox virus (UK 2,211,504, published 5 July 1989), adenovirus (such as Adenovirus 2), bovine papilloma virus, avian sarcoma virus, cytomegalovirus, a retrovirus, hepatitis-B virus and most preferably Simian Virus 40 (SV40), from heterologous mammalian promoters, e.g., the actin promoter or an immunoglobulin promoter, from heat-shock promoters, and from the promoter normally associated with heregulin sequence, provided such promoters are compatible with the host cell systems.

The early and late promoters of the SV40 virus are conveniently obtained as an SV40 restriction fragment that also contains the SV40 viral origin of replication (Fiers *et al.*, *Nature*, 273:113 (1978); Mulligan and Berg, *Science*, 209: 1422-1427 (1980); Pavlakis *et al.*, *Proc. Natl. Acad. Sci. USA*, 78: 7398-7402 (1981)). The immediate early promoter of the human cytomegalovirus is conveniently obtained as a *Hind*III E restriction fragment (Greenaway *et al.*, *Gene*, 18: 355-360 (1982)). A system for expressing DNA in mammalian hosts using the bovine papilloma virus as a vector is disclosed in U.S. 4,419,446. A modification of this system is described in U.S. 4,601,978. See also Gray *et al.*, *Nature*, 295: 503-508 (1982) on expressing cDNA encoding immune interferon in monkey cells; Reyes *et al.*, *Nature*, 297: 598-601 (1982) on expression of human b-interferon cDNA in mouse cells under the control of a thymidine kinase promoter from herpes simplex virus; Canaani and Berg, *Proc. Natl. Acad. Sci. USA*, 79: 5166-5170 (1982) on expression of the human interferon b1 gene in cultured mouse and rabbit cells; and Gorman *et al.*, *Proc. Natl. Acad. Sci. USA*, 79: 6777-6781 (1982) on expression of bacterial CAT sequences in CV-1 monkey kidney cells, chicken embryo fibroblasts, Chinese hamster ovary cells, HeLa cells, and mouse NIH-3T3 cells using the Rous sarcoma virus long terminal repeat as a promoter.

(v) Enhancer Element Component

Transcription of a DNA encoding heregulin of this invention by higher eukaryotes is often increased by inserting an enhancer sequence into the vector. Enhancers are cis-acting elements of DNA, usually about from 10-300 bp, that act on a promoter to increase its transcription. Enhancers are relatively orientation and position independent having been found 5' (Laimins *et al.*, *Proc. Natl. Acad. Sci. USA*, 78: 993, 1981) and 3' (Lusky *et al.*, *Mol. Cell Bio.*, 3: 1108, 1983) to the transcription unit, within an intron (Banerji *et al.*, *Cell*, 33: 729, 1983) as well as within the coding sequence itself (Osborne *et al.*, *Mol. Cell Bio.*, 4: 1293, 1984). Many enhancer sequences are now known from mammalian genes (globin, elastase, albumin, a-fetoprotein and insulin). Typically, however, one will use an enhancer from a eukaryotic cell virus. Examples include the SV40 enhancer on the late side of the replication origin (bp 100-270), the cytomegalovirus early promoter enhancer, the polyoma enhancer on the late side of the replication origin, and adenovirus enhancers (see also Yaniv, *Nature*, 297: 17-18 (1982)) on enhancing elements for activation of eukaryotic promoters. The enhancer may be spliced into the vector at a position 5' or 3' to heregulin DNA, but is preferably located at a site 5' from the promoter.

(vi) Transcription Termination Component

Expression vectors used in eukaryotic host cells (yeast, fungi, insect, plant, animal, human, or nucleated cells from other multicellular organisms) will also contain sequences necessary for the termination of transcription and for stabilizing the mRNA. Such sequences are commonly available from the 5' and, occasionally 3' untranslated regions of eukaryotic or viral DNAs or cDNAs. These regions contain nucleotide segments transcribed as polyadenylated fragments in the untranslated portion of the mRNA encoding heregulin. The 3' untranslated regions also include transcription termination sites.

Construction of suitable vectors containing one or more of the above listed components the desired coding and control sequences employs standard ligation techniques. Isolated plasmids or DNA fragments are cleaved, tailored, and religated in the form desired to generate the plasmids required.

For analysis to confirm correct sequences in plasmids constructed, the ligation mixtures are used to transform *E. coli* K12 strain 294 (ATCC 31,446) and successful transformants selected by ampicillin or tetracycline resistance where appropriate. Plasmids from the transformants are prepared, analyzed by restriction endonuclease digestion, and/or sequenced by the method of Messing *et al.*, *Nucleic Acids Res.* 9: 309 (1981) or by the method of Maxam *et al.*, *Methods in Enzymology* 65: 499 (1980).

Particularly useful in the practice of this invention are expression vectors that provide for the transient expression in mammalian cells of DNA encoding heregulin. In general, transient expression involves the use of an expression vector that is able to replicate efficiently in a host cell, such that the host cell accumulates many copies of the expression vector and, in turn, synthesizes high levels of a desired polypeptide encoded by the expression vector. Transient expression systems, comprising a suitable expression vector and a host cell, allow for the convenient positive identification of polypeptides encoded by cloned DNAs, as well as for the rapid screening of such polypeptides for desired biological or physiological properties. Thus, transient expression systems are particularly useful in the invention

for purposes of identifying analogs and variants of heregulin that have heregulin-like activity. Such a transient expression system is described in U.S. 5,024,939.

Other methods, vectors, and host cells suitable for adaptation to the synthesis of heregulin in recombinant vertebrate cell culture are described in Gething *et al.*, *Nature* 293: 620-625, 1981; Mantei *et al.*, *Nature*, 281: 40-46, 1979; Levinson *et al.*, EP 117,060 and EP 117,058. A particularly useful expression plasmid for mammalian cell culture expression of heregulin is pRK5 (EP pub. no. 307,247) or pSV16B (U.S. Ser. No. 07/441,574, filed 22 November 1989, the disclosure of which is incorporated herein by reference).

D. Selection and Transformation of Host Cells

Suitable host cells for cloning or expressing the vectors herein are the prokaryote, yeast, or higher eukaryote cells described above. Suitable prokaryotes include eubacteria, such as Gram-negative or Gram-positive organisms, for example, *E. coli*, *Bacilli* such as *B. subtilis*, *Pseudomonas* species such as *P. aeruginosa*, *Salmonella typhimurium*, or *Serratia marcescans*. One preferred *E. coli* cloning host is *E. coli* 294 (ATCC 31,446), although other strains such as *E. coli* B, *E. coli* x1776 (ATCC 31,537), and *E. coli* W3110 (ATCC 27,325) are suitable. These examples are illustrative rather than limiting. Preferably the host cell should secrete minimal amounts of proteolytic enzymes. Alternatively, *in vitro* methods of cloning, e.g., PCR or other nucleic acid polymerase reactions, are suitable.

In addition to prokaryotes, eukaryotic microbes such as filamentous fungi or yeast are suitable hosts for heregulin-encoding vectors. *Saccharomyces cerevisiae*, or common baker's yeast, is the most commonly used among lower eukaryotic host microorganisms. However, a number of other genera, species, and strains are commonly available and useful herein, such as *Schizosaccharomyces pombe* (Beach and Nurse, *Nature*, 290: 140 (1981); EP 139,383, published May 2, 1985), *Kluyveromyces* hosts (U.S.S.N. 4,943,529) such as, e.g., *K. lactis* (Louvencourt *et al.*, *J. Bacteriol.*, 737 (1983); *K. fragilis*, *K. bulgaricus*, *K. thermotolerans*, and *K. marxianus*, *yarrowia* (EP 402,226); *Pichia pastoris* (EP 183,070), Sreekrishna *et al.*, *J. Basic Microbiol.*, 28: 265-278 (1988); *Candida*, *Trichoderma reesia* (EP 244,234); *Neurospora crassa* (Case *et al.*, *Proc. Natl. Acad. Sci. USA*, 76: 5259-5263 (1979), and filamentous fungi such as, e.g., *Neurospora*, *Penicillium*, *Tolypocladium* (WO 91/00357, published 10 January 1991), and *Aspergillus* hosts such as *A. nidulans* (Ballance *et al.*, *Biochem. Biophys. Res. Commun.*, 112: 284-289 (1983); Tilburn *et al.*, *Gene*, 26: 205-221 (1983); Yelton *et al.*, *Proc. Natl. Acad. Sci. USA*, 81: 1470-1474 (1984) and *A. niger* (Kelly and Hynes, *EMBO J.*, 4: 475-479 (1985)).

Suitable host cells for the expression of glycosylated heregulin polypeptide are derived from multicellular organisms. Such host cells are capable of complex processing and glycosylation activities. In principle, any higher eukaryotic cell culture is workable, whether from vertebrate or invertebrate culture. Examples of invertebrate cells include plant and insect cells. Numerous baculoviral strains and variants and corresponding permissive insect host cells from hosts such as *Spodoptera frugiperda* (caterpillar), *Aedes aegypti* (mosquito), *Aedes albopictus* (mosquito), *Drosophila melanogaster* (fruitfly), and *Bombyx mori* host cells have been identified (see, e.g., Luckow *et al.*, *BioTechnology*, 6: 47-55 (1988); Miller *et al.*, in *Genetic Engineering*, Setlow, J.K. *et al.*, eds., Vol. 8 (Plenum Publishing, 1986), pp. 277-279; and Maeda *et al.*, *Nature*, 315: 592-594 (1985)). A variety of such viral strains are publicly available, e.g., the L-1 variant of *Autographa californica* NPV and the Bm-5 strain of *Bombyx mori* NPV,

and such viruses may be used as the virus her in according to the present invention, particularly for transfection of *Spodoptera frugiperda* cells. Plant cell cultures of cotton, corn, potato, soybean, petunia, tomato, and tobacco can be utilized as hosts. Typically, plant cells are transfected by incubation with certain strains of the bacterium *Agrobacterium tumefaciens*, which has been previously manipulated to contain heregulin DNA. During incubation of the plant cell culture with *A. tumefaciens*, the DNA encoding heregulin is transferred to the plant cell host such that it is transfected, and will, under appropriate conditions, express heregulin DNA. In addition, regulatory and signal sequences compatible with plant cells are available, such as the nopaline synthase promoter and polyadenylation signal sequences (Depicker *et al.*, *J. Mol. Appl. Gen.*, 1: 561 (1982)). In addition, DNA segments isolated from the upstream region of the T-DNA 780 gene are capable of activating or increasing transcription levels of plant-expressible genes in recombinant DNA-containing plant tissue (see EP 321,196, published 21 June 1989).

However, interest has been greatest in vertebrate cells, and propagation of vertebrate cells in culture (tissue culture) has become a routine procedure in recent years (*Tissue Culture*, Academic Press, Kruse and Patterson, editors (1973)). Examples of useful mammalian host cell lines are monkey kidney CV1 line transformed by SV40 (COS-7, ATCC CRL 1651); human embryonic kidney line (293 or 293 cells subcloned for growth in suspension culture, Graham *et al.*, *J. Gen Virol.*, 36: 59, 1977); baby hamster kidney cells (BHK, ATCC CCL 10); Chinese hamster ovary cells/DHFR (CHO, Urlaub and Chasin, *Proc. Natl. Acad. Sci. USA*, 77: 4216 (1980)); mouse sertoli cells (TM4, Mather, *Biol. Reprod.*, 23: 243-251 (1980)); monkey kidney cells (CV1 ATCC CCL 70); African green monkey kidney cells (VERO-76, ATCC CRL-1587); human cervical carcinoma cells (HELA, ATCC CCL 2); canine kidney cells (MDCK, ATCC CCL 34); buffalo rat liver cells (BRL 3A, ATCC CRL 1442); human lung cells (W138, ATCC CCL 75); human liver cells (Hep G2, HB 8065); mouse mammary tumor (MMT 060562, ATCC CCL51); TRI cells (Mather *et al.*, *Annals N.Y. Acad. Sci.*, 383: 44-68 (1982)); MRC 5 cells; FS4 cells; and a human hepatoma cell line (Hep G2). Preferred host cells are human embryonic kidney 293 and Chinese hamster ovary cells.

Host cells are transfected and preferably transformed with the above-described expression or cloning vectors of this invention and cultured in conventional nutrient media modified as appropriate for inducing promoters, selecting transformants, or amplifying the genes encoding the desired sequences.

Transfection refers to the taking up of an expression vector by a host cell whether or not any coding sequences are in fact expressed. Numerous methods of transfection are known to the ordinarily skilled artisan, for example, CaPO_4 and electroporation. Successful transfection is generally recognized when any indication of the operation of this vector occurs within the host cell.

Transformation means introducing DNA into an organism so that the DNA is replicable, either as an extrachromosomal element or by chromosomal integration. Depending on the host cell used, transformation is done using standard techniques appropriate to such cells. The calcium treatment employing calcium chloride, as described in section 1.82 of Sambrook *et al.*, *supra*, is generally used for prokaryotes or other cells that contain substantial cell-wall barriers. Infection with *Agrobacterium tumefaciens* is used for transformation of certain plant cells, as described by Shaw *et al.*, *Gene*, 23: 315 (1983) and WO 89/05859, published 29 June 1989. For mammalian cells without such cell walls, the calcium phosphate precipitation method described in sections 16.30-16.37 of Sambrook *et al.*, *supra*, is

preferred. General aspects of mammalian cell host system transformations have been described by Axel in U.S. 4,399,216, issued 16 August 1983. Transformations into yeast are typically carried out according to the method of Van Solingen *et al.*, *J. Bact.*, 130: 946 (1977) and Hsiao *et al.*, *Proc. Natl. Acad. Sci. (USA)*, 76: 3829 (1979). However, other methods for introducing DNA into cells such as by
5 nuclear injection, electroporation, or protoplast fusion may also be used.

E. Culturing the Host Cells

Prokaryotic cells used to produce heregulin polypeptide of this invention are cultured in suitable media as described generally in Sambrook *et al.*, *supra*.

The mammalian host cells used to produce heregulin of this invention may be cultured in a
10 variety of media. Commercially available media such as Ham's F10 (Sigma), Minimal Essential Medium ((MEM), Sigma), RPMI-1640 (Sigma), and Dulbecco's Modified Eagle's Medium ((DMEM), Sigma) are suitable for culturing the host cells. In addition, any of the media described in Ham and Wallace, *Meth. Enz.*, 58: 44 (1979), Barnes and Sato, *Anal. Biochem.*, 102: 255 (1980), U.S. 4,767,704; 4,657,866; 4,927,762; or 4,560,655; WO 90/03430; WO 87/00195; U.S. Pat. Re. 30,985; U.S. 5,122,469 or USSN
15 07/592,141, filed on 3 October 1990, the disclosures of all of which are incorporated herein by reference, may be used as culture media for the host cells. Any of these media may be supplemented as necessary with hormones and/or other growth factors (such as insulin, transferrin, or epidermal growth factor), salts (such as sodium chloride, calcium, magnesium, and phosphate), buffers (such as HEPES), nucleosides (such as adenosine and thymidine), antibiotics (such as GENTAMYCIN drug),
20 trace elements (defined as inorganic compounds usually present at final concentrations in the micromolar range), and glucose or an equivalent energy source. Any other necessary supplements may also be included at appropriate concentrations that would be known to those skilled in the art. The culture conditions, such as temperature, pH, and the like, are those previously used with the host cell selected for expression, and will be apparent to the ordinarily skilled artisan.

25 The host cells referred to in this disclosure encompass cells in *in vitro* culture as well as cells that are within a host animal.

It is further envisioned that heregulin of this invention may be produced by homologous recombination, or with recombinant production methods utilizing control elements introduced into cells already containing DNA encoding heregulin currently in use in the field. For example, a powerful
30 promoter/enhancer element, a suppresser, or an exogenous transcription modulatory element is inserted in the genome of the intended host cell in proximity and orientation sufficient to influence the transcription of DNA encoding the desired heregulin. The control element does not encode heregulin of this invention, but the DNA is present in the host cell genome. One next screens for cells making heregulin of this invention, or increased or decreased levels of expression, as desired.

35 F. Detecting Gene Amplification/Expression

Gene amplification and/or expression may be measured in a sample directly, for example, by conventional Southern blotting, Northern blotting to quantitate the transcription of mRNA (Thomas, *Proc. Natl. Acad. Sci. USA*, 77: 5201-5205 (1980)), dot blotting (DNA analysis), or *in situ* hybridization, using an appropriately labeled probe based on the sequences provided herein. Various labels may be
40 employed, most commonly radioisotopes, particularly ³²P. However, other techniques may also be employed, such as using biotin-modified nucleotides for introduction into a polynucleotide. The biotin

then serves as the site for binding to avidin or antibodies which may be labeled with a wide variety of labels, such as radionuclides, fluorescers, enzymes, or the like. Alternatively, antibodies may be employed that can recognize specific duplexes, including DNA duplexes, RNA duplexes, and DNA-RNA hybrid duplexes or DNA-protein duplexes. The antibodies in turn may be labeled and the assay may be carried out where the duplex is bound to a surface, so that upon the formation of duplex on the surface, the presence of antibody bound to the duplex can be detected.

Gene expression, alternatively, may be measured by immunological methods, such as immunohistochemical staining of tissue sections and assay of cell culture or body fluids, to quantitate directly the expression of gene product. With immunohistochemical staining techniques, a cell sample is prepared, typically by dehydration and fixation, followed by reaction with labeled antibodies specific for the gene product coupled where the labels are usually visually detectable such as enzymatic labels, fluorescent labels, luminescent labels, and the like. A particularly sensitive staining technique suitable for use in the present invention is described by Hsu *et al.*, *Am. J. Clin. Path.*, 75: 734-738 (1980).

Antibodies useful for immunohistochemical staining and/or assay of sample fluids may be either monoclonal or polyclonal, and may be prepared in any mammal. Conveniently, the antibodies may be prepared against a native heregulin polypeptide or against a synthetic peptide based on the DNA sequences provided herein as described further below.

G. Purification of The Heregulin Polypeptides

Heregulin is recovered from a cellular membrane fraction. Alternatively, a proteolytically cleaved or a truncated expressed soluble heregulin fragment or subdomain are recovered from the culture medium as a soluble polypeptide. A heregulin is recovered from host cell lysates when directly expressed without a secretory signal.

When heregulin is expressed in a recombinant cell other than one of human origin, heregulin is completely free of proteins or polypeptides of human origin. However, it is desirable to purify heregulin from recombinant cell proteins or polypeptides to obtain preparations that are substantially homogeneous as to heregulin. As a first step, the culture medium or lysate is centrifuged to remove particulate cell debris. The membrane and soluble protein fractions are then separated. Heregulin is then be purified from both the soluble protein fraction (requiring the presence of a protease) and from the membrane fraction of the culture lysate, depending on whether heregulin is membrane bound. The following procedures are exemplary of suitable purification procedures: fractionation on immunoaffinity or ion-exchange columns; ethanol precipitation; reverse phase HPLC; chromatography on silica, heparin SEPHAROSE or on a cation exchange resin such as DEAE; chromatofocusing; SDS-PAGE; ammonium sulfate precipitation; and gel filtration using, for example, SEPHADEX G-75.

Heregulin variants in which residues have been deleted, inserted or substituted are recovered in the same fashion as the native heregulin, taking account of any substantial changes in properties occasioned by the variation. For example, preparation of a heregulin fusion with another protein or polypeptide, e.g., a bacterial or viral antigen, facilitates purification; an immunoaffinity column containing antibody to the antigen can be used to adsorb the fusion. Immunoaffinity columns such as a rabbit polyclonal anti-heregulin column can be employed to absorb heregulin variant by binding it to at least one remaining immune epitope. A protease inhibitor such as phenylmethylsulfonylfluoride (PMSF) also may be useful to inhibit proteolytic degradation during purification, and antibiotics may be included to

prevent the growth of adventitious contaminants. One skilled in the art will appreciate that purification methods suitable for native heregulin may require modification to account for changes in the character of heregulin variants or upon expression in recombinant cell culture.

H. Covalent Modifications of Heregulin

5 Covalent modifications of heregulin polypeptides are included within the scope of this invention. Both native heregulin and amino acid sequence variants of heregulin optionally are covalently modified. One type of covalent modification included within the scope of this invention is a heregulin polypeptide fragment. Heregulin fragments, such as HRG-GDF, having up to about 40 amino acid residues are conveniently prepared by chemical synthesis, or by enzymatic or chemical cleavage of the full-length
10 heregulin polypeptide or heregulin variant polypeptide. Other types of covalent modifications of heregulin or fragments thereof are introduced into the molecule by reacting targeted amino acid residues of heregulin or fragments thereof with an organic derivatizing agent that is capable of reacting with selected side chains or the N- or C-terminal residues.

Cysteinyl residues most commonly are reacted with α -haloacetates (and corresponding
15 amines), such as chloroacetic acid or chloroacetamide, to give carboxymethyl or carboxyamidomethyl derivatives. Cysteinyl residues also are derivatized by reaction with bromotrifluoroacetone, α -bromo- β -(5-imidozoyl)propionic acid, chloroacetyl phosphate, N-alkylmaleimides, 3-nitro-2-pyridyl disulfide, methyl 2-pyridyl disulfide, p-chloromercuribenzoate, 2-chloromercuri-4-nitrophenol, or chloro-7-nitrobenzo-2-oxa-1,3-diazole.

20 Histidyl residues are derivatized by reaction with diethylpyrocarbonate at pH 5.5-7.0 because this agent is relatively specific for the histidyl side chain. Para-bromophenacyl bromide also is useful; the reaction is preferably performed in 0.1M sodium cacodylate at pH 6.0.

Lysinyl and amino terminal residues are reacted with succinic or other carboxylic acid anhydrides. Derivatization with these agents has the effect of reversing the charge of the lysinyl
25 residues. Other suitable reagents for derivatizing α -amino-containing residues include imidoesters such as methyl picolinimide; pyridoxal phosphate; pyridoxal; chloroborohydride; trinitrobenzenesulfonic acid; O-methylisourea; 2,4-pentanedione; and transaminase-catalyzed reaction with glyoxylate.

Arginyl residues are modified by reaction with one or several conventional reagents, among them phenylglyoxal, 2,3-butanedione, 1,2-cyclohexanedione, and ninhydrin. Derivatization of arginine
30 residues requires that the reaction be performed in alkaline conditions because of the high pK_a of the guanidine functional group. Furthermore, these reagents may react with the groups of lysine as well as the arginine epsilon-amino group.

The specific modification of tyrosyl residues may be made, with particular interest in introducing spectral labels into tyrosyl residues by reaction with aromatic diazonium compounds or
35 tetranitromethane. Most commonly, N-acetylimidazole and tetranitromethane are used to form O-acetyl tyrosyl species and 3-nitro derivatives, respectively. Tyrosyl residues are iodinated using ^{125}I or ^{131}I to prepare labeled proteins for use in radioimmunoassay, the chloramine T method described above being suitable.

Carboxyl side groups (aspartyl or glutamyl) are selectively modified by reaction with
40 carbodiimides ($R'-N=C=N-R'$), where R and R' are different alkyl groups, such as 1-cyclohexyl-3-(2-

morpholinyl-4-ethyl) carbodiimide or 1-ethyl-3-(4-azonia-4,4-dimethylpentyl) carbodiimide. Furthermore, aspartyl and glutamyl residues are converted to asparaginy and glutaminyl residues by reaction with ammonium ions.

Derivatization with bifunctional agents is useful for crosslinking heregulin to a water-insoluble support matrix or surface for use in a method for purifying anti-heregulin antibodies, and vice versa. Commonly used crosslinking agents include, e.g., 1,1-bis(diazoacetyl)-2-phenylethane, glutaraldehyde, N-hydroxysuccinimide esters, for example, esters with 4-azidosalicylic acid, homobifunctional imidoesters, including disuccinimidyl esters such as 3,3'-dithiobis(succinimidylpropionate), and bifunctional maleimides such as bis-N-maleimido-1,8-octane. Derivatizing agents such as methyl-3-((p-azidophenyl)dithio)propioimide yield photoactivatable intermediates that are capable of forming crosslinks in the presence of light. Alternatively, reactive water-insoluble matrices such as cyanogen bromide-activated carbohydrates and the reactive substrates described in U.S. 3,969,287; 3,691,016; 4,195,128; 4,247,642; 4,229,537; and 4,330,440 are employed for protein immobilization.

Glutaminy and asparaginy residues are frequently deamidated to the corresponding glutamyl and aspartyl residues, respectively. Alternatively, these residues are deamidated under mildly acidic conditions. Either form of these residues falls within the scope of this invention.

Other modifications include hydroxylation of proline and lysine, phosphorylation of hydroxyl groups of seryl or threonyl residues, methylation of the α -amino groups of lysine, arginine, and histidine side chains (T.E. Creighton, *Proteins: Structure and Molecular Properties*, W.H. Freeman & Co., San Francisco, pp. 79-86 (1983)), acetylation of the N-terminal amine, and amidation of any C-terminal carboxyl group.

Heregulin optionally is fused with a polypeptide heterologous to heregulin. The heterologous polypeptide optionally is an anchor sequence such as that found in a phage coat protein such as M13 gene III or gene VIII proteins. These heterologous polypeptides can be covalently coupled to heregulin polypeptide through side chains or through the terminal residues.

Heregulin may also be covalently modified by altering its native glycosylation pattern. One or more carbohydrate substituents in these embodiments, are modified by adding, removing or varying the monosaccharide components at a given site, or by modifying residues in heregulin as that glycosylation sites are added or deleted.

Glycosylation of polypeptides is typically either N-linked or O-linked. N-linked refers to the attachment of the carbohydrate moiety to the side chain of an asparagine residue. The tri-peptide sequences asparagine-X-serine and asparagine-X-threonine, where X is any amino acid except proline, are the recognition sequences for enzymatic attachment of the carbohydrate moiety to the asparagine side chain. Thus, the presence of either of these tri-peptide sequences in a polypeptide creates a potential glycosylation site. O-linked glycosylation refers to the attachment of one of the sugars N-acetylgalactosamine, galactose, or xylose, to a hydroxyamino acid, most commonly serine or threonine, although 5-hydroxyproline or 5-hydroxylysine may also be used.

Glycosylation sites are added to heregulin by altering its amino acid sequence to contain one or more of the above-described tri-peptide sequences (for N-linked glycosylation sites). The alteration may also be made by the addition of, or substitution by, one or more serine or threonine residues to heregulin (for O-linked glycosylation sites). For ease, heregulin is preferably altered through changes at

the DNA level, particularly by mutating the DNA encoding heregulin at preselected bases such that codons are generated that will translate into the desired amino acids.

Chemical or enzymatic coupling of glycosides to heregulin increases the number of carbohydrate substituents. These procedures are advantageous in that they do not require production of the polypeptide in a host cell that is capable of N- and O-linked glycosylation. Depending on the coupling mode used, the sugar(s) may be attached to (a) arginine and histidine, (b) free carboxyl groups, (c) free sulfhydryl groups such as those of cysteine, (d) free hydroxyl groups such as those of serine, threonine, or hydroxyproline, (e) aromatic residues such as those of phenylalanine, tyrosine, or tryptophan, or (f) the amide group of glutamine. These methods are described in WO 87/05330, published 11 September 1987, and in Aplin and Wriston (*CRC Crit. Rev. Biochem.*, pp. 259-306 (1981)).

Carbohydrate moieties present on an heregulin also are removed chemically or enzymatically. Chemical deglycosylation requires exposure of the polypeptide to the compound trifluoromethanesulfonic acid, or an equivalent compound. This treatment results in the cleavage of most or all sugars except the linking sugar (N-acetylglucosamine or N-acetylgalactosamine), while leaving the polypeptide intact. Chemical deglycosylation is described by Hakimuddin *et al.* (*Arch. Biochem. Biophys.*, 259:52 (1987)) and by Edge *et al.* (*Anal. Biochem.*, 118:131 (1981)). Carbohydrate moieties are removed from heregulin by a variety of endo- and exo- glycosidases as described by Thotakura *et al.* (*Meth. Enzymol.*, 138:350 (1987)).

Glycosylation also is suppressed by tunicamycin as described by Duskin *et al.* (*J. Biol. Chem.*, 257:3105 (1982)). Tunicamycin blocks the formation of protein-N-glycoside linkages.

Heregulin may also be modified by linking heregulin to various nonproteinaceous polymers, e.g., polyethylene glycol, polypropylene glycol or polyoxyalkylenes, in the manner set forth in U.S. 4,640,835; 4,496,689; 4,301,144; 4,670,417; 4,791,192 or 4,179,337.

One preferred way to increase the *in vivo* circulating half life of non-membrane bound heregulin is to conjugate it to a polymer that confers extended half-life, such as polyethylene glycol (PEG). (Maxfield, *et al.*, *Polymer* 16,505-509 (1975); Bailey, F. E., *et al.*, in *Nonionic Surfactants* (Schick, M. J., ed.) pp.794-821, 1967); (Abuchowski, A. *et al.*, *J. Biol. Chem.* 252, 3582-3586, 1977; Abuchowski, A. *et al.*, *Cancer Biochem. Biophys.* 7, 175-186, 1984); (Katre, N.V. *et al.*, *Proc. Natl. Acad. Sci.*, 84, 1487-1491, 1987; Goodson, R. *et al. Bio Technology*, 8, 343-346, 1990). Conjugation to PEG also has been reported to have reduced immunogenicity and toxicity (Abuchowski, A. *et al.*, *J. Biol. Chem.*, 252, 3578-3581, 1977).

Heregulin may also be entrapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization (for example, hydroxymethylcellulose or gelatin-microcapsules and poly-(methylmethacrylate) microcapsules, respectively), in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano-particles and nanocapsules), or in macroemulsions. Such techniques are disclosed in *Remington's Pharmaceutical Sciences*, 16th edition, Osol, A., Ed., (1980).

Those skilled in the art will be capable of screening variants in order to select the optimal variant for the purpose intended. For example, a change in the immunological character of heregulin, such as a change in affinity for a given antigen or for the HER2 receptor, is measured by a competitive-

type immunoassay using a standard or control such as a native heregulin (in particular native heregulin-GFD). Other potential modifications of protein or polypeptide properties such as redox or thermal stability, hydrophobicity, susceptibility to proteolytic degradation, stability in recombinant cell culture or in plasma, or the tendency to aggregate with carriers or into multimers are assayed by methods well known in the art.

I. Heregulin Antibody Preparation

The antibodies of this invention are obtained by routine screening and include polyclonal antibodies, monoclonal antibodies and fragments thereof.

Polyclonal antibodies are preferably raised in animals by multiple subcutaneous (sc) or intraperitoneal (ip) injections of the relevant antigen and an adjuvant. It may be useful to conjugate the relevant antigen to a protein that is immunogenic in the species to be immunized, e.g., keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, or soybean trypsin inhibitor using a bifunctional or derivatizing agent, for example, maleimidobenzoyl sulfosuccinimide ester (conjugation through cysteine residues), N-hydroxysuccinimide (through lysine residues), glutaraldehyde, succinic anhydride, SOCl_2 , or $\text{R}^1\text{N}=\text{C}=\text{NR}$, where R and R^1 are different alkyl groups.

Animals are immunized against the antigen, immunogenic conjugates, or derivatives by combining, e.g., 100 ug or 5 ug of the protein or conjugate (for rabbits or mice, respectively) with 3 volumes of Freund's complete adjuvant and injecting the solution intradermally at multiple sites. One month later the animals are boosted with 1/5 to 1/10 the original amount of peptide or conjugate in Freund's complete adjuvant by subcutaneous injection at multiple sites. Seven to 14 days later the animals are bled and the serum is assayed for antibody titer. Animals are boosted until the titer plateaus. Preferably, the animal is boosted with the conjugate of the same antigen, but conjugated to a different protein and/or through a different cross-linking reagent. Conjugates also can be made in recombinant cell culture as protein fusions. Also, aggregating agents such as alum are suitably used to enhance the immune response.

Monoclonal antibodies may be made using the hybridoma method first described by Kohler *et al.*, *Nature*, 256:495 (1975), or may be made by recombinant DNA methods (U.S. Patent No. 4,816,567).

In the hybridoma method, a mouse or other appropriate host animal, such as a hamster or macaque monkey, is immunized as hereinabove described to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the protein used for immunization. Alternatively, lymphocytes may be immunized *in vitro*. Lymphocytes then are fused with myeloma cells using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell (Goding, *Monoclonal Antibodies: Principles and Practice*, pp.59-103 (Academic Press, 1986)).

The hybridoma cells thus prepared are seeded and grown in a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, parental myeloma cells. For example, if the parental myeloma cells lack the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRT), the culture medium for the hybridomas typically will include hypoxanthine, aminopterin, and thymidine (HAT medium), which substances prevent the growth of HGPRT-deficient cells.

Preferred myeloma cells are those that fuse efficiently, support stable high-level production of antibody by the selected antibody-producing cells, and are sensitive to a medium such as HAT medium. Among these, preferred myeloma cell lines are murine myeloma lines, such as those derived from MOP-21 and M.C.-11 mouse tumors available from the Salk Institute Cell Distribution Center, San Diego, California USA, and SP-2 or X63-Ag8-653 cells available from the American Type Culture Collection, Rockville, Maryland USA. Human myeloma and mouse-human heteromyeloma cell lines also have been described for the production of human monoclonal antibodies (Kozbor, *J. Immunol.*, 133:3001 (1984); Brodeur *et al.*, *Monoclonal Antibody Production Techniques and Applications*, pp. 51-63 (Marcel Dekker, Inc., New York, 1987)).

Culture medium in which hybridoma cells are growing is assayed for production of monoclonal antibodies directed against the antigen. Preferably, the binding specificity of monoclonal antibodies produced by hybridoma cells is determined by immunoprecipitation or by an *in vitro* binding assay, such as radioimmunoassay (RIA) or enzyme-linked immunoabsorbent assay (ELISA).

The binding affinity of the monoclonal antibody can, for example, be determined by the Scatchard analysis of Munson *et al.*, *Anal. Biochem.*, 107:220 (1980).

After hybridoma cells are identified that produce antibodies of the desired specificity, affinity, and/or activity, the clones may be subcloned by limiting dilution procedures and grown by standard methods (Goding, *Monoclonal Antibodies: Principles and Practice*, pp.59-103 (Academic Press, 1986)). Suitable culture media for this purpose include, for example, D-MEM or RPMI-1640 medium. In addition, the hybridoma cells may be grown *in vivo* as ascites tumors in an animal.

The monoclonal antibodies secreted by the subclones are suitably separated from the culture medium, ascites fluid, or serum by conventional immunoglobulin purification procedures such as, for example, protein A-SEPHAROSE, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography.

DNA encoding the monoclonal antibodies is readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of the monoclonal antibodies). The hybridoma cells serve as a preferred source of such DNA. Once isolated, the DNA may be placed into expression vectors, which are then transfected into host cells such as *E. coli* cells, simian COS cells, Chinese hamster ovary (CHO) cells, or myeloma cells that do not otherwise produce immunoglobulin protein, to obtain the synthesis of monoclonal antibodies in the recombinant host cells. Recombinant production of antibodies will be described in more detail below.

Hybridoma cell lines producing antibodies are identified by screening the culture supernatants for antibody which binds to HER2 and/or HER3 receptors. This is routinely accomplished by conventional immunoassays using soluble receptor preparations or by FACS using cell-bound receptor and labeled candidate antibody. Agonist antibodies are preferably antibodies which stimulate autophosphorylation in the heregulin tyrosine autophosphorylation assay described above.

The hybrid cell lines can be maintained in culture *in vitro* in cell culture media. The cell lines of this invention can be selected and/or maintained in a composition comprising the continuous cell line in hypoxanthine-aminopterin thymidine (HAT) medium. In fact, once the hybridoma cell line is established, it can be maintained on a variety of nutritionally adequate media. Moreover, the hybrid cell

lines can be stored and preserved in any number of conventional ways, including freezing and storage under liquid nitrogen. Frozen cell lines can be revived and cultured indefinitely with resumed synthesis and secretion of monoclonal antibody. The secreted antibody is recovered from tissue culture supernatant by conventional methods such as precipitation, ion exchange chromatography, affinity chromatography, or the like. The antibodies described herein are also recovered from hybridoma cell cultures by conventional methods for purification of IgG or IgM as the case may be that heretofore have been used to purify these immunoglobulins from pooled plasma, e.g., ethanol or polyethylene glycol precipitation procedures.

Human antibodies may be used and are preferable. Such antibodies can be obtained by using human hybridomas (Cote *et al.*, *Monoclonal Antibodies and Cancer Therapy*, Alan R. Liss, p. 77 (1985)). Chimeric antibodies, Cabilly *et al.*, U.S. 4,816,567, (Morrison *et al.*, *Proc. Natl. Acad. Sci.*, 81:6851 (1984); Neuberger *et al.*, *Nature* 312:604 (1984); Takeda *et al.*, *Nature* 314:452 (1985)) containing a murine anti-HER2/HER3 variable region and a human constant region of appropriate biological activity (such as ability to activate human complement and mediate ADCC) are within the scope of this invention, as are humanized antibodies produced by conventional CDR-grafting methods (Riechmann *et al.*, *Nature* 332:333-327(1988); EP 0328404 A1; EP 02394000 A2).

Techniques for creating recombinant DNA versions of the antigen-binding regions of antibody molecules (Fab or variable regions fragments) which bypass the generation of monoclonal antibodies are also encompassed within the practice of this invention. One extracts antibody-specific messenger RNA molecules from immune system cells taken from an immunized subject, transcribes these into complementary DNA (cDNA), and clones the cDNA into a bacterial expression system and selects for the desired binding characteristic. The Scripps/Stratagene method uses a bacteriophage lambda vector system containing a leader sequence that causes the expressed Fab protein to migrate to the periplasmic space (between the bacterial cell membrane and the cell wall) or to be secreted. One can rapidly generate and screen great numbers of functional Fab fragments to identify those which bind the receptors with the desired characteristics. Alternatively, the antibodies can be prepared by the phage display techniques described in Hoogenboom, *Tibtech* February 1997 (vol 15); Neri *et al.*, *Cell Biophysics* 27:47-61 (1995); Winter *et al.*, *Annu. Rev. Immunol.* 12:433-55 (1994); and Soderlind *et al.*, *Immunol. Rev.* 130:109-124 (1992) and the references described therein as well as the monovalent phage display technique described in Lowman *et al.*, *Biochem.* 30:10832-10838 (1991).

2. Therapeutic Compositions, Administration and Use of Heregulins and Agonist Antibodies

The heregulin are used in the present invention to induce inner-ear-supporting cell proliferation to enhance new hair cell generation. These effects allow treatment of disease states associated with tissue damage, for example, ototoxic injury, or acoustic assault, degenerative hearing loss or balance impairments, or damage associated with surgery or physical injury.

The field of cochlear implantation has also provided insights into both the short- and long-term effects of cochlear fenestration on inner ear function. Administration of growth factors to the inner ears of animals is now possible with the use of implanted catheters and miniature infusion pumps. Localized application of heregulin to the human inner ear can be performed to treat inner ear disorders related to hair cell disfunction.

Therapeutic formulations of heregulin or agonist antibody are prepared for storage by mixing the heregulin protein having the desired degree of purity with optional physiologically acceptable carriers, excipients, or stabilizers (*Remington's Pharmaceutical Sciences, supra*), in the form of lyophilized cake or aqueous solutions. Acceptable carriers, excipients or stabilizers are nontoxic to
5 recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid; low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, arginine or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or
10 dextrans; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; salt-forming counterions such as sodium; and/or nonionic surfactants such as TWEEN, PLURONICS or polyethylene glycol (PEG).

Heregulin or agonist antibody to be used for *in vivo* administration must be sterile. This is readily accomplished by filtration through sterile filtration membranes, prior to or following lyophilization
15 and reconstitution. The heregulin or antibody ordinarily will be stored in lyophilized form or in solution.

Therapeutic heregulin or antibody compositions generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle.

The route of heregulin or antibody administration is in accord with known methods, e.g.,
20 injection or infusion administration to the inner ear, or intralesional routes, or by sustained release systems as noted below. The heregulin ligand may be administered continuously by infusion or by bolus injection. An agonist antibody is preferably administered in the same fashion.

The heregulin, heregulin variant or fragment and agonist antibodies may be spray dried or spray freeze dried using known techniques (Yeo et al, *Biotech. and Bioeng.*, 41:341-346 (1993);
25 Gombotz et al, PCT/US90/02421).

Suitable examples of sustained-release preparations include semipermeable matrices of solid hydrophobic polymers containing the protein, which matrices are in the form of shaped articles, e.g. films, or microcapsules. Examples of sustained-release matrices include polyesters, hydrogels (e.g., poly(2-hydroxyethyl-methacrylate) as described by Langer *et al.*, *J. Biomed. Mater. Res.*, 15: 167-277
30 (1981) and Langer, *Chem. Tech.*, 12: 98-105 (1982) or poly(vinylalcohol)), polylactides (U.S. 3,773,919, EP 58,481), copolymers of L-glutamic acid and gamma ethyl-L-glutamate (Sidman *et al.*, *Biopolymers*, 22: 547-556 (1983)), non-degradable ethylene-vinyl acetate (Langer *et al.*, *supra*), degradable lactic acid-glycolic acid copolymers such as the LUPRON DEPOT (injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate), and poly-D-(-)-3-hydroxybutyric acid (EP
35 133,988). While polymers such as ethylene-vinyl acetate and lactic acid-glycolic acid enable release of molecules for over 100 days, certain hydrogels release proteins for shorter time periods. When encapsulated proteins remain in the body for a long time, they may denature or aggregate as a result of exposure to moisture at 37°C, resulting in a loss of biological activity and possible changes in immunogenicity. Rational strategies can be devised for protein stabilization depending on the
40 mechanism involved. For example, if the aggregation mechanism is discovered to be intermolecular S-S bond formation through thio-disulfide interchange, stabilization may be achieved by modifying

sulfhydryl residues, lyophilizing from acidic solutions, controlling moisture content, using appropriate additives, and developing specific polymer matrix compositions.

Sustained-release heregulin or antibody compositions also include liposomally entrapped heregulin or antibody. Liposomes containing heregulin or antibody are prepared by methods known *per se*: DE 3,218,121; Epstein *et al.*, *Proc. Natl. Acad. Sci. USA*, 82: 3688-3692 (1985); Hwang *et al.*, *Proc. Natl. Acad. Sci. USA*, 77: 4030-4034 (1980); EP 52,322; EP 36,676; EP 88,046; EP 143,949; EP 142,641; Japanese patent application 83-118008; U.S. 4,485,045 and 4,544,545; and EP 102,324. Ordinarily the liposomes are of the small (about 200-800 Angstroms) unilamellar type in which the lipid content is greater than about 30 mol. % cholesterol, the selected proportion being adjusted for the optimal heregulin therapy. Liposomes with enhanced circulation time are disclosed in U.S. patent 5,013,556.

Accordingly, the methods and compositions of the invention find use for the prevention and treatment of opportunistic infections in animals and man which are immunosuppressed as a result of either congenital or acquired immunodeficiency or as a side-effect of chemotherapeutic treatment. According in an alternate embodiment of the present invention, a composition of the invention is used advantageously in combination with a known antimicrobial agent to provide improved methods and compositions to prevent and/or treat diseases induced by gram positive bacteria including, but not limited to: *Staphylococcus aureus*, *Streptococcus pneumonia*, *Hemophilus influenza*; gram negative bacteria including, but not limited to: *Escherichia coli*; *Bacterium enteritis*, *Francisella tularensis*; acid-fast bacteria including, but not limited to *Mycobacterium tuberculosis*, and *Mycobacterium leprae*. Use of a combination of an antimicrobial agent together with a composition of the invention is advantageous with antibacterial aminoglycosides such as gentamicin, streptomycin, and the like which are known to have serious ototoxicity, which reduce the usefulness of such antimicrobial agents. Use of a composition of the invention in combination with such agents permits a lower dosage of the toxic antimicrobial agents while still achieving therapeutic (antibacterial) effectiveness.

In some embodiments the composition of the invention is co-administered with an ototoxin. For example, an improved method is provided for treatment of infection of a mammal by administration of an aminoglycoside antibiotic, the improvement comprising administering a therapeutically effective amount of heregulin or agonist, to the patient in need of such treatment to reduce or prevent ototoxin-induced hearing impairment associated with the antibiotic. In yet another embodiment is provided an improved method for treatment of cancer in a mammal by administration of a chemotherapeutic compound, the improvement comprises administering a therapeutically effective amount of a composition of the invention to the patient in need of such treatment to reduce or prevent ototoxin-induced hearing impairment associated with the chemotherapeutic drug.

Also provided herein are methods for promoting new inner ear hair cells by inducing inner ear supporting cell proliferation, regeneration, or growth upon, prior to, or after exposure to an agent or effect that is capable of inducing a hearing or balance impairment or disorder. Such agents and effects are those described herein. The method includes the step of administering to the inner ear hair cell an effective amount of heregulin or agonist or factor disclosed herein as useful. Preferably, the method is used upon, prior to, or after exposure to a hearing-impairing ototoxin.

In one embodiment the methods of treatment are applied to hearing impairments resulting from the administration of a chemotherapeutic agent to treat its ototoxic side-effect. Ototoxic chemotherapeutic agents amenable to the methods of the invention include, but are not limited to an antineoplastic agent, including cisplatin or cisplatin-like compounds, taxol or taxol-like compounds, and
5 other chemotherapeutic agents believed to cause ototoxin-induced hearing impairments, e.g., vincristine, an antineoplastic drug used to treat hematological malignancies and sarcomas.

In one embodiment the methods of the invention are applied to hearing impairments resulting from the administration of quinine and its synthetic substitutes, typically used in the treatment of malaria, to treat its ototoxic side-effect.

10 In another embodiment the methods of the invention are applied to hearing impairments resulting from administration of a diuretic to treat its ototoxic side-effect. Diuretics, particularly "loop" diuretics, i.e. those that act primarily in the Loop of Henle, are candidate ototoxins. Illustrative examples, not limiting to the invention method, include furosemide, ethacrynic acid, and mercurials. Diuretics are typically used to prevent or eliminate edema. Diuretics are also used in nonedematous
15 states such as hypertension, hypercalcemia, idiopathic hypercalciuria, and nephrogenic diabetes insipidus.

In another embodiment the compositions of the invention are administered with an agent that promotes neuronal cell growth, proliferation, or regeneration. As known in the art, low concentrations of gentamicin preferentially kills hair cells while the damage to the ganglion neurons is not significant.
20 However, high concentrations of gentamicin induce degeneration of ganglion neurons as well as hair cells. Accordingly, this dual toxicity of aminoglycosides can be treated by the methods of the invention, preferably with compositions of the invention.

The heregulin or agonist is directly administered to the patient by any suitable technique, including parenterally, intranasally, intrapulmonary, orally, or by absorption through the skin. If they are
25 administered together, they need not be administered by the same route. They can be administered locally or systemically. Examples of parenteral administration include subcutaneous, intramuscular, intravenous, intraarterial, and intraperitoneal, and intracochlear administration. They can be administered by daily subcutaneous injection. They can be administered by implants. They can be administered in liquid drops to the ear canal, delivered to the scala tympani chamber of the inner ear, or
30 provided as a diffusible member of a cochlear hearing implant.

The heregulin or antibody agonist, can be combined and directly administered to the mammal by any suitable technique, including infusion and injection. The specific route of administration will depend, e.g., on the medical history of the patient, including any perceived or anticipated side effects using heregulin alone, and the particular disorder to be corrected. Examples of parenteral
35 administration include subcutaneous, intramuscular, intravenous, intraarterial, and intraperitoneal administration. Most preferably, the administration is by continuous infusion (using, e.g., slow-release devices or minipumps such as osmotic pumps or skin patches), or by injection (using, e.g., intravenous or subcutaneous means). The administration may also be as a single bolus or by slow-release depot formulation. The agonist(s) is administered in an acute or chronic fashion, as may be required, for
40 prophylactic and therapeutic applications, by a number of routes including: injection or infusion by intravenous, intraperitoneal, intracerebral, intramuscular, intradermally, intraocular, intraarterial,

subcutaneously, or intralesional routes, topical administration, orally if an orally active small molecule is employed, using sustained-release systems as noted below, or by an indwelling catheter using a continuous administration means such as a pump, by patch, or implant systems, e.g., implantation of a sustained-release vehicle or immuno-isolated cells secreting the growth factor(s) and/or neurotrophin(s). Agonist(s) is administered continuously by infusion or by periodic bolus injection if the clearance rate is sufficiently slow, or by administration into the blood stream, lymph, CNS or spinal fluid. A preferred administration mode is directly to the affected portion of the ear or vestibule, topically as by implant for example, and, preferably to the affected hair cells, their supporting cells, and (optionally to) associated neurons, so as to direct the molecule to the source and minimize side effects of the agonists.

As noted the compositions can be injected through chronically implanted cannulas or chronically infused with the help of osmotic minipumps. Subcutaneous pumps are available that deliver proteins through a small tubing to the appropriate area. Highly sophisticated pumps can be refilled through the skin and their delivery rate can be set without surgical intervention. Examples of suitable administration protocols and delivery systems involving a subcutaneous pump device or continuous infusion through a totally implanted drug delivery system are those used for the administration of dopamine, dopamine agonists, and cholinergic agonists to Alzheimer patients and animal models for Parkinson's disease described by Harbaugh, *J. Neural Transm. Suppl.*, 24: 271-277 (1987) and DeYebenes *et al.*, *Mov. Disord.*, 2: 143-158 (1987), the disclosures of which are incorporated herein by reference. It is envisioned that it may be possible to introduce cells actively producing agonist into areas in need of increased concentrations of agonist.

An effective amount of heregulin or antibody to be employed therapeutically will depend, for example, upon the therapeutic objectives, the route of administration, and the condition of the patient. Also, the amount of heregulin polypeptide will generally be less than the amount of an agonist antibody. Accordingly, it will be necessary for the therapist to titer the dosage and modify the route of administration as required to obtain the optimal therapeutic effect. A typical daily dosage might range from about 1 µg/kg to about 1 mg/kg and up to 100 mg/kg or more, depending on the factors mentioned above. Typically, the clinician will administer heregulin or antibody until a dosage is reached that achieves the desired effect. The progress of this therapy is easily monitored by conventional diagnostic clinical tests for hearing or balance improvement.

In a further embodiment, inner-ear-supporting cells may be obtained or isolated from a mammalian tissue to obtain a normal inner-ear-supporting cell sample using techniques well known in the art (biopsy, etc.). This sample may then be treated with a heregulin protein in order to induce hair cell or inner-ear-supporting cell growth and/or proliferation in the sample thereby expanding the population of inner-ear-supporting cells. Typically, heregulin will be added to the *in vitro* inner-ear-supporting cell culture at a concentration of about 0.1 to about 100 nM preferably 1-50 nM. If desired, the primary inner-ear-supporting cells may be cultured *in vitro* for several generations in order to sufficiently expand the hair cell or inner-ear-supporting cell population. The hair cell or inner-ear-supporting cells are cultured under conditions suitable for mammalian cell culture as discussed above. After expansion, the expanded sample is reintroduced into the mammal for the purpose of re-epithelializing the mammalian tissue.

The methods and procedures described herein with respect to HRG- α or heregulin in general may be applied similarly to other heregulin such as HRG- β 1, HRG- β 2 and HRG- β 3 and to variants thereof, as well as to the antibodies. All references cited in this specification are expressly incorporated by reference. The following examples are offered by way of illustration and not by way of limitation.

5

EXAMPLES

Example I

Characterization of Inner-Ear-Supporting Cell Cultures

Cultured undissociated utricular epithelial cells were determined to express features of epithelial cells, but not those of fibroblast, glial or neuronal cells. Utricular sheets were prepared by the
10 method of Zheng et al. (Journal of Neuroscience, 17(21):8270-82 (1997)) and Zheng et al. (Journal of Neuroscience, 17(1):216-226 (1997)). Utricular sheet cultures contained primarily supporting cells and hair cells.

Utricular epithelial sheets were separated from either postnatal day 3 (P3) or day 4-5 Wistar rats using 0.5 mg/ml thermolysin (Sigma; in Hank's calcium and magnesium-free balanced salt solution)
15 for 30 min at 37°C, based on the method reported previously (Corwin et al., 1995). The epithelial sheets were then incubated in a mixture of 0.125% trypsin and 0.125% collagenase for 8 min at 37°C. The enzyme activity was inactivated with a mixture of 0.005% soybean trypsin inhibitor (Sigma) and 0.005% DNase (Worthington) before being pipetted up and down with a 1 ml pipette tip 10 times in 0.05% DNase in BME. A 5% fetal bovine serum-supplemented medium was used. The cell
20 suspension was finally plated in polylysine (500 μ g/ml) coated 96-well plate (for tritiated thymidine assays) or 16-well LabTek slides (for BrdU labeling and other immunocytochemistry) in 200 μ l of serum-containing medium (DMEM plus 5% fetal bovine serum, 4.5 mg/ml glucose, 2 mM glutamine, 25 ng/ml fungizone and 10 units/ml penicillin) at a density of approximately 70 cells/mm². Typically, cells prepared from 4 litters of pups (40 P3 or P4-5 rats) were equally aliquoted into 80 wells.

While most isolated single cells died after 2 days in culture, the cell clumps containing
25 approximately 10-80 cells survived well and grew in patches in the serum-supplemented medium. Immunocytochemical staining with different types of cell markers revealed that these cultured cells expressed epithelial cell antigens including a tight junction protein ZO1, F-actin, and cytokeratin. They did not express antigens for other types of cells, such as glial filament protein (GFAP), the
30 oligodendrocyte antigen (myelin), neurofilament protein or fibroblast antigens, vimentin, and Thy1.1. Because the utricular epithelial sheets contained mainly supporting cells and hair cells, the vast majority of the surviving, mitotic cells in the cultures represented a population of utricular supporting cells.

Example II

Stimulation of Supporting Cell Proliferation and Hair Cell Generation

To examine whether any of the presently known growth factors stimulate proliferation of the
35 utricular supporting cells and stimulates an increase in number of dividing cells, bromo-deoxyuridine (BrdU) immunocytochemistry was performed as described in Zheng et al. (Journal of Neuroscience, 17(1):216-226 (1997)). Briefly, after 1 day in culture, BrdU (1:400; Amersham cell proliferation kit) was added to the culture medium for 24h. The cultures were fixed in 4% paraformaldehyde (30min), treated
40 with 2 N HCl (40 min), and incubated with an anti-BrdU monoclonal antibody (Becton-Dickinson, 1:40 in phosphate buffered saline containing 0.1% Triton-X100) overnight at 4°C. The cultures were then

processed with a Vector ABC kit. After diaminobenzidine-peroxidase reaction, the cells were dehydrated with ethanol, cleared in HistoClear (American Histology) and mounted in Permount (Fisher). BrdU-positive cells were counted from the entire areas of 10 or more culture wells for each of the experimental groups. Data was expressed as mean \pm s.e.m. Two-tailed, unpaired t-test was used for statistical analysis.

A much greater number of BrdU-positive cells were seen in the cultures containing heregulin (HRG- β 1-177-244) than any of the other factors known to activate Her receptors. Cell counts performed from the control cultures and cultures containing confirmed that heregulin significantly enhanced proliferation of the utricular supporting cells ($p < 0.0001$, Figure 9). IGF-1 at 100 nM, TGF- α at 100 nM (R & D Systems), EGF 100 nM (Collaborative Research), SMDF at 100 nM, β cellulin at 100 nM, neuregulin3 at 20 nM, HB-EGF at 100 nM (Elenius et al., EMBO Journal 16(6):1268-78 (1997)), and IGF1-binding protein at 100 nM were weaker mitogens, if at all, compared to heregulin. SMDF polypeptides are prepared as described in WO 96/15244. Neuregulin-3, a neural tissue-enriched protein that binds and activates erbB4, was prepared as described in Zhang et al., *Proceedings of the National Academy of Sciences*, 94(18):9562-7 (1997). β -cellulin was prepared as described in Daly et al., Cancer Research. 57(17):3804-11 (1997). The EGF-like domain of HRG β 1₍₁₇₇₋₂₄₄₎ was expressed in *E. coli*, purified and radioiodinated as described previously (Sliwkowski et al. *J. Biol. Chem.* 269:14661-14665 (1994)). All factors were added to the cultures at the time when the cells were plated.

To determine whether the effect of heregulin was dose-dependent, a dose-dependent study was carried out in the utricular epithelial sheet cultures at a range of 0.03 nM to 10 nM heregulin (Figure 10). A heregulin-dose-dependent increase in the number of BrdU positive cells was observed. Maximal effect of heregulin was seen at 3 nM.

Example III

Stimulation of Supporting Cell Proliferation and Hair Cell Generation in Utricle Explant Cultures

An organotype utricle explant culture that utilizes a 3-D collagen matrix cultures and maintains its normal, *in vivo* architecture was prepared as described in Zheng et al. (Journal of Neuroscience, 17(21):8270-82 (1997)). This system provides an excellent means to test the effect of heregulin on supporting cell proliferation in a physiologically significant system that mimics the *in vivo* state. In particular, the effects of heregulin after ototoxic-induced damage (e.g. antibiotic gentamycin) were examined.

The utricle was dissected with the vestibular ganglion attached, from P3 Wistar rats and cultured in three-dimensional ("3-D") collagen gel in serum free medium. In one embodiment a droplet (20 μ l) of freshly made collagen gel which was placed on the bottom of a 35 mm Nunc tissue culture dish, modified from what described previously (Gao et al., Neuron 6:705-715 (1991)) as follows. Rat tail collagen (type I, Collaborative Research) was mixed with 10x BME medium and 2% sodium carbonate in a ratio of 10:1:1 and placed on ice just before use. The collagen matrix containing the utricle explant was incubated at 37°C for 5-10 min until gellation. The matrix was then cultured in defined serum-free medium using sufficient medium to cover the explant (2 ml of serum-free medium (BME plus serum-free supplement (Sigma I-1884), 1% BSA, 2 mM glutamine, and 5 mg/ml glucose; containing no antibiotics). The culture medium was changed every other day thereafter.

Embedding the utricle explants in the 3-D collagen was better for maintaining their normal architecture than floating the explants or placing the explants on a monolayer substrate, since the explant tissue could be kept unfolded and cell migration out of the tissue could be limited. Utricle explant whole mount cultures maintained normal architecture in the 3-D collagen gel cultures as observed by Nomarski micrographs of utricle tissue dissected from P3 rats and grown for 2 days *in vitro* at low and high magnifications. The hair cells in the explants grew well and maintained their normal connectivity. The hair cells remained in their normal locations. No gross cell death of hair cells occurred under this culture condition.

Organ cultures of utricular whole mounts were cultured 1-2 days after explant, then treated with gentamycin (1 mM) for two days, and then treated with heregulin (3 nM) for 11 days in the presence of tritiated thymidine. To determine the number of labeled cells, the tissue was fixed, sectioned and processed for autoradiography. In response to heregulin, compared to control cultures, an increase in the number of ³H-thymidine labeled cells in both the supporting cell layer (SC) and the hair cell layer (HC) was observed as shown in Figures 11A-D, which represent similarly treated samples. The cell count of ³H-thymidine labeled cells in both the supporting cell layer and in the hair cell layer increased significantly compared to control cultures lacking heregulin as shown in Figure 12. The data is consistent with the data obtained in the utricular sheet cultures. And the data indicates that heregulin can act to increase inner-ear-supporting cell proliferation, which leads to hair cell generation, in instances following hair cell damage and injury.

20 Example IV

Heregulin Acts through the Her2 Receptor

To provide further evidence that heregulin is a physiologically relevant factor and that it acts through a physiologically relevant receptor, the mRNA expression levels of heregulin and its receptors Her2, Her3 and Her4 in the hair cell and supporting cell layers of the rat utricular sensory epithelium were determined. RNA was extracted from the P3 utricle sheet cultures and also from UEC4 cells (a inner-ear-supporting cell line). Using TaqMan PCR analysis with appropriate gene-specific primers (Heid et al., Genome Research. 6(10):986-94 (1996)), it was observed that all four were expressed in the inner ear, however, heregulin and Her2 were expressed at a higher level than either Her3 or Her4 (see Figure 13). Her4 was not expressed in the inner-ear-supporting cell line.

To determine that Her2 was indeed expressed at the protein level and to confirm its localization, fluorescently labeled anti-Her2 monoclonal antibody was used to immunostain rat P0 (day zero) cochlea and adult utricle. Her2 was localized to the hair cell and supporting cell sensory epithelium layers in the inner ear (see Figure 14 A (cochlea) and Figure 14B (utricle)). Anti-HER2 monoclonal antibodies 2C4 and 4D5 have been described elsewhere (Fendly *et al.* *Cancer Research* 50:1550-1558 (1990)). Consistent with this observation is that immunostaining with a heregulin antibody suggests that heregulin is expressed by hair cells of the inner ear.

Addition of neutralizing monoclonal antibodies against Her2, but not the addition of the immunoadhesin Her4-IgG, at saturating amounts to the utricular cultures, blocked the effects of heregulin. Thus, heregulin stimulates supporting cell proliferation and hence the generation of new hair cells by activating a Her2-mediated signaling pathway, but not a Her4-mediated pathway.

- In addition, preliminary experiments with embryonic rat inner ear explant cultures show that heregulin affects hair cell differentiation by enhancing proliferation of hair cell progenitors. Rat E14 otocyst cultures treated with heregulin respond with an increase in the number of hair cell progenitor cells compared to untreated cultures. This is consistent with the adult tissue studies, indicating that
- 5 heregulin stimulates the proliferation of cells that differentiate into hair cells.

Example V

Heregulin Acts In Vivo to Enhance Inner Ear Supporting Cell Proliferation and Hair Cell Generation Following Ototoxic Injury and Acoustic Assault

- Chinchillas are an accepted model to test the effects of factors and agents against or following
- 10 hair cell damage or injury. Chinchillas can be treated with gentamicin, caboplatin or acoustic trauma. Preferably, at least five chinchillas are in each of the test and the control groups. The control group is treated with the ototoxic agent or acoustic assault and allowed to recover. Typically, four to six weeks is sufficient for recovery. The test group is treated with heregulin in addition to the injury. All animals will receive BrdU, preferably subcutaneous infusion, using minipumps, to label the dividing cells during
- 15 the treatment period. Heregulin, or one of the heregulin factors as taught herein, will be administered to the inner ear. Minipumps can be used. The heregulin can be infused into the cochlea. After the treatment period, cochlea and utricular maculae are dissected out of the animals. The tissue is fixed and BrdU immunohistochemical labeling done. BrdU labeled cells in the inner ear sensory epithelium are counted. Cell counts from the two groups- are compared and analyzed statistically to determine the
- 20 amount of enhancement of proliferation of supporting cells and new hair cell generation induced by the heregulin treatment.

CITED REFERENCES

1. Acheson *et al.*, *Nature* 374:450-453 (1995).
2. Adler *et al.*, *Assoc Res Otolaryngol Abstr*, p4 (1996).
3. Anderson, *Neuron* 3, 1-12 (1989).
- 5 4. Balak *et al.*, *J Neurosci* 10:2505-2512 (1990).
5. Beck *et al.*, *Neuron* 14:717-730 (1995).
6. Bianchi *et al.*, *Assoc Res Otolaryngol Abstr*, p108 (1995).
7. Cattaneo *et al.*, *Nature* 347:762-765 (1990).
8. Corwin *et al.*, *Science* 240:1772-1774 (1988).
- 10 9. Corwin *et al.*, *Assoc Res Otolaryngol Abstr*, 18:87 (1995).
10. Cotanche, *Hear Res* 30:181-196 (1987).
11. Cotanche *et al.*, *Curr Opinion Neurobiol* 4:509-514 (1994).
12. Davis *et al.*, *Nature* 372:263-266 (1994).
13. Ernfors *et al.*, *Nature* 368:147-150 (1994).
- 15 14. Ernfors *et al.*, *Neuron* 14:1153-1164 (1995).
15. Farinas *et al.*, *Nature* 369:658-661 (1994).
16. Finley *et al.*, *Assoc Res Otolaryngol Abstr*, p84 (1995).
17. Forge *et al.*, *Science* 259:1616-1619 (1993).
18. Frenz *et al.*, *Development* 120:415-424 (1994).
- 20 19. Fritsch N *et al.*, *Auditory Neurosci* 1:401-417 (1995).
20. Gao *et al.*, *Neuron* 1: 269-277 (1988).
21. Gao *et al.*, *Neuron* 6:705-715 (1991).
22. Gao *et al.*, *J Neurosci* 15:2656-2667 (1995).
23. Ghosh *et al.*, *Neuron* 15:89-103 (1995).
- 25 24. Gray *et al.*, *Assoc Res Otolaryngol Abstr*, p198 (1996).
25. Holley *et al* (1995) *J Neurocytol* 24:853-864.
26. Johnson *et al* (1993) *Adv Cancer Res* 60:1-41.
27. Jones *et al* (1996) *J Neurosci* 16:649-662.
28. Kelley *et al* (1993) *Development* 119:1041-1053.
- 30 29. Kopke *et al* (1996) *Assoc Res Otolaryngol Abstr*, p198.
30. Lambert *et al* (1994) *Laryngoscope* 104:701-717.
31. Lee *et al* (1996) *Hear Res* 94:1-13.
32. Lefebvre *et al* (1994) *Neuroreport* 5:865-868.
33. Leon *et al* (1995) *Endocrinology* 136:3494-3503.
- 35 34. Li *et al* (1996) *Assoc Res Otolaryngol Abstr*, p7.
35. Li *et al* (1996) *Endocrine*, in press.
36. Low *et al* (1995) *Assoc Res Otolaryngol Abstr*, p200
37. Minichiello *et al* (1995) *Development* 121:4067-4075.
38. Miranda *et al* (1993) *Proc Natl Acad Sci USA* 90:6439-6443.
- 40 39. Neff *et al* (1993) *J Neurobiol* 24:1578-1588.
40. O sterle *et al* (1996) *Assoc Res Otolaryngol Abstr*, p198.

41. *Pirvola et al* (1995) *Proc Natl Acad Sci USA* 92:9269-9273.
42. *Rapheal et al* (1992) *J Neurocytol* 21:663-671.
43. *Reynold et al* (1992) *Science* 255:1707-1710.
44. *Ryals et al* (1988) *Science* 240:1774-1776.
- 5 45. *Sans et al* (1982) *J Comp Neurol* 206:1-8.
46. *Vicario-Abejon et al* (1995) *Neuron* 15:105-114.
47. *Warchol et al* (1993) *Hear Res* 71:28-36.
48. *Warchol et al* (1993) *Science* 259:1619-1622.
49. *Welsleder et al* (1992) *Exp Neurol* 115:2-6.
- 10 50. *Yamashita et al* (1995) *Proc Natl Acad Sci USA* 92:3152-3155.
51. *Zheng et al* (1996) *Eur J Neurosci*, 8:1897-1905.
52. *Zheng et al* (1995a) *J. Neurosci.* 15:5079-5087.
53. *Zheng et al* (1995b) *J. Neurobiol.* 28:330-340.
54. *Anniko et al* (1986) *Am J Otolaryngol* 7:276-293.
- 15 55. *Apfel et al* (1991) *Ann. Neurol.* 29:87-89.
56. *Ard et al.* (1985). *Neurosci.* 16:151-170.
57. *Au et al* (1987) *Biochem Biophys Acta* 902:80-86.
58. *Baired et al* (1992) *J. Neurosic.* 12:619-634.
59. *Barbacid et al.* (1993). *In Molecular Genetics of Nervous System Tumors.* (New York: Wiley-
- 20 Liss), pp123-136.
60. *Barde et al* (1982) *EMBO J.* 1:549-553.
61. *Bareggi et al* (1990). *Pharmacol. Res.* 22:635-644.
62. *Barker et al* (1994). *Neuron* 13:203-215.
63. *Berggren et al.,* (1990) *Acta Otolaryngol. (Stockh)* 109:57-65.
- 25 64. *Berkemeier et al.,* (1991) *Neuron* 7:857-866.
65. *Boettcher et al.,* (1989) *Hear Res* 42: 129-142.
66. *Boettcher et al.,* (1990) *Arch Otolaryngol Head Neck Surg* 116:681-684.
67. *Boettcher et al.,* (1991) *Am. J Otolaryngol* 12: 33-47.
68. *Carenza* (1986). *Gynecol. Oncol.* 25:244-249.
- 30 69. *Chao et al.,* (1986) *Science* 232:518-521.
70. *Chao et al.,* (1992). *Cell* 68:995-997.
71. *Clary et al.,* (1994). *Proc. Natl. Acad. Sci. USA* 91:11133-11137.
72. *Clary et al* (1994). *Mol. Biol. Cell* 5:549-563.
73. *Cohen et al.,* (1994) *J. Neurobiol.* 25:953-959.
- 35 74. *Cordon-Cardo et al* (1991), *Cell*, 66, 173-183
75. *Corwin et al* (1991) *Ann Rev Neurosci* 14: 301-333.
76. *Cotanche et al.,* (1994) *Curr Opinion Neurobiol* 4: 509-514.
77. *Davies et al.,* (1993) *Neuron* 11:565-574.
78. *Davies et al* (1993b) *J. N urosci.* 13:4961-4967.
- 40 79. *Davies et al.,* (1986) *Nature* 319:497-502.
80. *De Moura et al* (1968) *Arch Otolaryng* 87:60-64.

81. *Dublinet et al.*, (1976): *C. C. Thomas*.
82. *Duckert et al.*, *J. Comp. Neurol.* 331:75-96.
83. *Emfors et al* (1990) *Proc. Natl. Acad. Sci. USA* 87:5454-5458.
84. *Emfors et al.*, (1994). *Nature* 368:147-150.
- 5 85. *Ernforset al.*, (1995) *Assoc. Res Otolaryngol Abstr* p190.
86. *Escandon et al.*, (1994) *J. Neurosci.* 14:2954-2068.
87. *Falbe-Hansen et al.*, (1941) *Acta Otolaryng suppl* 44: 1-216.
88. *Fariñas et al* (1994). *Nature* 369:658-661.
89. *Fischer et al* (1994) *Proc. Natl. Acad. Sci. USA* 91:8607-8611.
- 10 90. *Fleischman et al* (1975) *Pharmacol.* 33:320-332.
91. *Forge et al* (1993) *Science* 259:1616-1619.
92. *Fritsch et al* (1995). *Assoc. Res. Otolaryngol. Abstr.* p190.
93. *Furley et al* (1990) *Cell* 61:157-170.
94. *Gao et al* (1991) *Neuron* 6:705-715.
- 15 95. *Gao et al* (1995b) *Ann Neurol* (1995) 38:30-37 .
96. *Gao et al* (1995) *J. Neurosci.* 15:2656-2667.
97. *Garner et al* (1994) *Neuron* 13:457-472.
98. *Gotz et al* (1994) *Nature* 372:266-269.
99. *Grotz et al.*, *Eur. J. Biochem.* 204:745-749 (1992)
- 20 100. *Guild et al* (1931). *Acta Otolaryngol. (Stockh)* 15:269-308.
101. *Hefti et al* (1986) *J Neurosci* 6:2155-2162.
102. *Hinojosa et al* (1987). *J. Infect. Dis.* 156: 449-455
103. *Hohn et al* (1990) *Nature* 344:339-341.
104. *Hood et al.*, *Contemporary applications of neurobiology in human hearing assessment* (Raven
- 25 Press, New York, 1986).
105. *Hulme, et al.*, *E.C. and Birdsall, M.J.M.*, *Strategy and Tactics in Receptor Binding Studies*, p63-212 in *Receptor-Ligand Interactions*, Ed. *E.C. Hulme*
106. *Hyman et al.*, (1991) *Nature* 350:230-233.
107. *Hynes et al.*, (1994) *J. Neurosci. Res.* 37:144-154.
- 30 108. *Ip et al.*, (1993) *Neuron* 110:137-149.
109. *Ip et al* (1992) *Proc. Nat. Acad. Sci. USA* 89:3060-3064.
110. *Jarvis et al.*, (1966) *J Laryngol* 80: 318-320.
111. *Jones et al.*, (1990) *Proc. Natl. Acad. Sci. USA* 87:8060-8064.
112. *Kaplan et a.,*, (1991) *Science* 252, 554-558
- 35 113. *Kaplan et al.*, (1991) *Nature* 350:158-160.
114. *Kelley et al.*, (1995) *J Neurosci* 15:3013-3026.
115. *Kelley et al.*, (1993) *Development* 119:1041-1053.
116. *Klein et al.*, (1991a) *Cell* 65:189-197.
117. *Klein et al.*, (1991b) *Cell* 66:395-403.
- 40 118. *Klein et al.*, (1990) *Development* 109:845-850.
119. *Klein, et al.*, (1992) *N uron* 8, 947-956

120. Klein, et al., (1989), *EMBO J.*, 8, 3701-3709
121. Knusel et al., (1992) *J Neurosci* 12:4391-4402.
122. Koliatsos et al., (1993) *Neuron* 10:359-367.
123. Konings et al., (1994) *Brain Res* 640:195-204.
- 5 124. Kopf-Maier et al., (1992) *Chem. Biol Interact* 82:295-316.
125. Korsching, et al., (1993). *J. Neurosci.* 13:2739-2748.
126. Lamballe et al., (1991) *Cell* 66:967-979.
127. Lambert et al., (1994) *Laryngoscope* 104:701-718.
128. Lärkfors et al., (1993) *Neurosci.* 19:A278.14.
- 10 129. Leake et al., (1992) *Hear Res* 64:99-117.
130. Lefebvre et al., (1994) *NeuroReport* 5:865-868.
131. Lefebvre, et al., (1993). *Science* 260:692-695.
132. Lefebvre et al., (1991). *Acta Otolaryngol (Stockh)* 111:304-311.
133. Lefebvre et al., (1995) *Science* 267: 709-711.
- 15 134. Leibrock et al., (1989) *Nature* 341:149-152.
135. Levi-Montalcini et al., (1987) *EMBO J.* 6:1145-1154.
136. Lim et al., (1986) *Am J Otolaryngol* 7: 73-99.
137. Lippe et al., (1995) *Assoc Res Otolaryngol Abstr.* p84.
138. Maisonpierre et al., (1990) *Science* 247:1446-1451.
- 20 139. Martin-Zanca et al., (1989), *Mol.Cell. Biol.*, 9, 24-33
140. McAlpine et al., (1990) *Hear Res* 47:191-204.
141. McCabe et al., (1965) *Ann Otol* 74: 312-324.
142. Mollman et al (1990) *N. Engl. J. Med.* 322:126-127.
143. Myers et al., (1965) *Arch Otolaryngl Head Neck Surg* 82: 483-493.
- 25 144. Nakai et al., (1982). *Acta Otolaryngol* 93:227-232.
145. Pirvola et al., (1992). *Proc. Natl. Acad. Sci. USA* 89:9915-9919.
146. Pryor et al., (1994) Chang LW, ed., *Marcel Dekker, Inc.* PP345-371.
147. Rastel et al., (1993) *J Neurosci Methods* 47:123-131.
148. Richardson et al., (1991) *Hear Res* 53:293-311.
- 30 149. Roelofs et al., (1984). *Neurology* 34:934-938.
150. Rosenthal et al., (1990) *Neuron* 4:767-773.
151. Rybak et al., (1986) In: *Neurobiology of Hearing*. Altschuler RA, Bobbin RP, Hoffman DW, Eds. Raven Press (New York) PP441-454.
152. Schacht et al., (1986) *Hear Res* 22: 297-304.
- 35 153. Schecterson et al., (1994). *Hear. Res.* 73:92-100.
154. Scopes et al., R., *Protein Purification*, Springer-Verlag, NY (1982)
155. Sera et al., (1987). *Scanning Microsc.* 1:1191-1197.
156. Shelton et al., (1995). *J. Neurosci.* 15:477-491.
157. Siegal et al., (1990) *Cancer* 66:1117-1123.
- 40 158. Snider et al., (1994) *Cell* 77: 627-638.
159. Sobkowicz et al., (1975) *J. neurocytol.* 4:543-572.

160. *Soppet et al.*, (1991) *Cell* 65:895-903.
161. *Squinto et al.*, (1991) *Cell* 65:885-893.
162. *Stadnicki et al.*, (1975). *Cancer Chemother. Rep.* 59:467-480.
163. *Thompson et al.*, (1984). *Cancer* 54:1269-1275.
- 5 164. *Tsoufas et al.*, (1993) *Neuron* 10:975-990.
165. *Tsue et al.*, (1994a) *Proc Natl Acad. Sci USA* 91:1584-1588.
166. *Tsue et al.*, (1994b) *Head Neck Surg* 111:281-301.
167. *Valenzuela et al.*, (1993) *Neuron* 10: 963-974.
168. *Vazquez et al.*, (1994) *Anat. Embryol.* 189:157-167.
- 10 169. *Verdi, et al.*, (1994). *Neuron* 12:733-745.
170. *Von Bartheld et al.*, (1991).. *Development* 113: 455-470.
171. *Warchol et al.*, (1993). *Science* 259:1619-1622.
172. *Weskamp et al.*, (1991). *Neuron* 6:649-663.
173. *Wheeler et al.*, (1994). *Hear. Res.* 73:46-56.
- 15 174. *Windebank et al.*, (1994) *Neurology* 44: 488-494.
175. *Wittnaack et al.*, (1903). *Pflueger Arch Ges Physiol* 95:237.
176. *Woodford et al.*, (1978) *Ann Otol Rhinol Laryngol* 87:117-127.
177. *Yamashita et al.*, (1995) *Proc Natl Acad Sci USA* 92:3152-3155.
178. *Yan et al.*, (1992) *Nature* 360:753-755.
- 20 179. *Yan et al.*, (1994). *Exper. Neurology* 127:23-36.
180. *Ylikoski et al.*, (1993). *Hear. Res.* 65:69-78.

Additional Cited References

- Anniko M, Sobin A (1986) Cisplatin: Evaluation of its ototoxic potential. *Am J Otolaryngol* 7:276-293.
- Apfel SC, Lipton RB, Arezzo JC, Kessler JA (1991) Nerve growth factor prevents toxic neuropathy in mice. *Ann. Neurol.* 29:87-89.
- 25 Ard, M. D., Morest, D. K., and Hauger, S. H. (1985). Trophic interactions between the cochleovestibular ganglion of the chick embryo and its synaptic targets in culture. *Neurosci.* 16:151-170.
- Au S, Weiner ND, Schacht J (1987) Aminoglycoside antibiotics preferentially increase permeability in phosphoinositide-containing membranes: a study with carboxyfluorescein in liposomes. *Biochem*
- 30 *Biophys Acta* 902:80-86.
- Baired DH, Hatten ME, Mason CA (1992) Cerebellar target neurons provide a stop signal for affrent neurite extension *in vitro*. *J. Neurosci.* 12:619-634.
- Barbacid, M. (1993). The trk family of neurotrophin receptors: molecular characterization and oncogenic activation in human tumors. *In Molecular Genetics of Nervous System Tumors*. Levin, A. G. and
- 35 Schmidek, H. H., eds. (New York: Wiley-Liss), pp123-136.
- Barde YA, Edgar D, Thoenen H (1982) Purification of a new neurotrophic factor from mammalian brain. *EMBO J.* 1:549-553.
- Bareggi, R., Grill, V., Narducci, P., Zwyer, M., Tesei, L, and Russolo, M. (1990). Genetamicin ototoxicity: Histological and ulstructural alterations after transtympanic administration. *Pharmacol. Res.*
- 40 22:635-644.

- Barker, P. A., and Shooter, E. M. (1994). Disruption of NGF binding to the low affinity neurotrophin receptor p75^{LNTR} reduces NGF binding to trkA on PC12 cells. *Neuron* 13:203-215.
- Berggren, D., Anniko, M., Thornell, L.-E., Ramakers, F. C. S., and Virtanen, I. (1990). Intermediate filament proteins in the embryonic inner ear of mice under normal conditions and after exposure to
 5 ototoxic drugs. *Acta Otolaryngol. (Stockh)* 109:57-65.
- Berkemeier LR, Winslow JW, Kaplan DR, Nikolics K, Goeddel DV, Rosenthal A (1991) Neurotrophin-5: A novel neurotrophic factor that activates trk and trkB. *Neuron* 7:857-866.
- Boettcher FA, Bancroft BR, Salvi RJ, Henderson D (1989) Effects of sodium salicylate on evoked-response measures of hearing. *Hear Res* 42: 129-142.
- 10 Boettcher FA, Bancroft BR, Salvi RJ, Henderson D (1990) Concentration of salicylate in serum and perilymph of the chinchilla. *Arch Otolaryngol Head Neck Surg* 116:681-684.
- Boettcher FA, Salvi RJ (1991) Salicylate ototoxicity: review and synthesis. *Am. J Otolaryngol* 12: 33-47.
- Carenza, L., Villani, C., Framarino dei Malatesta, M. L., Prosperi Porta, R., Millefiorine, M., Antonini, G., Bolasco, P., Bandiera, G., and Marzetti, L. (1986). Peripheral neuropathy and ototoxicity of
 15 dichlorodiamineplatinum: instrumental evaluation. *Gynecol. Oncol.* 25:244-249.
- Chao, M. V., Bothwell, M. A., Ross, A. H., Koprowski, H., Lanahan, A. A., Buck, C. R., and Sehgal, A. (1986). Gene transfer and molecular cloning of the human NGF receptor. *Science* 232:518-521.
- Chao, M. V. (1992). Growth factor signalling: where is the specificity? *Cell* 68:995-997.
- Clary, D. O., and Reichardt, L. F. (1994). An alternatively spliced form of the nerve growth factor
 20 receptor trkA confers an enhanced response to neurotrophin 3. *Proc. Natl. Acad. Sci. USA* 91:11133-11137.
- Clary, D. O., Weskamp, G., Austin, L. R., and Reichardt, L. F. (1994). trkA cross-linking mimics neuronal responses to nerve growth factor. *Mol. Biol. Cell* 5:549-563.
- Cohen A, Bray GM, Aguayo AJ (1994) Neurotrophin-4/5 (NT-4/5) increases adult rat retinal ganglion
 25 cell survival and neurite outgrowth *in vitro*. *J. Neurobiol.* 25:953-959.
- Cordon-Cardo, C., Tapley, P., Jing, S., Nanduri, V., O'Rourke, E., Lamballe, F., Kovary, K., Klein, R., Jones, K. R., Reichardt, L. F. and Barbacid, M. (1991), *Cell*, 66, 173-183
- Corwin JT, Warchol ME (1991) Auditory hair cells: structure, function, development, and degeneration. *Ann Rev Neurosci* 14: 301-333.
- 30 Cotanche DA, Lee KH (1994) Regeneration of hair cells in the vestibulocochlear system of birds and mammals. *Curr Opin Neurobiol* 4: 509-514.
- Davies, A. M., Lee, K. F., and Jaenisch, R. (1993). p75-deficient trigeminal sensory neurons have an altered response to NGF but not to other neurotrophins. *Neuron* 11:565-574.
- Davies AM, Horton A, Burton LE, Schmelzer C, Vandlen R, Rosenthal A (1993b) Neurotrophin-4/5 is a
 35 mammalian-specific survival factor for distinct populations of sensory neurons. *J. Neurosci.* 13:4961-4967.
- Davies, A. M., Thoenen, H., and Barde, Y.-A. (1986). Different factors from the central nervous system and peripheral regulate the survival of sensory neurons. *Nature* 319:497-502.
- De Moura LFP, Hayden RC (1968) Salicylate ototoxicity. *Arch Otolaryng* 87:60-64.
- 40 Dublin WB (1976) Fundamentals of sensorineural auditory pathology. Springfield, Illinois: C. C. Thomas.

- Duckert, L. G., and Rubel, E. W. (1994). Morphological correlates of the functional recovery in the chicken inner ear after gentamicin treatment. *J. Comp. Neurol.* 331:75-96.
- Ernfors P, Ibanez CF, Ebendal T, Olson L, Persson H (1990) Molecular cloning and neurotrophic activities of a protein with structural similarities to nerve growth factor: developmental and topographic expression in the brain. *Proc. Natl. Acad. Sci. USA* 87:5454-5458.
- 5 Ernfors, P., Lee, K.-F., and Jaenisch, R. (1994). Mice lacking brain-derived neurotrophic factor develop with sensory deficits. *Nature* 368:147-150.
- Ernfors P, Loring J, Jaenisch R, Van De Water TR (1995) Function of neurotrophins in the auditory and vestibular systems: Analysis of BDNF and NT-3 gene knockout mice. *Assoc. Res Otolaryngol Abstr*
- 10 p190.
- Escandon E, Soppet D, Rosenthal A, Mendoza-Ramirez J-L, Szonyi E, Burton LE, Henderson CE, Parada LF, Nikolics K (1994) Regulation of neurotrophin receptor expression during embryonic and postnatal development. *J. Neurosci.* 14:2954-2068.
- Falbe-Hansen J (1941) Clinical and experimental histological studies on effects of salicylate and quinine on the ear. *Acta Otolaryng suppl* 44: 1-216.
- 15 Fariñas, I., Jones, K. R., Backus, C., Wang, X.-Y., and Reichardt, L. F. (1994). Severe sensory and sympathetic deficits in mice lacking neurotrophins-3. *Nature* 369:658-661.
- Fischer W, Sirevaag A, Wiegand SJ, Lindsay RM, Björklund A (1994) Reversal of spatial memory impairments in aged rats by nerve growth factor and neurotrophins 3 and 4/5 but not by brain-derived
- 20 neurotrophic factor. *Proc. Natl. Acad. Sci. USA* 91:8607-8611.
- Fleischman, R. W., Stadnicki, S. W., Ethier, M. F., and Schaeppi, U. (1975). Ototoxicity of *cis*-dichlorodiammine platinum (II) in the guinea pig. *Toxicol Appl. Pharmacol.* 33:320-332.
- Forge A, Li L, Corwin JT, Nevill G (1993) Ultrastructural evidence for hair cell regeneration in the mammalian inner ear. *Science* 259:1616-1619.
- 25 Fritzsche, B., Smyene, R., Fagan, A., Selos-Santiago, I. (1995). Mice homologous for a non-functional trk-B receptor lack selectively in the innervation of semicircular canals. *Assoc. Res. Otolaryngol. Abstr.* p190.
- Furley A, Morton SB, Malano D, Karagogeos, Dodd J, Jessell TM (1990) The axonal glycoprotein TAG-1 is an immunoglobulin superfamily member with neurite outgrowth-promoting activity. *Cell* 61:157-170.
- 30 Gao W-Q, Heitz N, Hatten ME (1991) Cerebellar granule cell neurogenesis is regulated by cell-cell interactions *in vitro*. *Neuron* 6:705-715.
- Gao W-Q, Dybdal N, Shinsky N, Murnane A, Schmelzer C, Siegel M, Keller G, Hefti F, Phillips HS, Winslow JW (1995b) Neurotrophin-3 reverses experimental cisplatin-induced peripheral sensory neuropathy. *Ann Neurol* (1995) 38:30-37 .
- 35 Gao, W.-Q., Zheng, J. L., and Karihaloo, M. (1995). Neurotrophin-4/5 (NT-4/5) and brain-derived neurotrophic factor (BDNF) act at later stages of cerebellar granule cell differentiation. *J. Neurosci.* 15:2656-2667.
- Garner AS, Large TH (1994) Isoforms of the avian trkC receptor: A novel kinase insertion dissociates transformation and process outgrowth from survival. *Neuron* 13:457-472.
- 40 Gotz, R., Koster, R., Winkler, C., Raulf, F., Lottspeltch, F., Scharti, M., and Thoenen, H. (1994). Neurotrophin-6 is a new member of the nerve growth factor family. *Nature* 372:266-269.

- Grotz *et al.*, Eur. J. Biochem. 204:745-749 (1992)
- Guild S, Cowe S, Bunch C, Polvogt (1931) Correlations of differences in sensory of innervation of the organ of Corti with differences in the acuity of hearing, including evidences as to the location in the human cochlea of receptors for certain tones. Acta Otolaryngol. (Stockh) 15:269-308.
- 5 Hefti F (1986) Nerve growth factor (NGF) promotes survival of septal cholinergic neurons after fimbrial transections. J Neurosci 6:2155-2162.
- Hinojosa, R., and Lerner, S. A. (1987). Cochlear neural degeneration without hair cell loss in two patients with aminoglycoside ototoxicity. J. Infect. Dis. 156: 449-455
- Hohn A, Leibrock J, Bailey K, Barde YA (1990) Identification and characterization of a novel member of
- 10 the nerve growth factor/brain-derived neurotrophic factor family. Nature 344:339-341.
- Hood JL, Berlin CI, Ed., *Contemporary applications of neurobiology in human hearing assessment* (Raven Press, New York, 1986).
- Hulme, E.C. and Birdsall, M.J.M., Strategy and Tactics in Receptor Binding Studies, p63-212 in Receptor-Ligand Interactions, Ed. E.C. Hulme
- 15 Hyman C, Hofer M, Barde YA, Juhasz M, Yancopoulos GD, Squinto SP, Lindsay RM (1991) BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra. Nature 350:230-233.
- Hynes MA, Poulsen K, Armanini M, Berkemeier L, Phillips H, Rosenthal A (1994) Neurotrophin-4/5 is a survival factor for embryonic midbrain dopaminergic neurons in enriched cultures. J. Neurosci. Res. 37:144-154.
- 20 Ip NY, Stitt TN, Tapley P, Klein R, Glass DJ, Fandl J, Greene LA, Barbacid M, Yancopoulos GD (1993) Similarities and differences in the way neurotrophins interact with the trk receptors in neuronal and nonneuronal cells. Neuron 110:137-149.
- Ip NY, Ibáñez CF, Nye SH, McClain J, Jones PF, Gies DR, Belluscio L, LeBeau MM, Espinosa III R, Squinto SP, Persson H, Yancopoulos GD (1992) Mammalian neurotrophin-4: Structure, chromosomal
- 25 localization, tissue distribution, and receptor specificity. Proc. Nat. Acad. Sci. USA 89:3060-3064.
- Jarvis JF (1966) A case of unilateral permanent deafness following acetyl salicylic acid. J Laryngol 80: 318-320.
- Jones KR, Reichardt LF (1990) Molecular cloning of a human gene that is a member of the nerve growth factor family. Proc. Natl. Acad. Sci. USA 87:8060-8064.
- 30 Kaplan, D.R., Hempstead, B., Martin-Zanca, D., Chao, M., and Parada, L.F. (1991) Science 252, 554-558
- Kaplan DR, Martin ZD, Parada LF (1991) Tyrosine phosphorylation and tyrosine kinase activity of the trk proto-oncogene product induced by NGF. Nature 350:158-160.
- Kelley MW, Telreja DR, Corwin JT (1995) Replacement of hair cells after microbeam irradiation in
- 35 cultured organs of Corti from embryonic and neonatal mice. J Neurosci 15:3013-3026.
- Kelley MW, Xu X-M, Wagner MA, Warchol ME, Corwin JT (1993) The developing organ of Corti contains retinoic acid and forms supernumerary hair cells in response to exogenous retinoic acid in culture. Development 119:1041-1053.
- Klein R, Jing SQ, Nanduri V, O'Rourke E, Barbacid M (1991a) The trk proto-oncogene encodes a
- 40 receptor for nerve growth factor. Cell 65:189-197.

- Klein R, Nanduri V, Jing SA, Lamballe F, Tapley P, Bryant S, Cordon-Cardo C, Jones KR, Reichardt LF, Barbacid M (1991b) The trkB tyrosine protein kinase is a receptor for brain-derived neurotrophic factor and neurotrophin-3. *Cell* 66:395-403.
- Klein R, Martin-Zanca D, Barbacid M, Parada LF (1990) Expression of the tyrosine kinase receptor gene *trkB* is confined to the murine embryonic and adult nervous system. *Development* 109:845-850.
- 5 Klein, R., Lamballe, F., Bryant, S., and Barbacid, M. (1992) *Neuron* 8, 947-956
- Klein, R., Parada, L. F., Coulier, F. and Barbacid, M. (1989), *EMBO J.*, 8, 3701-3709
- Knusel B, Beck KD, Winslow JW, Rosenthal A, Burton LE, Widmer HR, Nikolics K, Hefti F (1992) Brain-derived neurotrophic factor administration protects basal forebrain cholinergic but not nigral dopaminergic neurons from degenerative changes after axotomy in the adult rat brain. *J Neurosci*
- 10 12:4391-4402.
- Koliatsos VE, Clatterbuck RE, Winslow JW, Cayouette MH, Price DL (1993) Evidence that brain-derived neurotrophic factor is a trophic factor for motor neurons *in vivo*. *Neuron* 10:359-367.
- Konings PNM, Makkink WK, van Delft AML, Ruigt GSF (1994) Reversal by NGF of cytostatic drug-induced reduction of neurite outgrowth in rat dorsal root ganglia *in vitro*. *Brain Res* 640:195-204.
- 15 Kopf-Maier P, Muhlhausen SK (1992) Changes in the cytoskeleton pattern of tumor cells by cisplatin *in vitro*. *Chem. Biol Interact* 82:295-316.
- Korsching, S. (1993). The neurotrophic factor concept: A reexamination. *J. Neurosci.* 13:2739-2748.
- Lamballe F, Klein R, Barbacid M (1991) trkC, a new member of the trk family of tyrosine protein kinase, is a receptor for neurotrophin-3. *Cell* 66:967-979.
- 20 Lambert PR (1994) Inner ear hair cell regeneration in a mammal: identification of a triggering factor. *Laryngoscope* 104:701-718.
- Lärkfors L, Ebendal T, Lindsay RM, Alderson RF (1993) Effects of neurotrophins on rat embryonic cerebellar purkinje cells *in vitro*. *Abstr. Soc. Neurosci.* 19:A278.14.
- 25 Leake PA, Snyder RL, Hradek GT, Rebscher SJ (1992) Chronic intracochlear electrical stimulation in neonatally deafened cats: effects of intensity and stimulating electrode location. *Hear Res* 64:99-117.
- Lefebvre PP, Malgrange B, Staecher H, Moghadass M, Van De Water TR, Moonen G (1994) Neurotrophins affect survival and neuritogenesis by adult injured auditory neurons *in vitro*. *NeuroReport* 5:865-868.
- 30 Lefebvre, P. P., Malgrange, B., Staecher, H., Moonen, G. and Van De Water, T. R. (1993). Retinoic acid stimulates regeneration of mammalian auditory hair cells. *Science* 260:692-695.
- Lefebvre, P. P., Van De Water, T. R., Represa, J., Liu, W., Bernd, P., Modlin, S., Moonen, G., and Mayer, M. B. (1991). Temporal pattern of nerve growth factor (NGF) binding *in vivo* and the *in vitro* effects of NGF on cultures of developing auditory and vestibular neurons. *Acta Otolaryngol (Stockh)*
- 35 111:304-311.
- Lefebvre PP, Malgrange B, Moonen G, Van De Water TR (1995) Response to: Regeneration and mammalian auditory hair cells. *Science* 267: 709-711.
- Leibrock J, Lottspeich F, Hohn A, Hofer M, Hengerer B, Masiakowski P, Thoenen H, Barde YA (1989) Molecular cloning and expression of brain-derived neurotrophic factor. *Nature* 341:149-152.
- 40 Levi-Montalcini R (1987) The nerve growth factor: thirty-five years later. *EMBO J.* 6:1145-1154.

- Lim DJ (1986) Effects of noise and ototoxic drugs at the cellular level in the cochlea: A review. *Am J Otolaryngol* 7: 73-99.
- Lippe WR, Hathaway O, Parlotz D (1995) Loss of avian spiral ganglion neurons following aminoglycoside-induced hair cell loss and regeneration. *Assoc Res Otolaryngol Abstr.* p84.
- 5 Maisonpierre PC, Belluscio L, Squinto S, Ip NY, Furth ME, Lindsay RM, Yancopoulos GD (1990) Neurotrophin-3: a neurotrophic factor related to NGF and BDNF. *Science* 247:1446-1451.
- Martin-Zanca, D., Oskam, R., Mitra, G., Copeland, T. and Barbacid, M. (1989), *Mol.Cell. Biol.*, 9, 24-33
- McAlpine D, Johnstone BM (1990) The ototoxic mechanism of cisplatin. *Hear Res* 47:191-204.
- McCabe P, Dey F (1965) The effects of aspirin upon auditory sensitivity. *Ann Otol* 74: 312-324.
- 10 Mollman JE (1990) Cisplatin neurotoxicity. *N. Engl. J. Med.* 322:126-127.
- Myers EN, Berstaein JM (1965) Salicylate ototoxicity: A clinical and experimental study. *Arch Otolaryngol Head Neck Surg* 82: 483-493.
- Nakai, Y., Konishi, K., Chang, K. C., Ohashi, K., Morisaki, N., Minowa, Y., and Morimoto, A. (1982). Ototoxicity of the anticancer drug cisplatin. *Acta Otolaryngol* 93:227-232.
- 15 Pirvola, U., Ylikoski, J., Palgi, J., Lehtonen, E., Arumäe, U., and Saarma, M. (1992). Brain-derived neurotrophic factor and neurotrophin 3 mRNAs in the peripheral target fields of developing inner ear ganglia. *Proc. Natl. Acad. Sci. USA* 89:9915-9919.
- Pryor G (1994) Assessment of auditory dysfunction. In *Principle of Neurotoxicology*. Chang LW, ed., Marcel Dekker, Inc. PP345-371.
- 20 Rastel D, Abdouh A, Dahl D, Roman R (1993) An original organotypic culture method to study the organ of Corti of the newborn rat *in vitro*. *J Neurosci Methods* 47:123-131.
- Richardson GP, Russell IJ (1991) Cochlear cultures as a model system for studying aminoglycoside ototoxicity. *Hear Res* 53:293-311.
- Roelofs, R. I., Hrushesky, W., Rogin, J., and Rosenberg, L. (1984). Peripheral sensory neuropathy and cisplatin chemotherapy. *Neurology* 34:934-938.
- 25 Rosenthal A, Goeddel D, Nguyen T, Lewis M, Shih A, Laramée GR, Nikolics K, Winslow JW (1990) Primary structure and biological activity of a novel human neurotrophic factor. *Neuron* 4:767-773.
- Rybak LP (1986) Ototoxic mechanisms. In: *Neurobiology of Hearing*. Altschuler RA, Bobbin RP, Hoffman DW, Eds. Raven Press (New York) PP441-454.
- 30 Schacht J (1986) Molecular mechanisms of drug-induced hearing loss. *Hear Res* 22: 297-304.
- Schechterson, L. C., and Bothwell, M. (1994). Neurotrophin and neurotrophin receptor mRNA expression in developing inner ear. *Hear. Res.* 73:92-100.
- Scopes, R., Protein Purification, Springer-Verlag, NY (1982)
- Sera, K., Harada, Y., Tagashira, N., Suzuki, M., Hirakawa, K., and Ohya, T. (1987). Morphological changes in the vestibular epithelia and ganglion induced by ototoxic drug. *Scanning Microsc.* 1:1191-1197.
- 35 Shelton, D. L., Sutherland, J., Gripp, J., Camertato, T., Armanini, M. P., Phillips, H. S., Carroll, K., Spencer, S. D., and Levinson, A. D. (1995). Human trks: Molecular cloning, tissue distribution, and expression of extracellular domain immunoadhesins. *J. Neurosci.* 15:477-491.
- 40 Siegal T, Haim N (1990) Cisplatin-induced peripheral neuropathy. *Cancer* 66:1117-1123.

- Snider, W. D. (1994), Functions of the neurotrophins during nervous system development: What the knockouts are teaching us. *Cell* 77: 627-638.
- Sobkowicz HM, Bereman B, Rose JE (1975) Organotypic development of the organ of Corti in culture. *J. neurocytol.* 4:543-572.
- 5 Soppet D, Escandon E, Maragos J, Middlemas DS, Reid SW, Blair J, Burton LE, Stanton BR, Kaplan DR, Hunter T, Nikolics K, Parada LF (1991) The neurotrophic factors brain-derived neurotrophic factor and neurotrophin-3 are ligands for the trkB tyrosine kinase receptor. *Cell* 65:895-903.
- Squinto SP, Stitt TN, Aldrich TH, Davis S, Bianco SM, Radziejewski C, Glass DJ, Masiakowski P, Furth ME, Valenzuela DM, DiStefano PS, Yancopoulos GD (1991) trkB encodes a functional receptor for
- 10 brain-derived neurotrophic factor and neurotrophin-3 but not nerve growth factor. *Cell* 65:885-893.
- Stadnicki, S. W., Fleischman, R. W., Schaeppi, U., and Merriam, P. (1975). *Cis*-dichlorodiammineplatinum (II) (NSC-119875): Hearing loss and other toxic effects in rhesus monkeys. *Cancer Chemother. Rep.* 59:467-480.
- Thompson, S. W., Davis, L. E., Kornfeld, M., Hilgers, R. D., and Standefer, J. C. (1984). Cisplatin neuropathy. *Cancer* 54:1269-1275.
- 15 Tsoulfas P, Soppet D, Escandon E, Tessarollo L, Mendoza-Ramirez J-L, Rosenthal A, Nikolics K, Parada LF (1993) The rat trkC locus encodes multiple neurogenic receptors that exhibit differential response to neurotrophin-3 in PC12 cells. *Neuron* 10:975-990.
- Tsue TT, Oesterle EC, Rubel EW (1994a) Diffusible factors regulate hair cell regeneration in the avian
- 20 inner ear. *Proc Natl Acad. Sci USA* 91:1584-1588.
- Tsue TT, Oesterle EC, Rubel EW (1994b) Hair cell regeneration in the inner ear. *Otolaryngol. Head Neck Surg* 111:281-301.
- Valenzuela DM, Maisonpierre PC, Glass DJ, Rojas E, Nunez L, Kong Y, Gies DR, Stitt TN, Ip NY, Yancopoulos GD (1993) Alternative forms of rat trkC with different functional capabilities. *Neuron* 10:
- 25 963-974.
- Vazquez E, Van De Water TR, Del Valle M, Veta JA, Staecker H, Giráldez F, Represa J (1994) Pattern of trkB protein-like immunoreactivity *in vivo* and the *in vitro* effects of brain-derived neurotrophic factor (BDNF) on developing cochlear and vestibular neurons. *Anat. Embryol.* 189:157-167.
- Verdi, J. M., Birren, S. J., Ibanez, C. F., Persson, H., Kaplan, D. R., Benedetti, M., Chao, M. V., and
- 30 Anderson, D. J. (1994). p75^{LNGFR} regulates trk signal transduction and NGF-induced neuronal differentiation in MAH cells. *Neuron* 12:733-745.
- Von Bartheld, C. S., Patterson, S. L., Heuer, J. G., Wheeler, E.F., Bothwell, M., and Rubel, E. W. (1991). Expression of nerve growth factor (NGF) receptors in the developing inner ear of chick and rat. *Development* 113: 455-470.
- 35 Warchol, M. E., Lambert, P. R., Goldstein, B. J., Forge, A., and Corwin, J. T. (1993). Regenerative proliferation in inner ear sensory epithelia from adult Guinea pigs and humans. *Science* 259:1619-1622.
- Weskamp, G., and Reichardt, L. F. (1991). Evidence that biological activity of NGF is mediated through a novel subclass of high affinity receptors. *Neuron* 6:649-663.
- Wheeler, E. F., Bothwell, M., Schecterson, L. C., and Von Bartheld, C. S. (1994). Expression of BDNF
- 40 and NT-3 mRNA in hair cells of the organ of corti: Quantitative analysis in developing rats. *Hear. Res.* 73:46-56.

- Windebank AJ, Smith AG, Russell JW (1994) The effect of nerve growth factor, ciliary neurotrophic factor, and ACTH analogs on cisplatin neurotoxicity *in vitro*. *Neurology* 44: 488-494.
- Wittmaack K (1903) Beitrage zur Kenntnis der Wirkung des Chinins auf das Gehoerorgan. *Pflueger Arch Ges Physiol* 95:237.
- 5 Woodford CM, Henderson D, HamernikRP (1978) Effects of combinations of sodium salicylate and noise on the auditory threshold. *Ann Otol Rhinol Laryngol* 87:117-127.
- Yamashita H, Oesterle EC (1995) Induction of cell proliferation in mammalian inner-ear sensory epithelia by transforing growth factor a and epidermal growth factor. *Proc Natl Acad Sci USA* 92:3152-3155.
- 10 Yan Q, Elliott JL, Snider WD (1992) Brain-derived neurotrophic factor rescues spinal motoneurons from axotomy induced cell death. *Nature* 360:753-755.
- Yan, Q., Matheson, C., Sun, J., Radeke, M. J., Feinstein, S. C., and Miller, J. A. (1994). Distribution of intracerebral ventricularly administered neurotrophins in rat brain and its correlation with trk receptor expression. *Exper. Neurology* 127:23-36.
- 15 Ylikoski, J., Pirvola, U., Moshnyakov, M., Palgi, J., Arumae, U., and Saarma, M. (1993). Expression patterns of neurotrophin and their receptor mRNAs in the rat inner ear. *Hear. Res.* 65:69-78.

WE CLAIM:

1. A method of inducing hair cell generation or inner-ear-supporting cell growth, regeneration, and/or proliferation, comprising contacting an inner-ear-supporting cell which expresses HER2 and/or HER3 receptors with an effective amount of an isolated ligand which activates HER2 and/or HER3 receptors or a combination thereof.
2. The method of Claim 1, wherein the activating ligand is a heregulin polypeptide, heregulin variant, heregulin agonist antibody or fragment thereof capable of binding to the HER2 or HER3 receptor.
3. The method of Claim 2, wherein the activating ligand is human heregulin or a fragment thereof.
4. The method of Claim 2, wherein the activating ligand is selected from the group consisting of HRG- α , - β 1, - β 2, - β 2-like, and - β 3 and fragments thereof.
5. The method of Claim 2, wherein the activating ligand is γ -HRG or a fragment thereof.
6. The method of Claim 2, wherein the activating ligand is recombinant human heregulin or a fragment thereof.
7. The method of claim 2, wherein the supporting cell is in cochlear implant.
8. The method of Claim 1, wherein the activating ligand is administered at a daily dose of about 1 μ g/kg to 100 mg/kg.
9. The method of Claim 2, wherein the activating ligand is an agonist antibody.
10. The method of Claim 1, wherein the contacting is by administration to a patient in need thereof.
11. The method of Claim 6, wherein the heregulin is rHRG- β 1-177-244.
12. The method of Claim 1, wherein the inner-ear-supporting cell is in the utricle or cochlea.
13. The method of Claim 1 wherein the inner-ear-supporting cell expresses HER2, HER3, or both.
14. A method of increasing the number of inner ear supporting cells, comprising administering to a patient in need thereof an effective amount of an isolated HER2 and/or HER3 activating ligand.
15. The method of Claim 14, wherein the activating ligand is a heregulin polypeptide, heregulin variant, heregulin agonist antibody or fragment thereof capable of binding to the HER2 and/or HER3 receptor.
16. A method of treating a hair cell related hearing disorder, comprising administering to a patient in need thereof an effective amount of an isolated HER2 and/or HER3 activating ligand.
17. The method of Claim 16, wherein the activating ligand is a heregulin polypeptide, heregulin variant, heregulin agonist antibody or fragment thereof capable of binding to the HER2 and/or HER3 receptor.
18. A method, comprising the steps of:
 - (a) obtaining an inner-ear-supporting cell sample from a mammal;
 - (b) contacting the sample with a ligand which activates HER2 or HER3 or a combination thereof to induce growth and/or proliferation of inner-ear-supporting cells in the sample and to obtain an expanded sample; and
 - (c) re-introducing the expanded sample into the mammal.

1/34

GG	GCG	CGA	GCG	CCT	CAG	CGC	GGC	CGC	TCG	CTC	TCC	CCC	38
	Ala	Arg	Ala	Pro	Gln	Arg	Gly	Arg	Ser	Leu	Ser	Pro	
	1				5					10			
TCG	AGG	GAC	AAA	CTT	TTC	CCA	AAC	CCG	ATC	CGA	GCC	CTT	77
Ser	Arg	Asp	Lys	Leu	Phe	Pro	Asn	Pro	Ile	Arg	Ala	Leu	
	15					20						25	
GGA	CCA	AAC	TCG	CCT	GCG	CCG	AGA	GCC	GTC	CGC	GTA	GAG	116
Gly	Pro	Asn	Ser	Pro	Ala	Pro	Arg	Ala	Val	Arg	Val	Glu	
				30					35				
CGC	TCC	GTC	TCC	GGC	GAG	ATG	TCC	GAG	CGC	AAA	GAA	GGC	155
Arg	Ser	Val	Ser	Gly	Glu	Met	Ser	Glu	Arg	Lys	Glu	Gly	
	40				45						50		
AGA	GGC	AAA	GGG	AAG	GGC	AAG	AAG	AAG	GAG	CGA	GGC	TCC	194
Arg	Gly	Lys	Gly	Lys	Gly	Lys	Lys	Lys	Glu	Arg	Gly	Ser	
			55					60					
GGC	AAG	AAG	CCG	GAG	TCC	GCG	GCG	GGC	AGC	CAG	AGC	CCA	233
Gly	Lys	Lys	Pro	Glu	Ser	Ala	Ala	Gly	Ser	Gln	Ser	Pro	
	65				70					75			
GCC	TTG	CCT	CCC	CGA	TTG	AAA	GAG	ATG	AAA	AGC	CAG	GAA	272
Ala	Leu	Pro	Pro	Arg	Leu	Lys	Glu	Met	Lys	Ser	Gln	Glu	
		80					85					90	
TCG	GCT	GCA	GGT	TCC	AAA	CTA	GTC	CTT	CGG	TGT	GAA	ACC	311
Ser	Ala	Ala	Gly	Ser	Lys	Leu	Val	Leu	Arg	Cys	Glu	Thr	
				95					100				
AGT	TCT	GAA	TAC	TCC	TCT	CTC	AGA	TTC	AAG	TGG	TTC	AAG	350
Ser	Ser	Glu	Tyr	Ser	Ser	Leu	Arg	Phe	Lys	Trp	Phe	Lys	
	105					110					115		
AAT	GGG	AAT	GAA	TTG	AAT	CGA	AAA	AAC	AAA	CCA	CAA	AAT	389
Asn	Gly	Asn	Glu	Leu	Asn	Arg	Lys	Asn	Lys	Pro	Gln	Asn	
			120					125					
ATC	AAG	ATA	CAA	AAA	AAG	CCA	GGG	AAG	TCA	GAA	CTT	CGC	428
Ile	Lys	Ile	Gln	Lys	Lys	Pro	Gly	Lys	Ser	Glu	Leu	Arg	
	130				135					140			
ATT	AAC	AAA	GCA	TCA	CTG	GCT	GAT	TCT	GGA	GAG	TAT	ATG	467
Ile	Asn	Lys	Ala	Ser	Leu	Ala	Asp	Ser	Gly	Glu	Tyr	Met	
		145					150					155	
TGC	AAA	GTG	ATC	AGC	AAA	TTA	GGA	AAT	GAC	AGT	GCC	TCT	506
Cys	Lys	Val	Ile	Ser	Lys	Leu	Gly	Asn	Asp	Ser	Ala	Ser	
				160					165				

FIG. 1A

2/34

GCC AAT ATC ACC ATC GTG GAA TCA AAC GAG ATC ATC ACT 545
 Ala Asn Ile Thr Ile Val Glu Ser Asn Glu Ile Ile Thr
 170 175 180

GGT ATG CCA GCC TCA ACT GAA GGA GCA TAT GTG TCT TCA 584
 Gly Met Pro Ala Ser Thr Glu Gly Ala Tyr Val Ser Ser
 185 190

GAG TCT CCC ATT AGA ATA TCA GTA TCC ACA GAA GGA GCA 623
 Glu Ser Pro Ile Arg Ile Ser Val Ser Thr Glu Gly Ala
 195 200 205

AAT ACT TCT TCA TCT ACA TCT ACA TCC ACC ACT GGG ACA 662
 Asn Thr Ser Ser Ser Thr Ser Thr Ser Thr Thr Gly Thr
 210 215 220

AGC CAT CTT GTA AAA TGT GCG GAG AAG GAG AAA ACT TTC 701
 Ser His Leu Val Lys Cys Ala Glu Lys Glu Lys Thr Phe
 225 230

TGT GTG AAT GGA GGG GAG TGC TTC ATG GTG AAA GAC CTT 740
 Cys Val Asn Gly Gly Glu Cys Phe Met Val Lys Asp Leu
 235 240 245

TCA AAC CCC TCG AGA TAC TTG TGC AAG TGC CAA CCT GGA 779
 Ser Asn Pro Ser Arg Tyr Leu Cys Lys Cys Gln Pro Gly
 250 255

TTC ACT GGA GCA AGA TGT ACT GAG AAT GTG CCC ATG AAA 818
 Phe Thr Gly Ala Arg Cys Thr Glu Asn Val Pro Met Lys
 260 265 270

GTC CAA AAC CAA GAA AAG GCG GAG GAG CTG TAC CAG AAG 857
 Val Gln Asn Gln Glu Lys Ala Glu Glu Leu Tyr Gln Lys
 275 280 285

AGA GTG CTG ACC ATA ACC GGC ATC TGC ATC GCC CTC CTT 896
 Arg Val Leu Thr Ile Thr Gly Ile Cys Ile Ala Leu Leu
 290 295

GTG GTC GGC ATC ATG TGT GTG GTG GCC TAC TGC AAA ACC 935
 Val Val Gly Ile Met Cys Val Val Ala Tyr Cys Lys Thr
 300 305 310

AAG AAA CAG CGG AAA AAG CTG CAT GAC CGT CTT CGG CAG 974
 Lys Lys Gln Arg Lys Lys Leu His Asp Arg Leu Arg Gln
 315 320

AGC CTT CGG TCT GAA CGA AAC AAT ATG ATG AAC ATT GCC 1013
 Ser Leu Arg Ser Glu Arg Asn Asn Met Met Asn Ile Ala
 325 330 335

FIG. 1B

3/34

AAT GGG CCT CAC CAT CCT AAC CCA CCC CCC GAG AAT GTC	1052
Asn Gly Pro His His Pro Asn Pro Pro Pro Glu Asn Val	
340 345 350	
CAG CTG GTG AAT CAA TAC GTA TCT AAA AAC GTC ATC TCC	1091
Gln Leu Val Asn Gln Tyr Val Ser Lys Asn Val Ile Ser	
355 360	
AGT GAG CAT ATT GTT GAG AGA GAA GCA GAG ACA TCC TTT	1130
Ser Glu His Ile Val Glu Arg Glu Ala Glu Thr Ser Phe	
365 370 375	
TCC ACC AGT CAC TAT ACT TCC ACA GCC CAT CAC TCC ACT	1169
Ser Thr Ser His Tyr Thr Ser Thr Ala His His Ser Thr	
380 385	
ACT GTC ACC CAG ACT CCT AGC CAC AGC TGG AGC AAC GGA	1208
Thr Val Thr Gln Thr Pro Ser His Ser Trp Ser Asn Gly	
390 395 400	
CAC ACT GAA AGC ATC CTT TCC GAA AGC CAC TCT GTA ATC	1247
His Thr Glu Ser Ile Leu Ser Glu Ser His Ser Val Ile	
405 410 415	
GTG ATG TCA TCC GTA GAA AAC AGT AGG CAC AGC AGC CCA	1286
Val Met Ser Ser Val Glu Asn Ser Arg His Ser Ser Pro	
420 425	
ACT GGG GGC CCA AGA GGA CGT CTT AAT GGC ACA GGA GGC	1325
Thr Gly Gly Pro Arg Gly Arg Leu Asn Gly Thr Gly Gly	
430 435 440	
CCT CGT GAA TGT AAC AGC TTC CTC AGG CAT GCC AGA GAA	1364
Pro Arg Glu Cys Asn Ser Phe Leu Arg His Ala Arg Glu	
445 450	
ACC CCT GAT TCC TAC CGA GAC TCT CCT CAT AGT GAA AGG	1403
Thr Pro Asp Ser Tyr Arg Asp Ser Pro His Ser Glu Arg	
455 460 465	
TAT GTG TCA GCC ATG ACC ACC CCG GCT CGT ATG TCA CCT	1442
Tyr Val Ser Ala Met Thr Thr Pro Ala Arg Met Ser Pro	
470 475 480	
GTA GAT TTC CAC ACG CCA AGC TCC CCC AAA TCG CCC CCT	1481
Val Asp Phe His Thr Pro Ser Ser Pro Lys Ser Pro Pro	
485 490	
TCG GAA ATG TCT CCA CCC GTG TCC AGC ATG ACG GTG TCC	1520
Ser Glu Met Ser Pro Pro Val Ser Ser Met Thr Val Ser	
495 500 505	

FIG. 1C

4/34

ATG CCT TCC ATG GCG GTC AGC CCC TTC ATG GAA GAA GAG 1559
 Met Pro Ser Met Ala Val Ser Pro Phe Met Glu Glu Glu
 510 515

AGA CCT CTA CTT CTC GTG ACA CCA CCA AGG CTG CGG GAG 1598
 Arg Pro Leu Leu Leu Val Thr Pro Pro Arg Leu Arg Glu
 520 525 530

AAG AAG TTT GAC CAT CAC CCT CAG CAG TTC AGC TCC TTC 1637
 Lys Lys Phe Asp His His Pro Gln Gln Phe Ser Ser Phe
 535 540 545

CAC CAC AAC CCC GCG CAT GAC AGT AAC AGC CTC CCT GCT 1676
 His His Asn Pro Ala His Asp Ser Asn Ser Leu Pro Ala
 550 555

AGC CCC TTG AGG ATA GTG GAG GAT GAG GAG TAT GAA ACG 1715
 Ser Pro Leu Arg Ile Val Glu Asp Glu Glu Tyr Glu Thr
 560 565 570

ACC CAA GAG TAC GAG CCA GCC CAA GAG CCT GTT AAG AAA 1754
 Thr Gln Glu Tyr Glu Pro Ala Gln Glu Pro Val Lys Lys
 575 580

CTC GCC AAT AGC CGG CGG GCC AAA AGA ACC AAG CCC AAT 1793
 Leu Ala Asn Ser Arg Arg Ala Lys Arg Thr Lys Pro Asn
 585 590 595

GGC CAC ATT GCT AAC AGA TTG GAA GTG GAC AGC AAC ACA 1832
 Gly His Ile Ala Asn Arg Leu Glu Val Asp Ser Asn Thr
 600 605 610

AGC TCC CAG AGC AGT AAC TCA GAG AGT GAA ACA GAA GAT 1871
 Ser Ser Gln Ser Ser Asn Ser Glu Ser Glu Thr Glu Asp
 615 620

GAA AGA GTA GGT GAA GAT ACG CCT TTC CTG GGC ATA CAG 1910
 Glu Arg Val Gly Glu Asp Thr Pro Phe Leu Gly Ile Gln
 625 630 635

AAC CCC CTG GCA GCC AGT CTT GAG GCA ACA CCT GCC TTC 1949
 Asn Pro Leu Ala Ala Ser Leu Glu Ala Thr Pro Ala Phe
 640 645

CGC CTG GCT GAC AGC AGG ACT AAC CCA GCA GGC CGC TTC 1988
 Arg Leu Ala Asp Ser Arg Thr Asn Pro Ala Gly Arg Phe
 650 655 660

TCG ACA CAG GAA GAA ATC CAG G 2010
 Ser Thr Gln Glu Glu Ile Gln
 665 669

FIG. 1D

5/34

```

GG  GAC AAA CTT TTC CCA AAC CCG ATC CGA GCC CTT GGA 38
    Asp Lys Leu Phe Pro Asn Pro Ile Arg Ala Leu Gly
      1           5           10

CCA AAC TCG CCT GCG CCG AGA GCC GTC CGC GTA GAG CGC 77
Pro Asn Ser Pro Ala Pro Arg Ala Val Arg Val Glu Arg
      15           20           25

TCC GTC TCC GGC GAG ATG TCC GAG CGC AAA GAA GGC AGA 116
Ser Val Ser Gly Glu Met Ser Glu Arg Lys Glu Gly Arg
      30           35

GGC AAA GGG AAG GGC AAG AAG AAG GAG CGA GGC TCC GGC 155
Gly Lys Gly Lys Gly Lys Lys Lys Glu Arg Gly Ser Gly
      40           45           50

AAG AAG CCG GAG TCC GCG GCG GGC AGC CAG AGC CCA GCC 194
Lys Lys Pro Glu Ser Ala Ala Gly Ser Gln Ser Pro Ala
      55           60

TTG CCT CCC CAA TTG AAA GAG ATG AAA AGC CAG GAA TCG 233
Leu Pro Pro Gln Leu Lys Glu Met Lys Ser Gln Glu Ser
      65           70           75

GCT GCA GGT TCC AAA CTA GTC CTT CGG TGT GAA ACC AGT 272
Ala Ala Gly Ser Lys Leu Val Leu Arg Cys Glu Thr Ser
      80           85           90

TCT GAA TAC TCC TCT CTC AGA TTC AAG TGG TTC AAG AAT 311
Ser Glu Tyr Ser Ser Leu Arg Phe Lys Trp Phe Lys Asn
      95           100

GGG AAT GAA TTG AAT CGA AAA AAC AAA CCA CAA AAT ATC 350
Gly Asn Glu Leu Asn Arg Lys Asn Lys Pro Gln Asn Ile
      105           110           115

AAG ATA CAA AAA AAG CCA GGG AAG TCA GAA CTT CGC ATT 389
Lys Ile Gln Lys Lys Pro Gly Lys Ser Glu Leu Arg Ile
      120           125

AAC AAA GCA TCA CTG GCT GAT TCT GGA GAG TAT ATG TGC 428
Asn Lys Ala Ser Leu Ala Asp Ser Gly Glu Tyr Met Cys
      130           135           140

AAA GTG ATC AGC AAA TTA GGA AAT GAC AGT GCC TCT GCC 467
Lys Val Ile Ser Lys Leu Gly Asn Asp Ser Ala Ser Ala
      145           150           155

AAT ATC ACC ATC GTG GAA TCA AAC GAG ATC ATC ACT GGT 506
Asn Ile Thr Ile Val Glu Ser Asn Glu Ile Ile Thr Gly
      160           165

```

FIG. 2A

6/34

ATG	CCA	GCC	TCA	ACT	GAA	GGA	GCA	TAT	GTG	TCT	TCA	GAG	545
Met	Pro	Ala	Ser	Thr	Glu	Gly	Ala	Tyr	Val	Ser	Ser	Glu	
	170					175					180		
TCT	CCC	ATT	AGA	ATA	TCA	GTA	TCC	ACA	GAA	GGA	GCA	AAT	584
Ser	Pro	Ile	Arg	Ile	Ser	Val	Ser	Thr	Glu	Gly	Ala	Asn	
			185					190					
ACT	TCT	TCA	TCT	ACA	TCT	ACA	TCC	ACC	ACT	GGG	ACA	AGC	623
Thr	Ser	Ser	Ser	Thr	Ser	Thr	Ser	Thr	Thr	Gly	Thr	Ser	
195					200					205			
CAT	CTT	GTA	AAA	TGT	GCG	GAG	AAG	GAG	AAA	ACT	TTC	TGT	662
His	Leu	Val	Lys	Cys	Ala	Glu	Lys	Glu	Lys	Thr	Phe	Cys	
		210					215					220	
GTG	AAT	GGA	GGG	GAG	TGC	TTC	ATG	GTG	AAA	GAC	CTT	TCA	701
Val	Asn	Gly	Gly	Glu	Cys	Phe	Met	Val	Lys	Asp	Leu	Ser	
				225					230				
AAC	CCC	TCG	AGA	TAC	TTG	TGC	AAG	TGC	CCA	AAT	GAG	TTT	740
Asn	Pro	Ser	Arg	Tyr	Leu	Cys	Lys	Cys	Pro	Asn	Glu	Phe	
	235					240					245		
ACT	GGT	GAT	CGC	TGC	CAA	AAC	TAC	GTA	ATG	GCC	AGC	TTC	779
Thr	Gly	Asp	Arg	Cys	Gln	Asn	Tyr	Val	Met	Ala	Ser	Phe	
			250					255					
TAC	AAG	CAT	CTT	GGG	ATT	GAA	TTT	ATG	GAG	GCG	GAG	GAG	818
Tyr	Lys	His	Leu	Gly	Ile	Glu	Phe	Met	Glu	Ala	Glu	Glu	
260					265					270			
CTG	TAC	CAG	AAG	AGA	GTG	CTG	ACC	ATA	ACC	GGC	ATC	TGC	857
Leu	Tyr	Gln	Lys	Arg	Val	Leu	Thr	Ile	Thr	Gly	Ile	Cys	
			275				280					285	
ATC	GCC	CTC	CTT	GTG	GTC	GGC	ATC	ATG	TGT	GTG	GTG	GCC	896
Ile	Ala	Leu	Leu	Val	Val	Gly	Ile	Met	Cys	Val	Val	Ala	
				290					295				
TAC	TGC	AAA	ACC	AAG	AAA	CAG	CGG	AAA	AAG	CTG	CAT	GAC	935
Tyr	Cys	Lys	Thr	Lys	Lys	Gln	Arg	Lys	Lys	Leu	His	Asp	
	300					305					310		
CGT	CTT	CGG	CAG	AGC	CTT	CGG	TCT	GAA	CGA	AAC	AAT	ATG	974
Arg	Leu	Arg	Gln	Ser	Leu	Arg	Ser	Glu	Arg	Asn	Asn	Met	
			315					320					
ATG	AAC	ATT	GCC	AAT	GGG	CCT	CAC	CAT	CCT	AAC	CCA	CCC	1013
Met	Asn	Ile	Ala	Asn	Gly	Pro	His	His	Pro	Asn	Pro	Pro	
325					330					335			

FIG. 2B

7/34

CCC	GAG	AAT	GTC	CAG	CTG	GTG	AAT	CAA	TAC	GTA	TCT	AAA	1052
Pro	Glu	Asn	Val	Gln	Leu	Val	Asn	Gln	Tyr	Val	Ser	Lys	
		340					345					350	
AAC	GTC	ATC	TCC	AGT	GAG	CAT	ATT	GTT	GAG	AGA	GAA	GCA	1091
Asn	Val	Ile	Ser	Ser	Glu	His	Ile	Val	Glu	Arg	Glu	Ala	
			355					360					
GAG	ACA	TCC	TTT	TCC	ACC	AGT	CAC	TAT	ACT	TCC	ACA	GCC	1130
Glu	Thr	Ser	Phe	Ser	Thr	Ser	His	Tyr	Thr	Ser	Thr	Ala	
	365					370					375		
CAT	CAC	TCC	ACT	ACT	GTC	ACC	CAG	ACT	CCT	AGC	CAC	AGC	1169
His	His	Ser	Thr	Thr	Val	Thr	Gln	Thr	Pro	Ser	His	Ser	
			380					385					
TGG	AGC	AAC	GGA	CAC	ACT	GAA	AGC	ATC	CTT	TCC	GAA	AGC	1208
Trp	Ser	Asn	Gly	His	Thr	Glu	Ser	Ile	Leu	Ser	Glu	Ser	
	390				395					400			
CAC	TCT	GTA	ATC	GTG	ATG	TCA	TCC	GTA	GAA	AAC	AGT	AGG	1247
His	Ser	Val	Ile	Val	Met	Ser	Ser	Val	Glu	Asn	Ser	Arg	
		405					410					415	
CAC	AGC	AGC	CCA	ACT	GGG	GGC	CCA	AGA	GGA	CGT	CTT	AAT	1286
His	Ser	Ser	Pro	Thr	Gly	Gly	Pro	Arg	Gly	Arg	Leu	Asn	
			420						425				
GGC	ACA	GGA	GGC	CCT	CGT	GAA	TGT	AAC	AGC	TTC	CTC	AGG	1325
Gly	Thr	Gly	Gly	Pro	Arg	Glu	Cys	Asn	Ser	Phe	Leu	Arg	
	430					435					440		
CAT	GCC	AGA	GAA	ACC	CCT	GAT	TCC	TAC	CGA	GAC	TCT	CCT	1364
His	Ala	Arg	Glu	Thr	Pro	Asp	Ser	Tyr	Arg	Asp	Ser	Pro	
			445					450					
CAT	AGT	GAA	AGG	TAT	GTG	TCA	GCC	ATG	ACC	ACC	CCG	GCT	1403
His	Ser	Glu	Arg	Tyr	Val	Ser	Ala	Met	Thr	Thr	Pro	Ala	
	455				460					465			
CGT	ATG	TCA	CCT	GTA	GAT	TTC	CAC	ACG	CCA	AGC	TCC	CCC	1442
Arg	Met	Ser	Pro	Val	Asp	Phe	His	Thr	Pro	Ser	Ser	Pro	
		470					475					480	
AAA	TCG	CCC	CCT	TCG	GAA	ATG	TCT	CCA	CCC	GTG	TCC	AGC	1481
Lys	Ser	Pro	Pro	Ser	Glu	Met	Ser	Pro	Pro	Val	Ser	Ser	
			485					490					
ATG	ACG	GTG	TCC	ATG	CCT	TCC	ATG	GCG	GTC	AGC	CCC	TTC	1520
Met	Thr	Val	Ser	Met	Pro	Ser	Met	Ala	Val	Ser	Pro	Phe	
	495					500					505		

FIG. 2C

8/34

ATG GAA GAA GAG AGA CCT CTA CTT CTC GTG ACA CCA CCA 1559
Met Glu Glu Glu Arg Pro Leu Leu 515
AGG CTG CGG GAG AAG AAG TTT GAC CAT CAC CCT CAG CAG 1598
Arg Leu Arg Glu Lys Lys Phe Asp His His Pro Gln Gln 530
520
TTC AGC TTC CAC CAC AAC CCC GCG CAT GAC AGT AAC 1637
Phe Ser Ser Phe His His Asn Pro Ala His Asp Ser Asn 545
535
AGC CTC CCT GCT AGC CCC TTG AGG ATA GTG GAG GAT GAG 1676
Ser Leu Pro Ala Ser Pro Leu Arg Ile Val Glu Asp Glu 555
550
GAG TAT GAA ACG ACC CAA GAG TAC GAG CCA GCC CAA GAG 1715
Glu Tyr Glu Thr Thr Gln Gln Tyr Glu Pro Ala Gln Glu 570
560
CCT GTT AAG AAA CTC GCC AAT AGC CGG CGG GCC AAA AGA 1754
Pro Val Lys Lys Leu Ala Asn Ser Arg Arg Ala Lys Arg 580
575
ACC AAG CCC AAT GGC CAC ATT GCT AAC AGA TTG GAA GTG 1793
Thr Lys Pro Asn Gly His Ile Ala Asn Arg Leu Glu Val 595
585
GAC AGC AAC ACA AGC TCC CAG AGC AGT AAC TCA GAG AGT 1832
Asp Ser Asn Thr Ser Ser Gln Ser Ser Asn Ser Glu Ser 610
600

FIG. 2D

9/34

```

GAA ACA GAA GAT GAA AGA GTA GGT GAA GAT ACG CCT TTC 1871
Glu Thr Glu Asp Glu 615 Arg Val Gly Glu Asp Thr Pro Phe
620

CTG GGC ATA CAG AAC CCC CTG GCA GCC AGT CTT GAG GCA 1910
Leu Gly Ile Gln Asn Pro Leu Ala Ala Ser Leu Glu Ala
625 630 635

ACA CCT GCC TTC CGC CTG GCT GAC AGC AGG ACT AAC CCA 1949
Thr Pro Ala Phe Arg Leu Ala Asp Ser Arg Thr Asn Pro
640 645

GCA GGC CGC TTC TCG ACA CAG GAA GAA ATC CAG GCC AGG 1988
Ala Gly Arg Phe Ser Thr Gln Glu Glu Ile Gln Ala Arg
650 655 660

CTG TCT AGT GTA ATT GCT AAC CAA GAC CCT ATT GCT GTA TA 2029
Leu Ser Ser Val Ile Ala Asn Gln Asp Pro Ile Ala Val
665 670 675

A AACCTAAATA AACACATAGA TTCACCTGTA AAACITTTATT 2070

TTATATAATA AAGTATTCCA CCTTAAATTA AACAAITTTAT TTTATTTTAG 2120

CAGTTCTGCA AATAGAAAAAC AGGAAAAAAA CTTTATATAAA TTAAATATAT 2170

GTATGTAAAA ATGAAAAAAA AAAAAAAA 2199

```

FIG.2E

10/34

GTGGCTGCGG GGCAATTGAA AAAGAGCCGG CGAGGAGTTC CCCGAAACTT 50
 GTTGGAAGCTC CGGGCTCGCG CGGAGGCCAG GAGCTGAGCG GCGGCGGCTG 100
 CCGGACGATG GGAGCGTGAG CAGGACGGTG ATAACCTCTC CCCGATCGGG 150
 TTGCGAGGGC GCCGGGCAGA GGCCAGGACG CGAGCCGCCA GCGGCGGGAC 200
 CCATCGACGA CTTCCCGGGG CGACAGGAGC AGCCCCGAGA GCCAGGGCGA 250
 GCGCCCGTTC CAGGTGGCCG GACCGCCCGC CGCGTCCGCG CCGCGCTCCC 300
 TGCAGGCAAC GGGAGACGCC CCCGCGCAGC GCGAGCGCCT CAGCGCGGCC 350
 GCTCGCTCTC CCCATCGAGG GACAACTTT TCCCAAACCC GATCCGAGCC 400
 CTTGGACCAA ACTCGCCTGC GCCGAGAGCC GTCCGCGTAG AGCGCTCCGT 450
 CTCCGGCGAG ATG TCC GAG CGC AAA GAA GGC AGA GGC AAA 490
 Met Ser Glu Arg Lys Glu Gly Arg Gly Lys
 1 5 10
 GGG AAG GGC AAG AAG AAG GAG CGA GGC TCC GGC AAG AAG 529
 Gly Lys Gly Lys Lys Lys Glu Arg Gly Ser Gly Lys Lys
 15 20
 CCG GAG TCC GCG GCG GGC AGC CAG AGC CCA GCC TTG CCT 568
 Pro Glu Ser Ala Ala Gly Ser Gln Ser Pro Ala Leu Pro
 25 30 35
 CCC CAA TTG AAA GAG ATG AAA AGC CAG GAA TCG GCT GCA 607
 Pro Gln Leu Lys Glu Met Lys Ser Gln Glu Ser Ala Ala
 40 45
 GGT TCC AAA CTA GTC CTT CGG TGT GAA ACC AGT TCT GAA 646
 Gly Ser Lys Leu Val Leu Arg Cys Glu Thr Ser Ser Glu
 50 55 60
 TAC TCC TCT CTC AGA TTC AAG TGG TTC AAG AAT GGG AAT 685
 Tyr Ser Ser Leu Arg Phe Lys Trp Phe Lys Asn Gly Asn
 65 70 75
 GAA TTG AAT CGA AAA AAC AAA CCA CAA AAT ATC AAG ATA 724
 Glu Leu Asn Arg Lys Asn Lys Pro Gln Asn Ile Lys Ile
 80 85

FIG. 3A

11/34

CAA AAA AAG CCA GGG AAG TCA GAA CTT CGC ATT AAC AAA 763
 Gln Lys Lys Pro Gly Lys Ser Glu Leu Arg Ile Asn Lys
 90 95 100

GCA TCA CTG GCT GAT TCT GGA GAG TAT ATG TGC AAA GTG 802
 Ala Ser Leu Ala Asp Ser Gly Glu Tyr Met Cys Lys Val
 105 110

ATC AGC AAA TTA GGA AAT GAC AGT GCC TCT GCC AAT ATC 841
 Ile Ser Lys Leu Gly Asn Asp Ser Ala Ser Ala Asn Ile
 115 120 125

ACC ATC GTG GAA TCA AAC GAG ATC ATC ACT GGT ATG CCA 880
 Thr Ile Val Glu Ser Asn Glu Ile Ile Thr Gly Met Pro
 130 135 140

GCC TCA ACT GAA GGA GCA TAT GTG TCT TCA GAG TCT CCC 919
 Ala Ser Thr Glu Gly Ala Tyr Val Ser Ser Glu Ser Pro
 145 150

ATT AGA ATA TCA GTA TCC ACA GAA GGA GCA AAT ACT TCT 958
 Ile Arg Ile Ser Val Ser Thr Glu Gly Ala Asn Thr Ser
 155 160 165

TCA TCT ACA TCT ACA TCC ACC ACT GGG ACA AGC CAT CTT 997
 Ser Ser Thr Ser Thr Ser Thr Thr Gly Thr Ser His Leu
 170 175

GTA AAA TGT GCG GAG AAG GAG AAA ACT TTC TGT GTG AAT 1036
 Val Lys Cys Ala Glu Lys Glu Lys Thr Phe Cys Val Asn
 180 185 190

GGA GGG GAG TGC TTC ATG GTG AAA GAC CTT TCA AAC CCC 1075
 Gly Gly Glu Cys Phe Met Val Lys Asp Leu Ser Asn Pro
 195 200 205

TCG AGA TAC TTG TGC AAG TGC CCA AAT GAG TTT ACT GGT 1114
 Ser Arg Tyr Leu Cys Lys Cys Pro Asn Glu Phe Thr Gly
 210 215

GAT CGC TGC CAA AAC TAC GTA ATG GCC AGC TTC TAC AAG 1153
 Asp Arg Cys Gln Asn Tyr Val Met Ala Ser Phe Tyr Lys
 220 225 230

GCG GAG GAG CTG TAC CAG AAG AGA GTG CTG ACC ATA ACC 1192
 Ala Glu Glu Leu Tyr Gln Lys Arg Val Leu Thr Ile Thr
 235 240

GGC ATC TGC ATC GCC CTC CTT GTG GTC GGC ATC ATG TGT 1231
 Gly Ile Cys Ile Ala Leu Leu Val Val Gly Ile Met Cys
 245 250 255

GTG GTG GCC TAC TGC AAA ACC AAG AAA CAG CGG AAA AAG 1270
 Val Val Ala Tyr Cys Lys Thr Lys Lys Gln Arg Lys Lys
 260 265 270

FIG. 3B

12/34

CTG CAT GAC CGT CTT CGG CAG AGC CTT CGG TCT GAA CGA 1309
 Leu His Asp Arg Leu Arg Gln Ser Leu Arg Ser Glu Arg
 275 280

AAC AAT ATG ATG AAC ATT GCC AAT GGG CCT CAC CAT CCT 1348
 Asn Asn Met Met Asn Ile Ala Asn Gly Pro His His Pro
 285 290 295

AAC CCA CCC CCC GAG AAT GTC CAG CTG GTG AAT CAA TAC 1387
 Asn Pro Pro Pro Glu Asn Val Gln Leu Val Asn Gln Tyr
 300 305

GTA TCT AAA AAC GTC ATC TCC AGT GAG CAT ATT GTT GAG 1426
 Val Ser Lys Asn Val Ile Ser Ser Glu His Ile Val Glu
 310 315 320

AGA GAA GCA GAG ACA TCC TTT TCC ACC AGT CAC TAT ACT 1465
 Arg Glu Ala Glu Thr Ser Phe Ser Thr Ser His Tyr Thr
 325 330 335

TCC ACA GCC CAT CAC TCC ACT ACT GTC ACC CAG ACT CCT 1504
 Ser Thr Ala His His Ser Thr Thr Val Thr Gln Thr Pro
 340 345

AGC CAC AGC TGG AGC AAC GGA CAC ACT GAA AGC ATC CTT 1543
 Ser His Ser Trp Ser Asn Gly His Thr Glu Ser Ile Leu
 350 355 360

TCC GAA AGC CAC TCT GTA ATC GTG ATG TCA TCC GTA GAA 1582
 Ser Glu Ser His Ser Val Ile Val Met Ser Ser Val Glu
 365 370

AAC AGT AGG CAC AGC AGC CCA ACT GGG GGC CCA AGA GGA 1621
 Asn Ser Arg His Ser Ser Pro Thr Gly Gly Pro Arg Gly
 375 380 385

CGT CTT AAT GGC ACA GGA GGC CCT CGT GAA TGT AAC AGC 1660
 Arg Leu Asn Gly Thr Gly Gly Pro Arg Glu Cys Asn Ser
 390 395 400

TTC CTC AGG CAT GCC AGA GAA ACC CCT GAT TCC TAC CGA 1699
 Phe Leu Arg His Ala Arg Glu Thr Pro Asp Ser Tyr Arg
 405 410

GAC TCT CCT CAT AGT GAA AGG TAT GTG TCA GCC ATG ACC 1738
 Asp Ser Pro His Ser Glu Arg Tyr Val Ser Ala Met Thr
 415 420 425

ACC CCG GCT CGT ATG TCA CCT GTA GAT TTC CAC ACG CCA 1777
 Thr Pro Ala Arg Met Ser Pro Val Asp Phe His Thr Pro
 430 435

AGC TCC CCC AAA TCG CCC CCT TCG GAA ATG TCT CCA CCC 1816
 Ser Ser Pro Lys Ser Pro Pro Ser Glu Met Ser Pro Pro
 440 445 450

FIG. 3C

13/34

GTG TCC AGC ATG ACG GTG TCC AAG CCT TCC ATG GCG GTC 1855
 Val Ser Ser Met Thr Val Ser Lys Pro Ser Met Ala Val
 455 460 465

AGC CCC TTC ATG GAA GAA GAG AGA CCT CTA CTT CTC GTG 1894
 Ser Pro Phe Met Glu Glu Glu Arg Pro Leu Leu Leu Val
 470 475

ACA CCA CCA AGG CTG CGG GAG AAG AAG TTT GAC CAT CAC 1933
 Thr Pro Pro Arg Leu Arg Glu Lys Lys Phe Asp His His
 480 485 490

CCT CAG CAG TTC AGC TCC TTC CAC CAC AAC CCC GCG CAT 1972
 Pro Gln Gln Phe Ser Ser Phe His His Asn Pro Ala His
 495 500

GAC AGT AAC AGC CTC CCT GCT AGC CCC TTG AGG ATA GTG 2011
 Asp Ser Asn Ser Leu Pro Ala Ser Pro Leu Arg Ile Val
 505 510 515

GAG GAT GAG GAG TAT GAA ACG ACC CAA GAG TAC GAG CCA 2050
 Glu Asp Glu Glu Tyr Glu Thr Thr Gln Glu Tyr Glu Pro
 520 525 530

GCC CAA GAG CCT GTT AAG AAA CTC GCC AAT AGC CGG CGG 2089
 Ala Gln Glu Pro Val Lys Lys Leu Ala Asn Ser Arg Arg
 535 540

GCC AAA AGA ACC AAG CCC AAT GGC CAC ATT GCT AAC AGA 2128
 Ala Lys Arg Thr Lys Pro Asn Gly His Ile Ala Asn Arg
 545 550 555

TTG GAA GTG GAC AGC AAC ACA AGC TCC CAG AGC AGT AAC 2167
 Leu Glu Val Asp Ser Asn Thr Ser Ser Gln Ser Ser Asn
 560 565

TCA GAG AGT GAA ACA GAA GAT GAA AGA GTA GGT GAA GAT 2206
 Ser Glu Ser Glu Thr Glu Asp Glu Arg Val Gly Glu Asp
 570 575 580

ACG CCT TTC CTG GGC ATA CAG AAC CCC CTG GCA GCC AGT 2245
 Thr Pro Phe Leu Gly Ile Gln Asn Pro Leu Ala Ala Ser
 585 590 595

CTT GAG GCA ACA CCT GCC TTC CGC CTG GCT GAC AGC AGG 2284
 Leu Glu Ala Thr Pro Ala Phe Arg Leu Ala Asp Ser Arg
 600 605

ACT AAC CCA GCA GGC CGC TTC TCG ACA CAG GAA GAA ATC 2323
 Thr Asn Pro Ala Gly Arg Phe Ser Thr Gln Glu Glu Ile
 610 615 620

CAG GCC AGG CTG TCT AGT GTA ATT GCT AAC CAA GAC CCT 2362
 Gln Ala Arg Leu Ser Ser Val Ile Ala Asn Gln Asp Pro
 625 630

FIG. 3D

14/34

ATT GCT GTA TAAACCTA AATAACACA TAGATTCACC GTAAACTT 2410
Ile Ala Val
635 637

TATTTTATAT AATAAGTAT TCCACCTTAA ATTAAACAAT TTATTTTATT 2460

TTAGCAGTTC TGCAAATAAA AAAAAAAAAA 2490

FIG. 3E

15/34

GCGCCTGCCT CCAACCTGCG GGC GGGAGGT GGGTGGCTGC GGGGCAATTG 50
 AAAAAGAGCC GGC GAGGAGT TCCCCGAAAC TTGTTGGAAC TCCGGGCTCG 100
 CGCGGAGGCC AGGAGCTGAG CGGCGGCGGC TGCCGGACGA TGGGAGCGTG 150
 AGCAGGACGG TGATAACCTC TCCCCGATCG GGTGCGAGG GCGCCGGGCA 200
 GAGGCCAGGA CGCGAGCCGC CAGCGGCGGG ACCCATCGAC GACTTCCCGG 250
 GGC GACAGGA GCAGCCCCGA GAGCCAGGGC GAGCGCCCGT TCCAGGTGGC 300
 CGGACCGCCC GCCGCGTCCG CGCCGCGCTC CCTGCAGGCA ACGGGAGACG 350
 CCCCCGCGCA GCGCGAGCGC CTCAGCGCGG CCGCTCGCTC TCCCCATCGA 400
 GGGACAAACT TTTCCCAAAC CCGATCCGAG CCCTTGACC AAACTCGCCT 450
 GCGCCGAGAG CCGTCCGCGT AGAGCGCTCC GTCTCCGGCG AG ATG 495
 Met
 1
 TCC GAG CGC AAA GAA GGC AGA GGC AAA GGG AAG GGC AAG 534
 Ser Glu Arg Lys Glu Gly Arg Gly Lys Gly Lys Gly Lys
 5 10
 AAG AAG GAG CGA GGC TCC GGC AAG AAG CCG GAG TCC GCG 573
 Lys Lys Glu Arg Gly Ser Gly Lys Lys Pro Glu Ser Ala
 15 20 25
 GCG GGC AGC CAG AGC CCA GCC TTG CCT CCC CAA TTG AAA 612
 Ala Gly Ser Gln Ser Pro Ala Leu Pro Pro Gln Leu Lys
 30 35 40
 GAG ATG AAA AGC CAG GAA TCG GCT GCA GGT TCC AAA CTA 651
 Glu Met Lys Ser Gln Glu Ser Ala Ala Gly Ser Lys Leu
 45 50
 GTC CTT CGG TGT GAA ACC AGT TCT GAA TAC TCC TCT CTC 690
 Val Leu Arg Cys Glu Thr Ser Ser Glu Tyr Ser Ser Leu
 55 60 65
 AGA TTC AAG TGG TTC AAG AAT GGG AAT GAA TTG AAT CGA 729
 Arg Phe Lys Trp Phe Lys Asn Gly Asn Glu Leu Asn Arg
 70 75

FIG. 4A

16/34

AAA AAC AAA CCA CAA AAT ATC AAG ATA CAA AAA AAG CCA 768
 Lys Asn Lys Pro Gln Asn Ile Lys Ile Gln Lys Lys Pro
 80 85 90

GGG AAG TCA GAA CTT CGC ATT AAC AAA GCA TCA CTG GCT 807
 Gly Lys Ser Glu Leu Arg Ile Asn Lys Ala Ser Leu Ala
 95 100 105

GAT TCT GGA GAG TAT ATG TGC AAA GTG ATC AGC AAA TTA 846
 Asp Ser Gly Glu Tyr Met Cys Lys Val Ile Ser Lys Leu
 110 115

GGA AAT GAC AGT GCC TCT GCC AAT ATC ACC ATC GTG GAA 885
 Gly Asn Asp Ser Ala Ser Ala Asn Ile Thr Ile Val Glu
 120 125 130

TCA AAC GAG ATC ATC ACT GGT ATG CCA GCC TCA ACT GAA 924
 Ser Asn Glu Ile Ile Thr Gly Met Pro Ala Ser Thr Glu
 135 140

GGA GCA TAT GTG TCT TCA GAG TCT CCC ATT AGA ATA TCA 963
 Gly Ala Tyr Val Ser Ser Glu Ser Pro Ile Arg Ile Ser
 145 150 155

GTA TCC ACA GAA GGA GCA AAT ACT TCT TCA TCT ACA TCT 1002
 Val Ser Thr Glu Gly Ala Asn Thr Ser Ser Ser Thr Ser
 160 165 170

ACA TCC ACC ACT GGG ACA AGC CAT CTT GTA AAA TGT GCG 1041
 Thr Ser Thr Thr Gly Thr Ser His Leu Val Lys Cys Ala
 175 180

GAG AAG GAG AAA ACT TTC TGT GTG AAT GGA GGG GAG TGC 1080
 Glu Lys Glu Lys Thr Phe Cys Val Asn Gly Gly Glu Cys
 185 190 195

TTC ATG GTG AAA GAC CTT TCA AAC CCC TCG AGA TAC TTG 1119
 Phe Met Val Lys Asp Leu Ser Asn Pro Ser Arg Tyr Leu
 200 205

TGC AAG TGC CCA AAT GAG TTT ACT GGT GAT CGC TGC CAA 1158
 Cys Lys Cys Pro Asn Glu Phe Thr Gly Asp Arg Cys Gln
 210 215 220

AAC TAC GTA ATG GCC AGC TTC TAC AGT ACG TCC ACT CCC 1197
 Asn Tyr Val Met Ala Ser Phe Tyr Ser Thr Ser Thr Pro
 225 230 235

TTT CTG TCT CTG CCT GAA TAGGA GCATGCTCAG TTGGTGCTGC 1240
 Phe Leu Ser Leu Pro Glu
 240 241

TTTCTTGTTG CTGCATCTCC CCTCAGATTC CACCTAGAGC TAGATGTGTC 1290

FIG. 4B

17/34

TTACCAGATC TAATATTGAC TGCCTCTGCC TGTCGCATGA GAACATTAAC 1340
AAAAGCAATT GTATTACTTC CTCTGTTTCGC GACTAGTTGG CTCTGAGATA 1390
CTAATAGGTG TGTGAGGCTC CGGATGTTTC TGGAAATTGAT ATTGAATGAT 1440
GTGATACAAA TTGATAGTCA ATATCAAGCA GTGAAATATG ATAATAAAGG 1490
CATTTCAAAG TCTCACTTTT ATTGATAAAA TAAAAATCAT TCTACTGAAC 1540
AGTCCATCTT CTTTATACAA TGACCACATC CTGAAAAGGG TGTTGCTAAG 1590
CTGTAACCGA TATGCACTTG AAATGATGGT AAGTTAATTT TGATTCAGAA 1640
TGTGTTATTT GTCACAAATA AACATAATAA AAGGAGTTCA GATGTTTTTC 1690
TTCATTAACC AAAAAAAAAA AAAAA 1715

FIG. 4C

18/34

GAGGCGCCTG CCTCCAACCT GCGGGCGGGA GGTGGGTGGC TCGGGGGCAA 50
 TTGAAAAAGA GCCGGCGAGG AGTTCCCCGA AACTTGTGG AACTCCGGGC 100
 TCGCGCGGAG GCCAGGAGCT GAGCGGCGGC GGCTGCCGGA CGATGGGAGC 150
 GTGAGCAGGA CGGTGATAAC CTCTCCCCGA TCGGGTTGCG AGGGCGCCGG 200
 GCAGAGGCCA GGACGCGAGC CGCCAGCGGC GGGACCCATC GACGACTTCC 250
 CGGGGCGACA GGAGCAGCCC CGAGAGCCAG GGCGAGCGCC CGTTCCAGGT 300
 GGCCGGACCG CCCGCCGCGT CCGCGCCGCG CTCCCTGCAG GCAACGGGAG 350
 ACGCCCCCGC GCAGCGCGAG CGCCTCAGCG CGGCCGCTCG CTCTCCCCAT 400
 CGAGGGACAA ACTTTTCCCA AACCCGATCC GAGCCCTTGG ACCAAACTCG 450
 CCTGCGCCGA GAGCCGTCCG CGTAGAGCGC TCCGTCTCCG GCGAG AT 497
 Met
 1
 G TCC GAG CGC AAA GAA GGC AGA GGC AAA GGG AAG GGC AAG 537
 Ser Glu Arg Lys Glu Gly Arg Gly Lys Gly Lys Gly Lys
 5 10
 AAG AAG GAG CGA GGC TCC GGC AAG AAG CCG GAG TCC GCG 576
 Lys Lys Glu Arg Gly Ser Gly Lys Lys Pro Glu Ser Ala
 15 20 25
 GCG GGC AGC CAG AGC CCA GCC TTG CCT CCC CAA TTG AAA 615
 Ala Gly Ser Gln Ser Pro Ala Leu Pro Pro Gln Leu Lys
 30 35 40
 GAG ATG AAA AGC CAG GAA TCG GCT GCA GGT TCC AAA CTA 654
 Glu Met Lys Ser Gln Glu Ser Ala Ala Gly Ser Lys Leu
 45 50
 GTC CTT CGG TGT GAA ACC AGT TCT GAA TAC TCC TCT CTC 693
 Val Leu Arg Cys Glu Thr Ser Ser Glu Tyr Ser Ser Leu
 55 60 65
 AGA TTC AAG TGG TTC AAG AAT GGG AAT GAA TTG AAT CGA 732
 Arg Phe Lys Trp Phe Lys Asn Gly Asn Glu Leu Asn Arg
 70 75

FIG. 5A

19/34

AAA AAC AAA CCA CAA AAT ATC AAG ATA CAA AAA AAG CCA 771
 Lys Asn Lys Pro Gln Asn Ile Lys Ile Gln Lys Lys Pro
 80 85 90

GGG AAG TCA GAA CTT CGC ATT AAC AAA GCA TCA CTG GCT 810
 Gly Lys Ser Glu Leu Arg Ile Asn Lys Ala Ser Leu Ala
 95 100 105

GAT TCT GGA GAG TAT ATG TGC AAA GTG ATC AGC AAA TTA 849
 Asp Ser Gly Glu Tyr Met Cys Lys Val Ile Ser Lys Leu
 110 115

GGA AAT GAC AGT GCC TCT GCC AAT ATC ACC ATC GTG GAA 888
 Gly Asn Asp Ser Ala Ser Ala Asn Ile Thr Ile Val Glu
 120 125 130

TCA AAC GAG ATC ATC ACT GGT ATG CCA GCC TCA ACT GAA 927
 Ser Asn Glu Ile Ile Thr Gly Met Pro Ala Ser Thr Glu
 135 140

GGA GCA TAT GTG TCT TCA GAG TCT CCC ATT AGA ATA TCA 966
 Gly Ala Tyr Val Ser Ser Glu Ser Pro Ile Arg Ile Ser
 145 150 155

GTA TCC ACA GAA GGA GCA AAT ACT TCT TCA TCT ACA TCT 1005
 Val Ser Thr Glu Gly Ala Asn Thr Ser Ser Ser Thr Ser
 160 165 170

ACA TCC ACC ACT GGG ACA AGC CAT CTT GTA AAA TGT GCG 1044
 Thr Ser Thr Thr Gly Thr Ser His Leu Val Lys Cys Ala
 175 180

GAG AAG GAG AAA ACT TTC TGT GTG AAT GGA GGG GAG TGC 1083
 Glu Lys Glu Lys Thr Phe Cys Val Asn Gly Gly Glu Cys
 185 190 195

TTC ATG GTG AAA GAC CTT TCA AAC CCC TCG AGA TAC TTG 1122
 Phe Met Val Lys Asp Leu Ser Asn Pro Ser Arg Tyr Leu
 200 205

TGC AAG TGC CCA AAT GAG TTT ACT GGT GAT CGC TGC CAA 1161
 Cys Lys Cys Pro Asn Glu Phe Thr Gly Asp Arg Cys Gln
 210 215 220

AAC TAC GTA ATG GCC AGC TTC TAC AAG GCG GAG GAG CTG 1200
 Asn Tyr Val Met Ala Ser Phe Tyr Lys Ala Glu Glu Leu
 225 230 235

TAC CAG AAG AGA GTG CTG ACC ATA ACC GGC ATC TGC ATC 1239
 Tyr Gln Lys Arg Val Leu Thr Ile Thr Gly Ile Cys Ile
 240 245

GCC CTC CTT GTG GTC GGC ATC ATG TGT GTG GTG GCC TAC 1278
 Ala Leu Leu Val Val Gly Ile Met Cys Val Val Ala Tyr
 250 255 260

FIG. 5B

20/34

TGC AAA ACC AAG AAA CAG CGG AAA AAG CTG CAT GAC CGT 1317
 Cys Lys Thr Lys Lys Gln Arg Lys Lys Leu His Asp Arg
 265 270

CTT CGG CAG AGC CTT CGG TCT GAA CGA AAC AAT ATG ATG 1356
 Leu Arg Gln Ser Leu Arg Ser Glu Arg Asn Asn Met Met
 275 280 285

AAC ATT GCC AAT GGG CCT CAC CAT CCT AAC CCA CCC CCC 1395
 Asn Ile Ala Asn Gly Pro His His Pro Asn Pro Pro Pro
 290 295 300

GAG AAT GTC CAG CTG GTG AAT CAA TAC GTA TCT AAA AAC 1434
 Glu Asn Val Gln Leu Val Asn Gln Tyr Val Ser Lys Asn
 305 310

GTC ATC TCC AGT GAG CAT ATT GTT GAG AGA GAA GCA GAG 1473
 Val Ile Ser Ser Glu His Ile Val Glu Arg Glu Ala Glu
 315 320 325

ACA TCC TTT TCC ACC AGT CAC TAT ACT TCC ACA GCC CAT 1512
 Thr Ser Phe Ser Thr Ser His Tyr Thr Ser Thr Ala His
 330 335

CAC TCC ACT ACT GTC ACC CAG ACT CCT AGC CAC AGC TGG 1551
 His Ser Thr Thr Val Thr Gln Thr Pro Ser His Ser Trp
 340 345 350

AGC AAC GGA CAC ACT GAA AGC ATC CTT TCC GAA AGC CAC 1590
 Ser Asn Gly His Thr Glu Ser Ile Leu Ser Glu Ser His
 355 360 365

TCT GTA ATC GTG ATG TCA TCC GTA GAA AAC AGT AGG CAC 1629
 Ser Val Ile Val Met Ser Ser Val Glu Asn Ser Arg His
 370 375

AGC AGC CCA ACT GGG GGC CCA AGA GGA CGT CTT AAT GGC 1668
 Ser Ser Pro Thr Gly Gly Pro Arg Gly Arg Leu Asn Gly
 380 385 390

ACA GGA GGC CCT CGT GAA TGT AAC AGC TTC CTC AGG CAT 1707
 Thr Gly Gly Pro Arg Glu Cys Asn Ser Phe Leu Arg His
 395 400

GCC AGA GAA ACC CCT GAT TCC TAC CGA GAC TCT CCT CAT 1746
 Ala Arg Glu Thr Pro Asp Ser Tyr Arg Asp Ser Pro His
 405 410 415

AGT GAA AGG TAAAA CCGAAGGCAA AGCTACTGCA GAGGAGAAAC 1790
 Ser Glu Arg
 420

FIG. 5C

21/34

TCAGTCAGAG AATCCCTGTG AGCACCTGCG GTCTCACCTC AGGAAATCTA 1840
CTCTAATCAG AATAAGGGGC GGCAGTTACC TGTTCTAGGA GTGCTCCTAG 1890
TTGATGAAGT CATCTCTTTG TTTGACGGAA CTTATTTCTT CTGAGCTTCT 1940
CTCGTCGTCC CAGTGA CTGA CAGGCAACAG ACTCTTAAAG AGCTGGGATG 1990
CTTTGATGCG GAAGGTGCAG CACATGGAGT TTCCAGCTCT GGCCATGGGC 2040
TCAGACCCAC TCGGGGTCTC AGTGTCTCA GTTGTAACAT TAGAGAGATG 2090
GCATCAATGC TTGATAAGGA CCCTTCTATA ATTCCAATTG CCAGTTATCC 2140
AAACTCTGAT TCGGTGGTCG AGCTGGCCTC GTGTTCTTAT CTGCTAACCC 2190
TGTCTTACCT TCCAGCCTCA GTTAAGTCAA ATCAAGGGCT ATGTCATTGC 2240
TGAATGTCAT GGGGGGCAAC TGCTTGCCCT CCACCCTATA GTATCTATTT 2290
TATGAAATTC CAAGAAGGGA TGAATAAATA AATCTCTTGG ATGCTGCGTC 2340
TGGCAGTCTT CACGGGTGGT TTTCAAAGCA GAAAAAAAAA AAAAAAAAAA 2390
AAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA A 2431

FIG. 5D

16	1	M	S	E	R	K	E	G	R	G	K	G	K	K	K	E	R	G	S	G	K	K	P	E	S	A	A	G	S	Q	S	P	A	L	P	P	R	L	K	E	M	K	S	Q	E	S	A	A	G		
11	1	M	S	E	R	K	E	G	R	G	K	G	K	K	K	E	R	G	S	G	K	K	P	E	S	A	A	G	S	Q	S	P	A	L	P	P	Q	L	K	E	M	K	S	Q	E	S	A	A	G		
76	1	M	S	E	R	K	E	G	R	G	K	G	K	K	K	E	R	G	S	G	K	K	P	E	S	A	A	G	S	Q	S	P	A	L	P	P	Q	L	K	E	M	K	S	Q	E	S	A	A	G		
84	1	M	S	E	R	K	E	G	R	G	K	G	K	K	K	E	R	G	S	G	K	K	P	E	S	A	A	G	S	Q	S	P	A	L	P	P	Q	L	K	E	M	K	S	Q	E	S	A	A	G		
78	1	M	S	E	R	K	E	G	R	G	K	G	K	K	K	E	R	G	S	G	K	K	P	E	S	A	A	G	S	Q	S	P	A	L	P	P	Q	L	K	E	M	K	S	Q	E	S	A	A	G		
16	51	S	K	L	V	L	R	C	E	T	S	S	E	Y	S	S	L	R	F	K	W	F	K	N	G	N	E	L	N	R	K	N	K	P	Q	N	I	K	I	Q	K	P	G	K	S	E	L	R	I	N	
11	51	S	K	L	V	L	R	C	E	T	S	S	E	Y	S	S	L	R	F	K	W	F	K	N	G	N	E	L	N	R	K	N	K	P	Q	N	I	K	I	Q	K	P	G	K	S	E	L	R	I	N	
76	51	S	K	L	V	L	R	C	E	T	S	S	E	Y	S	S	L	R	F	K	W	F	K	N	G	N	E	L	N	R	K	N	K	P	Q	N	I	K	I	Q	K	P	G	K	S	E	L	R	I	N	
84	51	S	K	L	V	L	R	C	E	T	S	S	E	Y	S	S	L	R	F	K	W	F	K	N	G	N	E	L	N	R	K	N	K	P	Q	N	I	K	I	Q	K	P	G	K	S	E	L	R	I	N	
78	51	S	K	L	V	L	R	C	E	T	S	S	E	Y	S	S	L	R	F	K	W	F	K	N	G	N	E	L	N	R	K	N	K	P	Q	N	I	K	I	Q	K	P	G	K	S	E	L	R	I	N	
16	101	K	A	S	L	A	D	S	G	E	Y	M	C	K	V	I	S	K	L	G	N	D	S	A	S	A	N	I	T	I	V	E	S	N	E	I	I	T	G	M	P	A	S	T	E	G	A	Y	V	S	S
11	101	K	A	S	L	A	D	S	G	E	Y	M	C	K	V	I	S	K	L	G	N	D	S	A	S	A	N	I	T	I	V	E	S	N	E	I	I	T	G	M	P	A	S	T	E	G	A	Y	V	S	S
76	101	K	A	S	L	A	D	S	G	E	Y	M	C	K	V	I	S	K	L	G	N	D	S	A	S	A	N	I	T	I	V	E	S	N	E	I	I	T	G	M	P	A	S	T	E	G	A	Y	V	S	S
84	101	K	A	S	L	A	D	S	G	E	Y	M	C	K	V	I	S	K	L	G	N	D	S	A	S	A	N	I	T	I	V	E	S	N	E	I	I	T	G	M	P	A	S	T	E	G	A	Y	V	S	S
78	101	K	A	S	L	A	D	S	G	E	Y	M	C	K	V	I	S	K	L	G	N	D	S	A	S	A	N	I	T	I	V	E	S	N	E	I	I	T	G	M	P	A	S	T	E	G	A	Y	V	S	S
16	151	E	S	P	I	R	I	S	V	S	T	E	G	A	N	T	S	S	S	T	S	T	S	T	T	G	T	S	H	L	V	K	C	A	E	K	E	K	T	F	C	V	N	G	G	E	C	F	M	V	K
11	151	E	S	P	I	R	I	S	V	S	T	E	G	A	N	T	S	S	S	T	S	T	S	T	T	G	T	S	H	L	V	K	C	A	E	K	E	K	T	F	C	V	N	G	G	E	C	F	M	V	K
76	151	E	S	P	I	R	I	S	V	S	T	E	G	A	N	T	S	S	S	T	S	T	S	T	T	G	T	S	H	L	V	K	C	A	E	K	E	K	T	F	C	V	N	G	G	E	C	F	M	V	K
84	151	E	S	P	I	R	I	S	V	S	T	E	G	A	N	T	S	S	S	T	S	T	S	T	T	G	T	S	H	L	V	K	C	A	E	K	E	K	T	F	C	V	N	G	G	E	C	F	M	V	K
78	151	E	S	P	I	R	I	S	V	S	T	E	G	A	N	T	S	S	S	T	S	T	S	T	T	G	T	S	H	L	V	K	C	A	E	K	E	K	T	F	C	V	N	G	G	E	C	F	M	V	K

FIG. 6A

[illegible]

FIG. 6B

24/34

16	396	GGPRECN	FLRHARET	PDSYRDS	PHSERYVS	AMTTPAR	MSPVDF	HTPSSP
11	401	GGPRECN	FLRHARET	PDSYRDS	PHSERYVS	AMTTPAR	MSPVDF	HTPSSP
76	393	GGPRECN	FLRHARET	PDSYRDS	PHSERYVS	AMTTPAR	MSPVDF	HTPSSP
84	393	GGPRECN	FLRHARET	PDSYRDS	PHSER			
16	446	KSPPPSE	MSPPVSS	MTVSMPS	MAVSPF	MEEERPL	LLVTPP	RRLREK
11	451	KSPPPSE	MSPPVSS	MTVSMPS	MAVSPF	MEEERPL	LLVTPP	RRLREK
76	443	KSPPPSE	MSPPVSS	MTVSK	PSMAVSP	FMEERPL	LLVTPP	RRLREK
16	496	QQFSSF	HHPAH	DSNSL	PASPLR	IVEDEE	EYETTQ	EYEPAQ
11	501	QQFSSF	HHPAH	DSNSL	PASPLR	IVEDEE	EYETTQ	EYEPAQ
76	493	QQFSSF	HHPAH	DSNSL	PASPLR	IVEDEE	EYETTQ	EYEPAQ
16	546	RAKRTK	PNNGH	IANRLE	VDSNTS	SSQSSN	SESETE	DERVGE
11	551	RAKRTK	PNNGH	IANRLE	VDSNTS	SSQSSN	SESETE	DERVGE
76	543	RAKRTK	PNNGH	IANRLE	VDSNTS	SSQSSN	SESETE	DERVGE
16	596	AASLEA	TPAFRL	ADSRTN	PAGRFST	QEEIQ		
11	601	AASLEA	TPAFRL	ADSRTN	PAGRFST	QEEIQ	ARLSSV	IANQDP
76	593	AASLEA	TPAFRL	ADSRTN	PAGRFST	QEEIQ	ARLSSV	IANQDP

FIG. 6C

25/34

1 GGGTACCATGGGTGCGTGAGCGCGTTTCCCGCCTGAGCGCAACTAGCGGC
51 GGGTCGTGGGCACCTCCAGAAAAGATCCCGCACCATCCTCCAGGATCCAA
101 TGGCCTTGGAGAGAGGGCTGCAGGGCCCACGGACATTGCTGACTCTTCAG
151 AACGTGCTGACATGGAGCCAGGTAGACTGAAATTATCATGTGTCCAAATT
201 AAAATTGCATACTTCAAGGATTATTTGAAGGACTATTCTTAGACCCCTTT
251 AAGAAGATTTAAAGAAAAACCACTCGGCCCTGAGTGCGGCGAGGACCCTG
301 TTTGTGGATGTGGAGGAGCGCGGGCCGAGGCCATGGACGTGAAGGAGAG
1 M D V K E R
351 GAAGCCTTACCGCTCGCTGACCCGGCGCCGCGACGCCGAGCGCCGCTACA
7 K P Y R S L T R R R D A E R R Y T
401 CCAGCTCGTCCGCGGACAGCGAGGAGGGCAAAGCCCCGCAGAAATCGTAC
24 S S S A D S E E G K A P Q K S Y
451 AGCTCCAGCGAGACCCTGAAGGCCTACGACCAGGACGCCCGCCTAGCCTA
40 S S S E T L K A Y D Q D A R L A Y
501 TGGCAGCCGCGTCAAGGACATTGTGCCGACGAGGCCGAGGAATTCTGCC
57 G S R V K D I V P Q E A E E F C R
551 GCACAGGTGCCAACTTACCCCTGCGGGAGCTGGGGCTGGAAGAAGTAACG
74 T G A N F T L R E L G L E E V T
601 CCCCCTCACGGGACCCTGTACCGGACAGACATTGGCCTCCCCCACTGCGG
90 P P H G T L Y R T D I G L P H C G
651 CTACTCCATGGGGGCTGGCTCTGATGCCGACATGGAGGCTGACACGGTGC
107 Y S M G A G S D A D M E A D T V L
701 TGTCCCCTGAGCACCCCGTGCCTCTGTGGGGCCGAGCACACGGTCAGGG
124 S P E H P V R L W G R S T R S G
751 CGCAGCTCCTGCCTGTCCAGCCGGGCCAATTCCAATCTCACACTCACCGA
140 R S S C L S S R A N S N L T L T D
801 CACCGAGCATGAAAACACTGAGACTGATCATCCGGGCGGCCTGCAGAACC
157 T E H E N T E T D H P G G L Q N H
851 ACGCGCGGCTCCGGACGCCGCGCCGCGCTCTCGCACGCCACACCCCC
174 A R L R T P P P P L S H A H T P
901 AACCAGCACCACGCGGCCTCCATTAACCTCCCTGAACCGGGGCAACTTCAC
190 N Q H H A A S I N S L N R G N F T
951 GCCGAGGAGCAACCCCAGCCCCGCCCCACGGACCACTCGCTCTCCGGAG
207 P R S N P S P A P T D H S L S G E
1001 AGCCCCCTGCCGGCGGCGCCCAGGAGCCTGCCACGCCAGGAGAAGTGG
224 P P A G G A Q E P A H A Q E N W
1051 CTGCTCAACAGCAACATCCCCCTGGAGACCAGAAACCTAGGCAAGCAGCC
240 L L N S N I P L E T R N L G K Q P

FIG. 7A

26/34

2001 CACCACTGCCATTGCCTTGCCTCCCCGATTGAAAGAGATGAAAAGCCAGG
557 T T A I A L P P R L K E M K S Q E

2051 AATCGGCTGCAGGTTCCAAACTAGTCCTTCGGTGTGAAACCAGTTCTGAA
574 S A A G S K L V L R C E T S S E

2101 TACTCCTCTCTCAGATTCAAGTGGTTCAAGAATGGGAATGAATTGAATCG
590 Y S S L R F K W F K N G N E L N R

2151 AAAAAACAAACCACAAAATATCAAGATACAAAAAAGCCAGGGAAGTCAG
607 K N K P Q N I K I Q K K P G K S E

2201 AACTTCGCATTAAACAAAGCATCACTGGCTGATTCTGGAGAGTATATGTGC
624 L R I N K A S L A D S G E Y M C

2251 AAAGTGATCAGCAAATTAGGAAATGACAGTGCCTCTGCCAATATCACCAT
640 K V I S K L G N D S A S A N I T I

2301 CGTGGAATCAAACGAGATCATCACTGGTATGCCAGCCTCAACTGAAGGAG
657 V E S N E I I T G M P A S T E G A

2351 CATATGTGTCTTCAGAGTCTCCCATTAAGAATATCAGTATCCACAGAAGGA
674 Y V S S E S P I R I S V S T E G

2401 GCAAATACTTCTTCATCTACATCTACATCCACCCTGGGACAAGCCATCT
690 A N T S S S T S T S T T G T S H L

2451 TGTAATAATGTGCGGAGAAGGAGAAAACCTTTCTGTGTGAATGGACGGGAGT
707 V K (C) A E K E K T F (C) V N G G E (C)

2501 GCTTCATGGTGAAAGACCTTTCAAACCCCTCGAGATACTTGTGCAAGTGC
724 F M V K D L S N P S R Y L (C) K (C)

2551 CCAAATGAGTTTACTGGTGATCGCTGCCAAAACCTACGTAATGGCCAGCTT
740 P N E F T G D R (C) Q N Y V M A S F

2601 CTACAGTACGTCCACTCCCTTTCTGTCTCTGCCTGAATAGGAGCATGCTC
757 Y S T S T P F L S L P E

2651 AGTTGGTGCTGCTTTCTTGTGTGCTGCATCTCCCCTCAGATTCCACCTAGA

2701 GCTAGATGTGTCTTACCAGATCTAATATTGACTGCCTCTGCCTGTGCGCAT
2751 GAGAACATTAACAAAAGCAATTGTATTACTTCCCTCTGTTTCGCGACTAGTT
2801 GGCTCTGAGATACTAATAGGTGTGTGAGGCTCCGGATGTTTCTGGAATTG
2851 ATATTGAATGATGTGATACAAATTGATAGTCAATATCAAGCAGTGAAATA
2901 TGATAATAAAGGCATTTCAAAGTCTCACTTTTATTGATAAAATAAAAATC
2951 ATTCTACTGAACAGTCCATCTTCTTTATACAATGACCACATCCTGAAAAG
3001 GGTGTTGCTAAGCTGTAACCGATATGCACTTGAAATGATGGTAAGTTAAT
3051 TTTGATTCAAGATGTGTTATTTGTGCACAAATAAACATAATAAAAGGAAAA
3101 AAAAAAAAAA

FIG. 7B

27/34

1101 ATTCCTAGGGACATTGCAGGACAACCTCATTGAGATGGACATTCTCGGCG
257 F L G T L Q D N L I E M D I L G A

1151 CCTCCCGCCATGATGGGGCTTACAGTGACGGGCACTTCCTCTTCAAGCCT
274 S R H D G A Y S D G H F L F K P

1201 GGAGGCACCTCCCCGCTCTTCTGCACCACATCACCAGGGTACCCACTGAC
290 G G T S P L F C T T S P G Y P L T

1251 GTCCAGCACAGTGTACTCTCCTCCGCCCCGACCCCTGCCCCGCAGCACCT
307 S S T V Y S P P P R P L P R S T F

1301 TCGCCCGGCGCGCCTTTAACCTCAAGAAGCCCTCCAAGTACTGTAAGTGG
324 A R P A F N L K K P S K Y C N W

1351 AAGTGCGCAGCCCTGAGCGCCATCGTCATCTCAGCCACTCTGGTCATCCT
340 K C A A L S A I V I S A T L V I L

1401 GCTGGCATACTTTGTGGCCATGCACCTGTTTGGCCTAAACTGGCACCTGC
357 L A Y F V A M H L F G L N W H L Q

1451 AGCCGATGGAGGGGCAGATGTATGAGATCACGGAGGACACAGCCAGCAGT
374 P M E G Q M Y E I T E D T A S S

1501 TGGCCTGTGCCAACCGACGTCTCCCTATAACCCCTCAGGGGGCACTGGCTT
390 W P V P T D V S L Y P S G G T G L

1551 AGAGACCCCTGACAGGAAAGGCAAAGGAACACAGAAGGAAAGCCAGTA
407 E T P D R K G K G T T E G K P S S

1601 GTTTCTTTCCAGAGGACAGTTTCATAGATTCTGGAGAAATTGATGTGGGA
424 F F P E D S F I D S G E I D V G

1651 AGGCGAGCTTCCCAGAAGATTCCTCCTGGCACTTTCTGGAGATCTCAAGT
440 R R A S Q K I P P G T F W R S Q V

1701 GTTCATAGACCATCCTGTGCATCTGAAATTCAATGTGTCTCTGGGAAAGG
457 F I D H P V H L K F N V S L G K A

1751 CAGCCCTGGTTGGCATTATGAGCAGAAAAGGCCTCCCTCCTTCACATACA
474 A L V G I Y G R K G L P P S H T

1801 CAGTTTGACTTTGTGGAGCTGCTGGATGGCAGGAGGCTCCTAACCAGGA
490 Q F D F V E L L D G R R L L T Q E

1851 GGCGCGGAGCCTAGAGGGGACCCCGGCCAGTCTCGGGGAAGTGTGCCCC
507 A R S L E G T P R Q S R G T V P P

1901 CCTCCAGCCATGAGACAGGCTTCATCCAGTATTTGGATTACAGGAATCTGG
524 S S H E T G F I Q Y L D S G I W

1951 CACTTGGCTTTTTTACAATGACGGAAGGAGTCAGAAGTGGTTTCTTTCT
540 H L A F Y N D G K E S E V V S F L

FIG. 7C

28/34

1 GAATTCGGGACAGCCTCTCCTGCCGCCGCTGCTGCTGCCGCCGCCGCCACCGCCGGCTGGTCTCTCTCTGCTTT
 76 TACTTCTCTGTCATGACAGTTGTTTTCTTCATCTGAGCAGACACCAGCTTCAGATGCTCGAGGTGAGAAACATGC
 151 CTTTCAGTTTGGGCTACTGGTTTACTTAATTAATCAGCCGGCAGCTCCGTCGATCTATTTTCGTCCCTGTCTCT
 226 TGACGAGCCCGGATGGTTTGGAGTAGCATTTAAAAGAACTAGAAAAGTGGCCAGAAAACAGCAGCTTAAAGAAT
 301 TATTACGATATACTTTGATTTTGTAGTTGCTAGGAGCTTTTCTTCCCCCTTGCATCTTTCTGAACCTCTCTTGA
 376 TTTTAATAATGGCCTTGGACTTGGACGATTTATCGATTTCCCCCTGTAAGATGCTGTATCATTTGGTTGGGGGG
 451 CCTCTGCGTGGTAATGGACCGTGAGAGCGGCCAGGCCTTCTTCTGGAGGTGAGCCGATGGAGATTTATCCCCAG
 1 M E I Y S P D
 526 ACATGTCTGAGGTGCGCCGCCGAGAGGTCTCCAGCCCCCTCACTCAGCTGAGTGCAGACCCATCTCTTGATGGGC
 8 H S E V A A E R S S S P S T Q L S A D P S L D G L
 601 TTCCGGCAGCAGAAGACATGCCAGAGCCCCAGACTGAAGATGGGAGAACCCCTGGACTCGTGGCCTGGCCGTGC
 33 P A A E D M P E P Q T E D G R T P G L V G L A V P
 676 CCTGCTGTGCGTGCCTAGAAGCTGAGCGCCTGAGAGGTTCCTCAACTCAGAGAAAACTGCATTGTCCCCATCC
 58 [C] [C] A [C] L E A E R L R G [C] L N S E K I [C] I V P I L
 751 TGGCTTGCTGTGTCAGCCTCTGCCTCTGCATCGCCGGCTCAAGTGGGTATTGTGAGCAAGATCTTGAATATG
 83 A [C] L V S L [C] L [C] I A G L K W V F V D K I F E Y D
 826 ACTCTCTACTCACCTTGACCCTGGGGGTTAGGCCAGGACCTATTATTTCTCTGGACGCAACTGCTGCCTCAG
 108 S P T H L D P G G L G Q D P I I S L D A T A A S A
 901 CTGTGTGGGTGTCGTCTGAGGCATACACTTCACCTGTCTCTAGGGCTCAATCTGAAAGTGAGGTTCAGTTACAG
 133 V W V S S E A Y T S P V S R A Q S E S E V Q V T V
 976 TGCAAGGTGACAAGGCTGTGTCTCTTTGAACCATCAGCGCACCGACACCGAAGAATCGTATTTTGCCTTTT
 158 Q G D K A V V S F E P S A A P T P K N R I F A F S
 1051 CTTTCTTGCCG1CCACTGCGCCATCCTTCCCTTCACCCACCCGGAACCTTGAGGTGAGAACGCCCAAGTCAGCAA
 183 F L P S T A P S F P S P T R N P E V R T P K S A T
 1126 CTCAGCCACAAACAACAGAACTAATCTCCAACTGCTCCTAACTTTCTACATCTACATCCACCACTGGGACAA
 208 Q P Q T T E T N L Q T A P K L S T S T S T S T G T S
 1201 GCCATCTTGTAATAATGTCGGGAGAAGGAGAAAACCTTCTGTGTGAATGGAGGGGAGTCTTCATGGTGAAAGACC
 233 H L V K [C] A E K E K T F [C] V N G G E [C] F M V K D L
 1276 TTTCAAACCCCTCGAGATACTTGTGCAAGTGCCCAATGAGTTTACTGGTGATCGCTGCCAAACTACGTAATGG
 258 S N P S R Y L [C] K [C] P N E F T G D R [C] Q N Y V M A
 1351 CCAGCTTCTACAGTACGTCCACTCCCTTCTGTCTCTGCCTGAATAGGAGCATGCTCAGTTGGTGCTGCTTTCTT
 283 S F Y S T S T P F L S L P E O
 1426 GTTGCTGCATCTCCCCCTCAGATTCCACCTAGAGCTAGATGTGTCTTACCAGATCTAATATTGACTGCCTCTGCCT
 1501 GTCGCATGAGAACATTAACAAAAGCAATTGTATTACTTCTCTGTTCGCGACTAGTTGGCTCTGAGATACTAATA
 1576 GGTGTGTGAGGCTCCGGATGTTTCTGGAATTGATATTGAATGATGTGATACAAATTGATAGTCAATATCAAGCAG
 1651 TGAAATATGATAATAAAGGCATTTCAAAGTCTCACTTTTATTGATAAAAATAAAATCATTCTACTGAACAGTCCA
 1726 TCTTCTTTATACAATGACCACATCTTGAAAAGGGTGTGCTAAGCTGTAACCGATATGCACCTGAAAATGATGGTA
 1801 AGTTAATTTTGATTGAGAAATGCTGTTATTGTGCAAAATAACATAATAAAGGAAAAAAAAAACCCGAATTC

EGF
-like

FIG. 8

29/34





FIG. 9

30/34

*FIG. 10*

31/34

Heregulin increases the number of ^3H -thymidine labeled cells in supporting and hair cell layers in gentamicin-treated utricles






FIG. 11

32/34

Heregulin Enhances the Numbers of ^3H -thymidine Labeled Cells in Both Supporting and Hair Cell Layers

*FIG. 12*

33/34

*FIG. 13*

34/34

HER-2 Immunostaining




FIG. 14

Sequence Listing

<110> Genentech, Inc.
Gao, Wei-Qiang

<120> Hair Cell Disorders

5 <130> P1715R1PCT

<160> 14

<210> 1

<211> 669

<212> PRT

10 <213> Homo sapiens

<400> 1

	Ala	Arg	Ala	Pro	Gln	Arg	Gly	Arg	Ser	Leu	Ser	Pro	Ser	Arg	Asp	
	1				5					10					15	
15	Lys	Leu	Phe	Pro	Asn	Pro	Ile	Arg	Ala	Leu	Gly	Pro	Asn	Ser	Pro	
					20					25					30	
	Ala	Pro	Arg	Ala	Val	Arg	Val	Glu	Arg	Ser	Val	Ser	Gly	Glu	Met	
					35					40					45	
	Ser	Glu	Arg	Lys	Glu	Gly	Arg	Gly	Lys	Gly	Lys	Gly	Lys	Lys	Lys	
					50					55					60	
20	Glu	Arg	Gly	Ser	Gly	Lys	Lys	Pro	Glu	Ser	Ala	Ala	Gly	Ser	Gln	
					65					70					75	
	Ser	Pro	Ala	Leu	Pro	Pro	Arg	Leu	Lys	Glu	Met	Lys	Ser	Gln	Glu	
					80					85					90	
25	Ser	Ala	Ala	Gly	Ser	Lys	Leu	Val	Leu	Arg	Cys	Glu	Thr	Ser	Ser	
					95					100					105	
	Glu	Tyr	Ser	Ser	Leu	Arg	Phe	Lys	Trp	Phe	Lys	Asn	Gly	Asn	Glu	
					110					115					120	
	Leu	Asn	Arg	Lys	Asn	Lys	Pro	Gln	Asn	Ile	Lys	Ile	Gln	Lys	Lys	
					125					130					135	
30	Pro	Gly	Lys	Ser	Glu	Leu	Arg	Ile	Asn	Lys	Ala	Ser	Leu	Ala	Asp	
					140					145					150	
	Ser	Gly	Glu	Tyr	Met	Cys	Lys	Val	Ile	Ser	Lys	Leu	Gly	Asn	Asp	
					155					160					165	
35	Ser	Ala	Ser	Ala	Asn	Ile	Thr	Ile	Val	Glu	Ser	Asn	Glu	Ile	Ile	
					170					175					180	
	Thr	Gly	Met	Pro	Ala	Ser	Thr	Glu	Gly	Ala	Tyr	Val	Ser	Ser	Glu	
					185					190					195	
	Ser	Pro	Ile	Arg	Ile	Ser	Val	Ser	Thr	Glu	Gly	Ala	Asn	Thr	Ser	
					200					205					210	
40	Ser	Ser	Thr	Ser	Thr	Ser	Thr	Thr	Gly	Thr	Ser	His	Leu	Val	Lys	
					215					220					225	
	Cys	Ala	Glu	Lys	Glu	Lys	Thr	Phe	Cys	Val	Asn	Gly	Gly	Glu	Cys	
					230					235					240	

	Phe Met Val Lys Asp Leu Ser Asn Pro Ser Arg Tyr Leu Cys Lys	245	250	255
	Cys Gln Pro Gly Phe Thr Gly Ala Arg Cys Thr Glu Asn Val Pro	260	265	270
5	Met Lys Val Gln Asn Gln Glu Lys Ala Glu Glu Leu Tyr Gln Lys	275	280	285
	Arg Val Leu Thr Ile Thr Gly Ile Cys Ile Ala Leu Leu Val Val	290	295	300
10	Gly Ile Met Cys Val Val Ala Tyr Cys Lys Thr Lys Lys Gln Arg	305	310	315
	Lys Lys Leu His Asp Arg Leu Arg Gln Ser Leu Arg Ser Glu Arg	320	325	330
	Asn Asn Met Met Asn Ile Ala Asn Gly Pro His His Pro Asn Pro	335	340	345
15	Pro Pro Glu Asn Val Gln Leu Val Asn Gln Tyr Val Ser Lys Asn	350	355	360
	Val Ile Ser Ser Glu His Ile Val Glu Arg Glu Ala Glu Thr Ser	365	370	375
20	Phe Ser Thr Ser His Tyr Thr Ser Thr Ala His His Ser Thr Thr	380	385	390
	Val Thr Gln Thr Pro Ser His Ser Trp Ser Asn Gly His Thr Glu	395	400	405
	Ser Ile Leu Ser Glu Ser His Ser Val Ile Val Met Ser Ser Val	410	415	420
25	Glu Asn Ser Arg His Ser Ser Pro Thr Gly Gly Pro Arg Gly Arg	425	430	435
	Leu Asn Gly Thr Gly Gly Pro Arg Glu Cys Asn Ser Phe Leu Arg	440	445	450
30	His Ala Arg Glu Thr Pro Asp Ser Tyr Arg Asp Ser Pro His Ser	455	460	465
	Glu Arg Tyr Val Ser Ala Met Thr Thr Pro Ala Arg Met Ser Pro	470	475	480
	Val Asp Phe His Thr Pro Ser Ser Pro Lys Ser Pro Pro Ser Glu	485	490	495
35	Met Ser Pro Pro Val Ser Ser Met Thr Val Ser Met Pro Ser Met	500	505	510
	Ala Val Ser Pro Phe Met Glu Glu Glu Arg Pro Leu Leu Leu Val	515	520	525
40	Thr Pro Pro Arg Leu Arg Glu Lys Lys Phe Asp His His Pro Gln	530	535	540
	Gln Phe Ser Ser Phe His His Asn Pro Ala His Asp Ser Asn Ser	545	550	555
	Leu Pro Ala Ser Pro Leu Arg Ile Val Glu Asp Glu Glu Tyr Glu	560	565	570

Thr Thr Gln Glu Tyr Glu Pro Ala Gln Glu Pro Val Lys Lys Leu
 575 580 585
 Ala Asn Ser Arg Arg Ala Lys Arg Thr Lys Pro Asn Gly His Ile
 590 595 600
 5 Ala Asn Arg Leu Glu Val Asp Ser Asn Thr Ser Ser Gln Ser Ser
 605 610 615
 Asn Ser Glu Ser Glu Thr Glu Asp Glu Arg Val Gly Glu Asp Thr
 620 625 630
 10 Pro Phe Leu Gly Ile Gln Asn Pro Leu Ala Ala Ser Leu Glu Ala
 635 640 645
 Thr Pro Ala Phe Arg Leu Ala Asp Ser Arg Thr Asn Pro Ala Gly
 650 655 660
 Arg Phe Ser Thr Gln Glu Glu Ile Gln
 665 669
 15 <210> 2
 <211> 2226
 <212> DNA
 <213> Homo sapiens
 <400> 2
 20 g ggc gcg agc gcc tca gcg cgg ccg ctc gct ctc ccc 37
 Gly Ala Ser Ala Ser Ala Arg Pro Leu Ala Leu Pro
 1 5 10
 ctc gag gga caa act ttt ccc aaa ccc gat ccg agc cct 76
 Leu Glu Gly Gln Thr Phe Pro Lys Pro Asp Pro Ser Pro
 15 20 25
 25 tgg acc aaa ctc gcc tgc gcc gag agc cgt ccg cgt aga 115
 Trp Thr Lys Leu Ala Cys Ala Glu Ser Arg Pro Arg Arg
 30 35
 gcg ctc cgt ctc cgg cga gat gtc cga gcg caa aga agg 154
 30 Ala Leu Arg Leu Arg Arg Asp Val Arg Ala Gln Arg Arg
 40 45 50
 cag agg caa agg gaa ggg caa gaa gaa gga gcg agg ctc 193
 Gln Arg Gln Arg Glu Gly Gln Glu Glu Gly Ala Arg Leu
 55 60
 35 cgg caa gaa gcc gga gtc cgc ggc ggg cag cca gag ccc 232
 Arg Gln Glu Ala Gly Val Arg Gly Gly Gln Pro Glu Pro
 65 70 75
 agc ctt gcc tcc ccg att gaa aga gat gaa aag cca gga 271
 Ser Leu Ala Ser Pro Ile Glu Arg Asp Glu Lys Pro Gly
 40 80 85 90
 atc ggc tgc agg ttc caa act agt cct tcg gtg tga aac 310
 Ile Gly Cys Arg Phe Gln Thr Ser Pro Ser Val Xaa Asn
 95 100
 45 cag ttc tga ata ctc ctc tct cag att caa gtg gtt caa 349
 Gln Phe Xaa Ile Leu Leu Ser Gln Ile Gln Val Val Gln
 105 110 115
 gaa tgg gaa tga att gaa tcg aaa aaa caa acc aca aaa 388
 Glu Trp Glu Xaa Ile Glu Ser Lys Lys Gln Thr Thr Lys

		120		125	
		tat caa gat aca aaa aaa gcc agg gaa gtc aga act tcg	427		
		Tyr Gln Asp Thr Lys Lys Ala Arg Glu Val Arg Thr Ser			
		130	135	140	
5		cat taa caa agc atc act gcc tga ttc tgg aga gta tat	466		
		His Xaa Gln Ser Ile Thr Gly Xaa Phe Trp Arg Val Tyr			
		145	150	155	
		gtg caa agt gat cag caa att agg aaa tga cag tgc ctc	505		
		Val Gln Ser Asp Gln Gln Ile Arg Lys Xaa Gln Cys Leu			
10		160	165		
		tgc caa tat cac cat cgt gga atc aaa cga gat cat cac	544		
		Cys Gln Tyr His His Arg Gly Ile Lys Arg Asp His His			
		170	175	180	
		tgg tat gcc agc ctc aac tga agg agc ata tgt gtc ttc	583		
		Trp Tyr Ala Ser Leu Asn Xaa Arg Ser Ile Cys Val Phe			
15		185	190		
		aga gtc tcc cat tag aat atc agt atc cac aga agg agc	622		
		Arg Val Ser His Xaa Asn Ile Ser Ile His Arg Arg Ser			
		195	200	205	
		aaa tac ttc ttc atc tac atc tac atc cac cac tgg gac	661		
		Lys Tyr Phe Phe Ile Tyr Ile Tyr Ile His His Trp Asp			
20		210	215	220	
		aag cca tct tgt aaa atg tgc gga gaa gga gaa aac ttt	700		
		Lys Pro Ser Cys Lys Met Cys Gly Glu Gly Glu Asn Phe			
25		225	230		
		ctg tgt gaa tgg agg gga gtg ctt cat ggt gaa aga cct	739		
		Leu Cys Glu Trp Arg Gly Val Leu His Gly Glu Arg Pro			
		235	240	245	
		ttc aaa ccc ctc gag ata ctt gtg caa gtg cca acc tgg	778		
		Phe Lys Pro Leu Glu Ile Leu Val Gln Val Pro Thr Trp			
30		250	255		
		att cac tgg agc aag atg tac tga gaa tgt gcc cat gaa	817		
		Ile His Trp Ser Lys Met Tyr Xaa Glu Cys Ala His Glu			
		260	265	270	
		agt cca aaa cca aga aaa gcc gga gga gct gta cca gaa	856		
		Ser Pro Lys Pro Arg Lys Gly Gly Gly Ala Val Pro Glu			
35		275	280	285	
		gag agt gct gac cat aac cgg cat ctg cat cgc cct cct	895		
		Glu Ser Ala Asp His Asn Arg His Leu His Arg Pro Pro			
40		290	295		
		tgt ggt cgg cat cat gtg tgt ggt gcc cta ctg caa aac	934		
		Cys Gly Arg His His Val Cys Gly Gly Leu Leu Gln Asn			
		300	305	310	
		caa gaa aca gcg gaa aaa gct gca tga ccg tct tcg gca	973		
		Gln Glu Thr Ala Glu Lys Ala Ala Xaa Pro Ser Ser Ala			
45		315	320		
		gag cct tcg gtc tga acg aaa caa tat gat gaa cat tgc	1012		
		Glu Pro Ser Val Xaa Thr Lys Gln Tyr Asp Glu His Cys			
		325	330	335	

caa tgg gcc tca cca tcc taa ccc acc ccc cga gaa tgt 1051
 Gln Trp Ala Ser Pro Ser Xaa Pro Thr Pro Arg Glu Cys
 340 345 350

5 cca gct ggt gaa tca ata cgt atc taa aaa cgt cat ctc 1090
 Pro Ala Gly Glu Ser Ile Arg Ile Xaa Lys Arg His Leu
 355 360

cag tga gca tat tgt tga gag aga agc aga gac atc ctt 1129
 Gln Xaa Ala Tyr Cys Xaa Glu Arg Ser Arg Asp Ile Leu
 365 370 375

10 ttc cac cag tca cta tac ttc cac agc cca tca ctc cac 1168
 Phe His Gln Ser Leu Tyr Phe His Ser Pro Ser Leu His
 380 385

tac tgt cac cca gac tcc tag cca cag ctg gag caa cgg 1207
 Tyr Cys His Pro Asp Ser Xaa Pro Gln Leu Glu Gln Arg
 15 390 395 400

aca cac tga aag cat cct ttc cga aag cca ctc tgt aat 1246
 Thr His Xaa Lys His Pro Phe Arg Lys Pro Leu Cys Asn
 405 410 415

20 cgt gat gtc atc cgt aga aaa cag tag gca cag cag ccc 1285
 Arg Asp Val Ile Arg Arg Lys Gln Xaa Ala Gln Gln Pro
 420 425

aac tgg ggg ccc aag agg acg tct taa tgg cac agg agg 1324
 Asn Trp Gly Pro Lys Arg Thr Ser Xaa Trp His Arg Arg
 430 435 440

25 ccc tcg tga atg taa cag ctt cct cag gca tgc cag aga 1363
 Pro Ser Xaa Met Xaa Gln Leu Pro Gln Ala Cys Gln Arg
 445 450

aac ccc tga ttc cta ccg aga ctc tcc tca tag tga aag 1402
 Asn Pro Xaa Phe Leu Pro Arg Leu Ser Ser Xaa Xaa Lys
 30 455 460 465

gta tgt gtc agc cat gac cac ccc ggc tcg tat gtc acc 1441
 Val Cys Val Ser His Asp His Pro Gly Ser Tyr Val Thr
 470 475 480

35 tgt aga ttt cca cac gcc aag ctc ccc caa atc gcc ccc 1480
 Cys Arg Phe Pro His Ala Lys Leu Pro Gln Ile Ala Pro
 485 490

ttc gga aat gtc tcc acc cgt gtc cag cat gac ggt gtc 1519
 Phe Gly Asn Val Ser Thr Arg Val Gln His Asp Gly Val
 495 500 505

40 cat gcc ttc cat ggc ggt cag ccc ctt cat gga aga aga 1558
 His Ala Phe His Gly Gly Gln Pro Leu His Gly Arg Arg
 510 515

gag acc tct act tct cgt gac acc acc aag gct gcg gga 1597
 Glu Thr Ser Thr Ser Arg Asp Thr Thr Lys Ala Ala Gly
 45 520 525 530

gaa gaa gtt tga cca tca ccc tca gca gtt cag ctc ctt 1636
 Glu Glu Val Xaa Pro Ser Pro Ser Ala Val Gln Leu Leu
 535 540 545

cca cca caa ccc cgc gca tga cag taa cag cct ccc tgc 1675

Pro Pro Gln Pro Arg Ala Xaa Gln Xaa Gln Pro Pro Cys
550 555

tag ccc ctt gag gat agt gga gga tga gga gta tga aac 1714
Xaa Pro Leu Glu Asp Ser Gly Gly Xaa Gly Val Xaa Asn
5 560 565 570

gac cca aga gta cga gcc agc cca aga gcc tgt taa gaa 1753
Asp Pro Arg Val Arg Ala Ser Pro Arg Ala Cys Xaa Glu
575 580

act cgc caa tag ccg gcg ggc caa aag aac caa gcc caa 1792
10 Thr Arg Gln Xaa Pro Ala Gly Gln Lys Asn Gln Ala Gln
585 590 595

tgg cca cat tgc taa cag att gga agt gga cag caa cac 1831
Trp Pro His Cys Xaa Gln Ile Gly Ser Gly Gln Gln His
600 605 610

aag ctc cca gag cag taa ctc aga gag tga aac aga aga 1870
15 Lys Leu Pro Glu Gln Xaa Leu Arg Glu Xaa Asn Arg Arg
615 620

tga aag agt agg tga aga tac gcc ttt cct ggg cat aca 1909
20 Xaa Lys Ser Arg Xaa Arg Tyr Ala Phe Pro Gly His Thr
625 630 635

gaa ccc cct ggc agc cag tct tga ggc aac acc tgc ctt 1948
Glu Pro Pro Gly Ser Gln Ser Xaa Gly Asn Thr Cys Leu
640 645

ccg cct ggc tga cag cag gac taa ccc agc agg ccg ctt 1987
25 Pro Pro Gly Xaa Gln Gln Asp Xaa Pro Ser Arg Pro Leu
650 655 660

ctc gac aca gga aga aat cca g g ccaggctgtc tagtgtaatt 2030
Leu Asp Thr Gly Arg Asn Pro
665 669

gctaaccaag accctattgc tgtataaaac cttaaataaac acatagattc 2080
30 accctgtaaaaa ctttatttta tataataaag tattccacct taaattaaac 2130
aatttatttt attttagcag ttctgcaaat agaaaacagg aaaaaaactt 2180
ttataaatta aatatatgta tgtaaaaatg aaaaaaaaaa aaaaaa 2226

<210> 3
35 <211> 675
<212> PRT
<213> Homo sapiens

<400> 3
40 Asp Lys Leu Phe Pro Asn Pro Ile Arg Ala Leu Gly Pro Asn Ser
1 5 10 15

Pro Ala Pro Arg Ala Val Arg Val Glu Arg Ser Val Ser Gly Glu
20 25 30

Met Ser Glu Arg Lys Glu Gly Arg Gly Lys Gly Lys Gly Lys Lys
35 40 45

45 Lys Glu Arg Gly Ser Gly Lys Lys Pro Glu Ser Ala Ala Gly Ser
50 55 60

	Gln Ser Pro Ala Leu Pro Pro Gln Leu Lys Glu Met Lys Ser Gln	65	70	75
	Glu Ser Ala Ala Gly Ser Lys Leu Val Leu Arg Cys Glu Thr Ser	80	85	90
5	Ser Glu Tyr Ser Ser Leu Arg Phe Lys Trp Phe Lys Asn Gly Asn	95	100	105
	Glu Leu Asn Arg Lys Asn Lys Pro Gln Asn Ile Lys Ile Gln Lys	110	115	120
10	Lys Pro Gly Lys Ser Glu Leu Arg Ile Asn Lys Ala Ser Leu Ala	125	130	135
	Asp Ser Gly Glu Tyr Met Cys Lys Val Ile Ser Lys Leu Gly Asn	140	145	150
	Asp Ser Ala Ser Ala Asn Ile Thr Ile Val Glu Ser Asn Glu Ile	155	160	165
15	Ile Thr Gly Met Pro Ala Ser Thr Glu Gly Ala Tyr Val Ser Ser	170	175	180
	Glu Ser Pro Ile Arg Ile Ser Val Ser Thr Glu Gly Ala Asn Thr	185	190	195
20	Ser Ser Ser Thr Ser Thr Ser Thr Thr Gly Thr Ser His Leu Val	200	205	210
	Lys Cys Ala Glu Lys Glu Lys Thr Phe Cys Val Asn Gly Gly Glu	215	220	225
	Cys Phe Met Val Lys Asp Leu Ser Asn Pro Ser Arg Tyr Leu Cys	230	235	240
25	Lys Cys Pro Asn Glu Phe Thr Gly Asp Arg Cys Gln Asn Tyr Val	245	250	255
	Met Ala Ser Phe Tyr Lys His Leu Gly Ile Glu Phe Met Glu Ala	260	265	270
30	Glu Glu Leu Tyr Gln Lys Arg Val Leu Thr Ile Thr Gly Ile Cys	275	280	285
	Ile Ala Leu Leu Val Val Gly Ile Met Cys Val Val Ala Tyr Cys	290	295	300
	Lys Thr Lys Lys Gln Arg Lys Lys Leu His Asp Arg Leu Arg Gln	305	310	315
35	Ser Leu Arg Ser Glu Arg Asn Asn Met Met Asn Ile Ala Asn Gly	320	325	330
	Pro His His Pro Asn Pro Pro Pro Glu Asn Val Gln Leu Val Asn	335	340	345
40	Gln Tyr Val Ser Lys Asn Val Ile Ser Ser Glu His Ile Val Glu	350	355	360
	Arg Glu Ala Glu Thr Ser Phe Ser Thr Ser His Tyr Thr Ser Thr	365	370	375
	Ala His His Ser Thr Thr Val Thr Gln Thr Pro Ser His Ser Trp	380	385	390

Ser Asn Gly His Thr Glu Ser Ile Leu Ser Glu Ser His Ser Val
 395 400 405
 Ile Val Met Ser Ser Val Glu Asn Ser Arg His Ser Ser Pro Thr
 410 415 420
 5 Gly Gly Pro Arg Gly Arg Leu Asn Gly Thr Gly Gly Pro Arg Glu
 425 430 435
 Cys Asn Ser Phe Leu Arg His Ala Arg Glu Thr Pro Asp Ser Tyr
 440 445 450
 10 Arg Asp Ser Pro His Ser Glu Arg Tyr Val Ser Ala Met Thr Thr
 455 460 465
 Pro Ala Arg Met Ser Pro Val Asp Phe His Thr Pro Ser Ser Pro
 470 475 480
 Lys Ser Pro Pro Ser Glu Met Ser Pro Pro Val Ser Ser Met Thr
 485 490 495
 15 Val Ser Met Pro Ser Met Ala Val Ser Pro Phe Met Glu Glu Glu
 500 505 510
 Arg Pro Leu Leu Leu Val Thr Pro Pro Arg Leu Arg Glu Lys Lys
 515 520 525
 Phe Asp His His Pro Gln Gln Phe Ser Ser Phe His His Asn Pro
 20 530 535 540
 Ala His Asp Ser Asn Ser Leu Pro Ala Ser Pro Leu Arg Ile Val
 545 550 555
 Glu Asp Glu Glu Tyr Glu Thr Thr Gln Glu Tyr Glu Pro Ala Gln
 560 565 570
 25 Glu Pro Val Lys Lys Leu Ala Asn Ser Arg Arg Ala Lys Arg Thr
 575 580 585
 Lys Pro Asn Gly His Ile Ala Asn Arg Leu Glu Val Asp Ser Asn
 590 595 600
 30 Thr Ser Ser Gln Ser Ser Asn Ser Glu Ser Glu Thr Glu Asp Glu
 605 610 615
 Arg Val Gly Glu Asp Thr Pro Phe Leu Gly Ile Gln Asn Pro Leu
 620 625 630
 Ala Ala Ser Leu Glu Ala Thr Pro Ala Phe Arg Leu Ala Asp Ser
 635 640 645
 35 Arg Thr Asn Pro Ala Gly Arg Phe Ser Thr Gln Glu Glu Ile Gln
 650 655 660
 Ala Arg Leu Ser Ser Val Ile Ala Asn Gln Asp Pro Ile Ala Val
 665 670 675
 <210> 4
 40 <211> 2199
 <212> DNA
 <213> Homo sapiens
 <400> 4
 45 gg gac aaa ctt ttc cca aac ccg atc cga gcc ctt gga 38
 Asp Lys Leu Phe Pro Asn Pro Ile Arg Ala Leu Gly

	1	5	10
	cca aac tcg cct gcg ccg aga gcc gtc cgc gta gag cgc 77		
	Pro Asn Ser Pro Ala Pro Arg Ala Val Arg Val Glu Arg		
	15	20	25
5	tcc gtc tcc ggc gag atg tcc gag cgc aaa gaa ggc aga 116		
	Ser Val Ser Gly Glu Met Ser Glu Arg Lys Glu Gly Arg		
	30	35	
	ggc aaa ggg aag ggc aag aag aag gag cga ggc tcc ggc 155		
	Gly Lys Gly Lys Gly Lys Lys Lys Glu Arg Gly Ser Gly		
10	40	45	50
	aag aag ccg gag tcc gcg gcg ggc agc cag agc cca gcc 194		
	Lys Lys Pro Glu Ser Ala Ala Gly Ser Gln Ser Pro Ala		
	55	60	
	ttg cct ccc caa ttg aaa gag atg aaa agc cag gaa tcg 233		
	Leu Pro Pro Gln Leu Lys Glu Met Lys Ser Gln Glu Ser		
15	65	70	75
	gct gca ggt tcc aaa cta gtc ctt cgg tgt gaa acc agt 272		
	Ala Ala Gly Ser Lys Leu Val Leu Arg Cys Glu Thr Ser		
	80	85	90
	tct gaa tac tcc tct ctc aga ttc aag tgg ttc aag aat 311		
	Ser Glu Tyr Ser Ser Leu Arg Phe Lys Trp Phe Lys Asn		
20	95	100	
	ggg aat gaa ttg aat cga aaa aac aaa cca caa aat atc 350		
	Gly Asn Glu Leu Asn Arg Lys Asn Lys Pro Gln Asn Ile		
25	105	110	115
	aag ata caa aaa aag cca ggg aag tca gaa ctt cgc att 389		
	Lys Ile Gln Lys Lys Pro Gly Lys Ser Glu Leu Arg Ile		
	120	125	
	aac aaa gca tca ctg gct gat tct gga gag tat atg tgc 428		
	Asn Lys Ala Ser Leu Ala Asp Ser Gly Glu Tyr Met Cys		
30	130	135	140
	aaa gtg atc agc aaa tta gga aat gac agt gcc tct gcc 467		
	Lys Val Ile Ser Lys Leu Gly Asn Asp Ser Ala Ser Ala		
	145	150	155
	aat atc acc atc gtg gaa tca aac gag atc atc act ggt 506		
	Asn Ile Thr Ile Val Glu Ser Asn Glu Ile Ile Thr Gly		
35	160	165	
	atg cca gcc tca act gaa gga gca tat gtg tct tca gag 545		
	Met Pro Ala Ser Thr Glu Gly Ala Tyr Val Ser Ser Glu		
40	170	175	180
	tct ccc att aga ata tca gta tcc aca gaa gga gca aat 584		
	Ser Pro Ile Arg Ile Ser Val Ser Thr Glu Gly Ala Asn		
	185	190	
	act tct tca tct aca tct aca tcc acc act ggg aca agc 623		
	Thr Ser Ser Ser Thr Thr Ser Thr Thr Gly Thr Ser		
45	195	200	205
	cat ctt gta aaa tgt gcg gag aag gag aaa act ttc tgt 662		
	His Leu Val Lys Cys Ala Glu Lys Glu Lys Thr Phe Cys		
	210	215	220

gtg aat gga ggg gag tgc ttc atg gtg aaa gac ctt tca 701
 Val Asn Gly Gly Glu Cys Phe Met Val Lys Asp Leu Ser
 225 230

5 aac ccc tcg aga tac ttg tgc aag tgc cca aat gag ttt 740
 Asn Pro Ser Arg Tyr Leu Cys Lys Cys Pro Asn Glu Phe
 235 240 245

act ggt gat cgc tgc caa aac tac gta atg gcc agc ttc 779
 Thr Gly Asp Arg Cys Gln Asn Tyr Val Met Ala Ser Phe
 250 255

10 tac aag cat ctt ggg att gaa ttt atg gag gcg gag gag 818
 Tyr Lys His Leu Gly Ile Glu Phe Met Glu Ala Glu Glu
 260 265 270

15 ctg tac cag aag aga gtg ctg acc ata acc ggc atc tgc 857
 Leu Tyr Gln Lys Arg Val Leu Thr Ile Thr Gly Ile Cys
 275 280 285

atc gcc ctc ctt gtg gtc ggc atc atg tgt gtg gtg gcc 896
 Ile Ala Leu Leu Val Val Gly Ile Met Cys Val Val Ala
 290 295

20 tac tgc aaa acc aag aaa cag cgg aaa aag ctg cat gac 935
 Tyr Cys Lys Thr Lys Lys Gln Arg Lys Lys Leu His Asp
 300 305 310

cgt ctt cgg cag agc ctt cgg tct gaa cga aac aat atg 974
 Arg Leu Arg Gln Ser Leu Arg Ser Glu Arg Asn Asn Met
 315 320

25 atg aac att gcc aat ggg cct cac cat cct aac cca ccc 1013
 Met Asn Ile Ala Asn Gly Pro His His Pro Asn Pro Pro
 325 330 335

30 ccc gag aat gtc cag ctg gtg aat caa tac gta tct aaa 1052
 Pro Glu Asn Val Gln Leu Val Asn Gln Tyr Val Ser Lys
 340 345 350

aac gtc atc tcc agt gag cat att gtt gag aga gaa gca 1091
 Asn Val Ile Ser Ser Glu His Ile Val Glu Arg Glu Ala
 355 360

35 gag aca tcc ttt tcc acc agt cac tat act tcc aca gcc 1130
 Glu Thr Ser Phe Ser Thr Ser His Tyr Thr Ser Thr Ala
 365 370 375

cat cac tcc act act gtc acc cag act cct agc cac agc 1169
 His His Ser Thr Thr Val Thr Gln Thr Pro Ser His Ser
 380 385

40 tgg agc aac gga cac act gaa agc atc ctt tcc gaa agc 1208
 Trp Ser Asn Gly His Thr Glu Ser Ile Leu Ser Glu Ser
 390 395 400

45 cac tct gta atc gtg atg tca tcc gta gaa aac agt agg 1247
 His Ser Val Ile Val Met Ser Ser Val Glu Asn Ser Arg
 405 410 415

cac agc agc cca act ggg ggc cca aga gga cgt ctt aat 1286
 His Ser Ser Pro Thr Gly Gly Pro Arg Gly Arg Leu Asn
 420 425

ggc aca gga ggc cct cgt gaa tgt aac agc ttc ctc agg 1325

Gly Thr Gly Gly Pro Arg Glu Cys Asn Ser Phe Leu Arg
 430 435 440
 cat gcc aga gaa acc cct gat tcc tac cga gac tct cct 1364
 His Ala Arg Glu Thr Pro Asp Ser Tyr Arg Asp Ser Pro
 445 450
 cat agt gaa agg tat gtg tca gcc atg acc acc ccg gct 1403
 His Ser Glu Arg Tyr Val Ser Ala Met Thr Thr Pro Ala
 455 460 465
 cgt atg tca cct gta gat ttc cac acg cca agc tcc ccc 1442
 Arg Met Ser Pro Val Asp Phe His Thr Pro Ser Ser Pro
 470 475 480
 aaa tcg ccc cct tcg gaa atg tct cca ccc gtg tcc agc 1481
 Lys Ser Pro Pro Ser Glu Met Ser Pro Pro Val Ser Ser
 485 490
 atg acg gtg tcc atg cct tcc atg gcg gtc agc ccc ttc 1520
 Met Thr Val Ser Met Pro Ser Met Ala Val Ser Pro Phe
 495 500 505
 atg gaa gaa gag aga cct cta ctt ctc gtg aca cca cca 1559
 Met Glu Glu Glu Arg Pro Leu Leu Val Thr Pro Pro
 510 515
 agg ctg cgg gag aag aag ttt gac cat cac cct cag cag 1598
 Arg Leu Arg Glu Lys Lys Phe Asp His His Pro Gln Gln
 520 525 530
 ttc agc tcc ttc cac cac aac ccc gcg cat gac agt aac 1637
 Phe Ser Ser Phe His His Asn Pro Ala His Asp Ser Asn
 535 540 545
 agc ctc cct gct agc ccc ttg agg ata gtg gag gat gag 1676
 Ser Leu Pro Ala Ser Pro Leu Arg Ile Val Glu Asp Glu
 550 555
 gag tat gaa acg acc caa gag tac gag cca gcc caa gag 1715
 Glu Tyr Glu Thr Thr Gln Glu Tyr Glu Pro Ala Gln Glu
 560 565 570
 cct gtt aag aaa ctc gcc aat agc cgg cgg gcc aaa aga 1754
 Pro Val Lys Lys Leu Ala Asn Ser Arg Arg Ala Lys Arg
 575 580
 acc aag ccc aat ggc cac att gct aac aga ttg gaa gtg 1793
 Thr Lys Pro Asn Gly His Ile Ala Asn Arg Leu Glu Val
 585 590 595
 gac agc aac aca agc tcc cag agc agt aac tca gag agt 1832
 Asp Ser Asn Thr Ser Ser Gln Ser Ser Asn Ser Glu Ser
 600 605 610
 gaa aca gaa gat gaa aga gta ggt gaa gat acg cct ttc 1871
 Glu Thr Glu Asp Glu Arg Val Gly Glu Asp Thr Pro Phe
 615 620
 ctg ggc ata cag aac ccc ctg gca gcc agt ctt gag gca 1910
 Leu Gly Ile Gln Asn Pro Leu Ala Ala Ser Leu Glu Ala
 625 630 635
 aca cct gcc ttc cgc ctg gct gac agc agg act aac cca 1949
 Thr Pro Ala Phe Arg Leu Ala Asp Ser Arg Thr Asn Pro

640 645

gca ggc cgc ttc tcg aca cag gaa gaa atc cag gcc agg 1988
 Ala Gly Arg Phe Ser Thr Gln Glu Glu Ile Gln Ala Arg
 650 655 660

5 ctg tct agt gta att gct aac caa gac cct att gct gta ta 2029
 Leu Ser Ser Val Ile Ala Asn Gln Asp Pro Ile Ala Val
 665 670 675

a aacctaata aacacataga ttcacctgta aaactttatt 2070

ttatataata aagtattcca ccttaaatta aacaatttat tttatttttag 2120

10 cagttctgca aatagaaaac aggaaaaaaa cttttataaa ttaaatatat 2170

gtatgtaaaa atgaaaaaaa aaaaaaaaa 2199

<210> 5
 <211> 637
 <212> PRT
 15 <213> Homo sapiens

<400> 5
 Met Ser Glu Arg Lys Glu Gly Arg Gly Lys Gly Lys Gly Lys Lys
 1 5 10 15

Lys Glu Arg Gly Ser Gly Lys Lys Pro Glu Ser Ala Ala Gly Ser
 20 20 25 30

Gln Ser Pro Ala Leu Pro Pro Gln Leu Lys Glu Met Lys Ser Gln
 35 40 45

Glu Ser Ala Ala Gly Ser Lys Leu Val Leu Arg Cys Glu Thr Ser
 50 55 60

25 Ser Glu Tyr Ser Ser Leu Arg Phe Lys Trp Phe Lys Asn Gly Asn
 65 70 75

Glu Leu Asn Arg Lys Asn Lys Pro Gln Asn Ile Lys Ile Gln Lys
 80 85 90

Lys Pro Gly Lys Ser Glu Leu Arg Ile Asn Lys Ala Ser Leu Ala
 30 95 100 105

Asp Ser Gly Glu Tyr Met Cys Lys Val Ile Ser Lys Leu Gly Asn
 110 115 120

Asp Ser Ala Ser Ala Asn Ile Thr Ile Val Glu Ser Asn Glu Ile
 125 130 135

35 Ile Thr Gly Met Pro Ala Ser Thr Glu Gly Ala Tyr Val Ser Ser
 140 145 150

Glu Ser Pro Ile Arg Ile Ser Val Ser Thr Glu Gly Ala Asn Thr
 155 160 165

Ser Ser Ser Thr Ser Thr Ser Thr Thr Gly Thr Ser His Leu Val
 40 170 175 180

Lys Cys Ala Glu Lys Glu Lys Thr Phe Cys Val Asn Gly Gly Glu
 185 190 195

Cys Phe Met Val Lys Asp Leu Ser Asn Pro Ser Arg Tyr Leu Cys
 200 205 210

	Lys Cys Pro Asn Glu Phe Thr Gly Asp Arg Cys Gln Asn Tyr Val	215	220	225
	Met Ala Ser Phe Tyr Lys Ala Glu Glu Leu Tyr Gln Lys Arg Val	230	235	240
5	Leu Thr Ile Thr Gly Ile Cys Ile Ala Leu Leu Val Val Gly Ile	245	250	255
	Met Cys Val Val Ala Tyr Cys Lys Thr Lys Lys Gln Arg Lys Lys	260	265	270
10	Leu His Asp Arg Leu Arg Gln Ser Leu Arg Ser Glu Arg Asn Asn	275	280	285
	Met Met Asn Ile Ala Asn Gly Pro His His Pro Asn Pro Pro Pro	290	295	300
	Glu Asn Val Gln Leu Val Asn Gln Tyr Val Ser Lys Asn Val Ile	305	310	315
15	Ser Ser Glu His Ile Val Glu Arg Glu Ala Glu Thr Ser Phe Ser	320	325	330
	Thr Ser His Tyr Thr Ser Thr Ala His His Ser Thr Thr Val Thr	335	340	345
20	Gln Thr Pro Ser His Ser Trp Ser Asn Gly His Thr Glu Ser Ile	350	355	360
	Leu Ser Glu Ser His Ser Val Ile Val Met Ser Ser Val Glu Asn	365	370	375
	Ser Arg His Ser Ser Pro Thr Gly Gly Pro Arg Gly Arg Leu Asn	380	385	390
25	Gly Thr Gly Gly Pro Arg Glu Cys Asn Ser Phe Leu Arg His Ala	395	400	405
	Arg Glu Thr Pro Asp Ser Tyr Arg Asp Ser Pro His Ser Glu Arg	410	415	420
30	Tyr Val Ser Ala Met Thr Thr Pro Ala Arg Met Ser Pro Val Asp	425	430	435
	Phe His Thr Pro Ser Ser Pro Lys Ser Pro Pro Ser Glu Met Ser	440	445	450
	Pro Pro Val Ser Ser Met Thr Val Ser Lys Pro Ser Met Ala Val	455	460	465
35	Ser Pro Phe Met Glu Glu Glu Arg Pro Leu Leu Leu Val Thr Pro	470	475	480
	Pro Arg Leu Arg Glu Lys Lys Phe Asp His His Pro Gln Gln Phe	485	490	495
40	Ser Ser Phe His His Asn Pro Ala His Asp Ser Asn Ser Leu Pro	500	505	510
	Ala Ser Pro Leu Arg Ile Val Glu Asp Glu Glu Tyr Glu Thr Thr	515	520	525
	Gln Glu Tyr Glu Pro Ala Gln Glu Pro Val Lys Lys Leu Ala Asn	530	535	540

Ser Arg Arg Ala Lys Arg Thr Lys Pro Asn Gly His Ile Ala Asn
 545 550 555
 Arg Leu Glu Val Asp Ser Asn Thr Ser Ser Gln Ser Ser Asn Ser
 560 565 570
 5 Glu Ser Glu Thr Glu Asp Glu Arg Val Gly Glu Asp Thr Pro Phe
 575 580 585
 Leu Gly Ile Gln Asn Pro Leu Ala Ala Ser Leu Glu Ala Thr Pro
 590 595 600
 10 Ala Phe Arg Leu Ala Asp Ser Arg Thr Asn Pro Ala Gly Arg Phe
 605 610 615
 Ser Thr Gln Glu Glu Ile Gln Ala Arg Leu Ser Ser Val Ile Ala
 620 625 630
 Asn Gln Asp Pro Ile Ala Val
 635 637
 15 <210> 6
 <211> 2490
 <212> DNA
 <213> Homo sapiens
 <400> 6
 20 gtggctgcgg ggcaattgaa aaagagccgg cgaggagttc cccgaaactt 50
 gttggaactc cgggctcgcg cggaggccag gagctgagcg gcggcggctg 100
 ccggacgatg ggagcgtgag caggacggtg ataacctctc cccgatcggg 150
 ttgcgagggc gccgggcaga ggccaggacg cgagccgcca gcggcgggac 200
 ccatcgacga cttcccgggg cgacaggagc agccccgaga gccagggcga 250
 25 gcgcccgttc caggtggccg gaccgcccgc cgcgtccgcg ccgcgctccc 300
 tgcaggcaac gggagacgcc cccgcgcagc gcgagcgctt cagcgcggcc 350
 gctcgtctct cccatcgagg gacaaacttt tcccaaacc gatccgagcc 400
 cttggaccaa actcgcttgc gccgagagcc gtccgcgtag agcgctccgt 450
 ctccggcgag atg tcc gag cgc aaa gaa ggc aga ggc aaa 490
 30 Met Ser Glu Arg Lys Glu Gly Arg Gly Lys
 1 5 10
 ggg aag ggc aag aag aag gag cga ggc tcc ggc aag aag 529
 Gly Lys Gly Lys Lys Lys Glu Arg Gly Ser Gly Lys Lys
 15 20
 35 ccg gag tcc gcg gcg ggc agc cag agc cca gcc ttg cct 568
 Pro Glu Ser Ala Ala Gly Ser Gln Ser Pro Ala Leu Pro
 25 30 35
 ccc caa ttg aaa gag atg aaa agc cag gaa tcg gct gca 607
 40 Pro Gln Leu Lys Glu Met Lys Ser Gln Glu Ser Ala Ala
 40 45
 ggt tcc aaa cta gtc ctt cgg tgt gaa acc agt tct gaa 646
 Gly Ser Lys Leu Val Leu Arg Cys Glu Thr Ser Ser Glu
 50 55 60

tac tcc tct ctc aga ttc aag tgg ttc aag aat ggg aat 685
 Tyr Ser Ser Leu Arg Phe Lys Trp Phe Lys Asn Gly Asn
 65 70 75

5 gaa ttg aat cga aaa aac aaa cca caa aat atc aag ata 724
 Glu Leu Asn Arg Lys Asn Lys Pro Gln Asn Ile Lys Ile
 80 85

caa aaa aag cca ggg aag tca gaa ctt cgc att aac aaa 763
 Gln Lys Lys Pro Gly Lys Ser Glu Leu Arg Ile Asn Lys
 90 95 100

10 gca tca ctg gct gat tct gga gag tat atg tgc aaa gtg 802
 Ala Ser Leu Ala Asp Ser Gly Glu Tyr Met Cys Lys Val
 105 110

atc agc aaa tta gga aat gac agt gcc tct gcc aat atc 841
 15 Ile Ser Lys Leu Gly Asn Asp Ser Ala Ser Ala Asn Ile
 115 120 125

acc atc gtg gaa tca aac gag atc atc act ggt atg cca 880
 Thr Ile Val Glu Ser Asn Glu Ile Ile Thr Gly Met Pro
 130 135 140

20 gcc tca act gaa gga gca tat gtg tct tca gag tct ccc 919
 Ala Ser Thr Glu Gly Ala Tyr Val Ser Ser Glu Ser Pro
 145 150

att aga ata tca gta tcc aca gaa gga gca aat act tct 958
 Ile Arg Ile Ser Val Ser Thr Glu Gly Ala Asn Thr Ser
 155 160 165

25 tca tct aca tct aca tcc acc act ggg aca agc cat ctt 997
 Ser Ser Thr Ser Thr Ser Thr Thr Gly Thr Ser His Leu
 170 175

gta aaa tgt gcg gag aag gag aaa act ttc tgt gtg aat 1036
 30 Val Lys Cys Ala Glu Lys Glu Lys Thr Phe Cys Val Asn
 180 185 190

gga ggg gag tgc ttc atg gtg aaa gac ctt tca aac ccc 1075
 Gly Gly Glu Cys Phe Met Val Lys Asp Leu Ser Asn Pro
 195 200 205

tcg aga tac ttg tgc aag tgc cca aat gag ttt act ggt 1114
 35 Ser Arg Tyr Leu Cys Lys Cys Pro Asn Glu Phe Thr Gly
 210 215

gat cgc tgc caa aac tac gta atg gcc agc ttc tac aag 1153
 Asp Arg Cys Gln Asn Tyr Val Met Ala Ser Phe Tyr Lys
 220 225 230

40 gcg gag gag ctg tac cag aag aga gtg ctg acc ata acc 1192
 Ala Glu Glu Leu Tyr Gln Lys Arg Val Leu Thr Ile Thr
 235 240

ggc atc tgc atc gcc ctc ctt gtg gtc ggc atc atg tgt 1231
 45 Gly Ile Cys Ile Ala Leu Leu Val Val Gly Ile Met Cys
 245 250 255

gtg gtg gcc tac tgc aaa acc aag aaa cag cgg aaa aag 1270
 Val Val Ala Tyr Cys Lys Thr Lys Lys Gln Arg Lys Lys
 260 265 270

ctg cat gac cgt ctt cgg cag agc ctt cgg tct gaa cga 1309

Leu His Asp Arg Leu Arg Gln Ser Leu Arg Ser Glu Arg
 275 280

5 aac aat atg atg aac att gcc aat ggg cct cac cat cct 1348
 Asn Asn Met Met Asn Ile Ala Asn Gly Pro His His Pro
 285 290 295

aac cca ccc ccc gag aat gtc cag ctg gtg aat caa tac 1387
 Asn Pro Pro Pro Glu Asn Val Gln Leu Val Asn Gln Tyr
 300 305

10 gta tct aaa aac gtc atc tcc agt gag cat att gtt gag 1426
 Val Ser Lys Asn Val Ile Ser Ser Glu His Ile Val Glu
 310 315 320

aga gaa gca gag aca tcc ttt tcc acc agt cac tat act 1465
 Arg Glu Ala Glu Thr Ser Phe Ser Thr Ser His Tyr Thr
 325 330 335

15 tcc aca gcc cat cac tcc act act gtc acc cag act cct 1504
 Ser Thr Ala His His Ser Thr Thr Val Thr Gln Thr Pro
 340 345

agc cac agc tgg agc aac gga cac act gaa agc atc ctt 1543
 Ser His Ser Trp Ser Asn Gly His Thr Glu Ser Ile Leu
 20 350 355 360

tcc gaa agc cac tct gta atc gtg atg tca tcc gta gaa 1582
 Ser Glu Ser His Ser Val Ile Val Met Ser Ser Val Glu
 365 370

aac agt agg cac agc agc cca act ggg ggc cca aga gga 1621
 Asn Ser Arg His Ser Ser Pro Thr Gly Gly Pro Arg Gly
 25 375 380 385

cgt ctt aat ggc aca gga ggc cct cgt gaa tgt aac agc 1660
 Arg Leu Asn Gly Thr Gly Gly Pro Arg Glu Cys Asn Ser
 390 395 400

30 ttc ctc agg cat gcc aga gaa acc cct gat tcc tac cga 1699
 Phe Leu Arg His Ala Arg Glu Thr Pro Asp Ser Tyr Arg
 405 410

gac tct cct cat agt gaa agg tat gtg tca gcc atg acc 1738
 Asp Ser Pro His Ser Glu Arg Tyr Val Ser Ala Met Thr
 35 415 420 425

acc ccg gct cgt atg tca cct gta gat ttc cac acg cca 1777
 Thr Pro Ala Arg Met Ser Pro Val Asp Phe His Thr Pro
 430 435

agc tcc ccc aaa tcg ccc cct tcg gaa atg tct cca ccc 1816
 Ser Ser Pro Lys Ser Pro Pro Ser Glu Met Ser Pro Pro
 40 440 445 450

gtg tcc agc atg acg gtg tcc aag cct tcc atg gcg gtc 1855
 Val Ser Ser Met Thr Val Ser Lys Pro Ser Met Ala Val
 455 460 465

45 agc ccc ttc atg gaa gaa gag aga cct cta ctt ctc gtg 1894
 Ser Pro Phe Met Glu Glu Glu Arg Pro Leu Leu Leu Val
 470 475

aca cca cca agg ctg cgg gag aag aag ttt gac cat cac 1933
 Thr Pro Pro Arg Leu Arg Glu Lys Lys Phe Asp His His

	480	485	490	
	cct cag cag ttc agc tcc ttc cac cac aac ccc gcg cat			1972
	Pro Gln Gln Phe Ser Ser Phe His His Asn Pro Ala His			
	495	500		
5	gac agt aac agc ctc cct gct agc ccc ttg agg ata gtg			2011
	Asp Ser Asn Ser Leu Pro Ala Ser Pro Leu Arg Ile Val			
	505	510	515	
	gag gat gag gag tat gaa acg acc caa gag tac gag cca			2050
	Glu Asp Glu Glu Tyr Glu Thr Thr Gln Glu Tyr Glu Pro			
10	520	525	530	
	gcc caa gag cct gtt aag aaa ctc gcc aat agc cgg cgg			2089
	Ala Gln Glu Pro Val Lys Lys Leu Ala Asn Ser Arg Arg			
	535	540		
	gcc aaa aga acc aag ccc aat ggc cac att gct aac aga			2128
15	Ala Lys Arg Thr Lys Pro Asn Gly His Ile Ala Asn Arg			
	545	550	555	
	ttg gaa gtg gac agc aac aca agc tcc cag agc agt aac			2167
	Leu Glu Val Asp Ser Asn Thr Ser Ser Gln Ser Ser Asn			
	560	565		
20	tca gag agt gaa aca gaa gat gaa aga gta ggt gaa gat			2206
	Ser Glu Ser Glu Thr Glu Asp Glu Arg Val Gly Glu Asp			
	570	575	580	
	acg cct ttc ctg ggc ata cag aac ccc ctg gca gcc agt			2245
	Thr Pro Phe Leu Gly Ile Gln Asn Pro Leu Ala Ala Ser			
25	585	590	595	
	ctt gag gca aca cct gcc ttc cgc ctg gct gac agc agg			2284
	Leu Glu Ala Thr Pro Ala Phe Arg Leu Ala Asp Ser Arg			
	600	605		
	act aac cca gca ggc cgc ttc tcg aca cag gaa gaa atc			2323
30	Thr Asn Pro Ala Gly Arg Phe Ser Thr Gln Glu Glu Ile			
	610	615	620	
	cag gcc agg ctg tct agt gta att gct aac caa gac cct			2362
	Gln Ala Arg Leu Ser Ser Val Ile Ala Asn Gln Asp Pro			
	625	630		
35	att gct gta taaaaccta aataaacaca tagattcacc tgtaaaactt			2410
	Ile Ala Val			
	635	637		
	tattttatat aataaagtat tccaccttaa attaaacaat ttattttatt			2460
	ttagcagttc tgcaaataaa aaaaaaaaaa			2490
40	<210> 7			
	<211> 241			
	<212> PRT			
	<213> Homo sapiens			
	<400> 7			
45	Met Ser Glu Arg Lys Glu Gly Arg Gly Lys Gly Lys Gly Lys Lys			
	1	5	10	15
	Lys Glu Arg Gly Ser Gly Lys Lys Pro Glu Ser Ala Ala Gly Ser			
	20	25	30	

Gln Ser Pro Ala Leu Pro Pro Gln Leu Lys Glu Met Lys Ser Gln
 35 40 45
 Glu Ser Ala Ala Gly Ser Lys Leu Val Leu Arg Cys Glu Thr Ser
 50 55 60
 5 Ser Glu Tyr Ser Ser Leu Arg Phe Lys Trp Phe Lys Asn Gly Asn
 65 70 75
 Glu Leu Asn Arg Lys Asn Lys Pro Gln Asn Ile Lys Ile Gln Lys
 80 85 90
 10 Lys Pro Gly Lys Ser Glu Leu Arg Ile Asn Lys Ala Ser Leu Ala
 95 100 105
 Asp Ser Gly Glu Tyr Met Cys Lys Val Ile Ser Lys Leu Gly Asn
 110 115 120
 Asp Ser Ala Ser Ala Asn Ile Thr Ile Val Glu Ser Asn Glu Ile
 125 130 135
 15 Ile Thr Gly Met Pro Ala Ser Thr Glu Gly Ala Tyr Val Ser Ser
 140 145 150
 Glu Ser Pro Ile Arg Ile Ser Val Ser Thr Glu Gly Ala Asn Thr
 155 160 165
 20 Ser Ser Ser Thr Ser Thr Ser Thr Thr Gly Thr Ser His Leu Val
 170 175 180
 Lys Cys Ala Glu Lys Glu Lys Thr Phe Cys Val Asn Gly Gly Glu
 185 190 195
 Cys Phe Met Val Lys Asp Leu Ser Asn Pro Ser Arg Tyr Leu Cys
 200 205 210
 25 Lys Cys Pro Asn Glu Phe Thr Gly Asp Arg Cys Gln Asn Tyr Val
 215 220 225
 Met Ala Ser Phe Tyr Ser Thr Ser Thr Pro Phe Leu Ser Leu Pro
 230 235 240
 Glu
 30 241

<210> 8
 <211> 1715
 <212> DNA
 <213> Homo sapiens

35 <400> 8
 gcgcctgcct ccaacctgcg ggcgggaggt ggggtggctgc ggggcaattg 50
 aaaaagagcc ggcgaggagt tccccgaaac ttgttggaac tccgggctcg 100
 cgcgagggcc aggagctgag cggcggcggc tgccggacga tgggagcgtg 150
 agcaggacgg tgataacctc tccccgatcg ggttgcgagg gcgccgggca 200
 40 gaggccagga cgcgagccgc cagcggcggg acccatcgac gacttcccg 250
 ggcgacagga gcagccccga gagccagggc gagcgcccg tccaggtggc 300
 cggaccgccc gccgcgtccg cgccgcgctc cctgcaggca acgggagacg 350

```

ccccgcgcga gcgcgagcgc ctcagcgcgg ccgctcgcgc tccccatcga 400
gggacaaact tttcccaaac ccgatccgag cccttgacc aaactcgctt 450
gcgcgcgagag ccgtccgcgt agagcgcctcc gtctccggcg ag  atg 495
                                     Met
5                                     1

tcc gag cgc aaa gaa ggc aga ggc aaa ggg aag ggc aag 534
Ser Glu Arg Lys Glu Gly Arg Gly Lys Gly Lys Gly Lys
                    5                                10

aag aag gag cga ggc tcc ggc aag aag ccg gag tcc gcg 573
Lys Lys Glu Arg Gly Ser Gly Lys Lys Pro Glu Ser Ala
15                    20                                25

gcg ggc agc cag agc cca gcc ttg cct ccc caa ttg aaa 612
Ala Gly Ser Gln Ser Pro Ala Leu Pro Pro Gln Leu Lys
                    30                                35                                40

15 gag atg aaa agc cag gaa tcg gct gca ggt tcc aaa cta 651
Glu Met Lys Ser Gln Glu Ser Ala Ala Gly Ser Lys Leu
                    45                                50

gtc ctt cgg tgt gaa acc agt tct gaa tac tcc tct ctg 690
Val Leu Arg Cys Glu Thr Ser Ser Glu Tyr Ser Ser Leu
20                    55                                60                                65

aga ttc aag tgg ttc aag aat ggg aat gaa ttg aat cga 729
Arg Phe Lys Trp Phe Lys Asn Gly Asn Glu Leu Asn Arg
                    70                                75

aaa aac aaa cca caa aat atc aag ata caa aaa aag cca 768
Lys Asn Lys Pro Gln Asn Ile Lys Ile Gln Lys Lys Pro
25                    80                                85                                90

ggg aag tca gaa ctt cgc att aac aaa gca tca ctg gct 807
Gly Lys Ser Glu Leu Arg Ile Asn Lys Ala Ser Leu Ala
                    95                                100                                105

30 gat tct gga gag tat atg tgc aaa gtg atc agc aaa tta 846
Asp Ser Gly Glu Tyr Met Cys Lys Val Ile Ser Lys Leu
                    110                                115

gga aat gac agt gcc tct gcc aat atc acc atc gtg gaa 885
Gly Asn Asp Ser Ala Ser Ala Asn Ile Thr Ile Val Glu
35                    120                                125                                130

tca aac gag atc atc act ggt atg cca gcc tca act gaa 924
Ser Asn Glu Ile Ile Thr Gly Met Pro Ala Ser Thr Glu
                    135                                140

gga gca tat gtg tct tca gag tct ccc att aga ata tca 963
Gly Ala Tyr Val Ser Ser Glu Ser Pro Ile Arg Ile Ser
40                    145                                150                                155

gta tcc aca gaa gga gca aat act tct tca tct aca tct 1002
Val Ser Thr Glu Gly Ala Asn Thr Ser Ser Ser Thr Ser
                    160                                165                                170

45 aca tcc acc act ggg aca agc cat ctt gta aaa tgt gcg 1041
Thr Ser Thr Thr Gly Thr Ser His Leu Val Lys Cys Ala
                    175                                180

gag aag gag aaa act ttc tgt gtg aat gga ggg gag tgc 1080

```

Glu Lys Glu Lys Thr Phe Cys Val Asn Gly Gly Glu Cys
 185 190 195
 ttc atg gtg aaa gac ctt tca aac ccc tcg aga tac ttg 1119
 Phe Met Val Lys Asp Leu Ser Asn Pro Ser Arg Tyr Leu
 200 205
 tgc aag tgc cca aat gag ttt act ggt gat cgc tgc caa 1158
 Cys Lys Cys Pro Asn Glu Phe Thr Gly Asp Arg Cys Gln
 210 215 220
 aac tac gta atg gcc agc ttc tac agt acg tcc act ccc 1197
 Asn Tyr Val Met Ala Ser Phe Tyr Ser Thr Ser Thr Pro
 225 230 235
 ttt ctg tct ctg cct gaa tagga gcatgctcag ttggtgctgc 1240
 Phe Leu Ser Leu Pro Glu
 240 241
 tttcttggtg ctgcatctcc cctcagattc cacctagagc tagatgtgtc 1290
 ttaccagatc taatattgac tgcctctgcc tgtcgcata gaacattaac 1340
 aaaagcaatt gtattacttc ctctgttcgc gactagttgg ctctgagata 1390
 ctaatagggtg tgtgaggctc cggatgtttc tggaattgat attgaatgat 1440
 gtgatacaaa ttgatagtca atatcaagca gtgaaatatg ataataaagg 1490
 catttcaaag tctcactttt attgataaaa taaaaatcat tctactgaac 1540
 agtccatctt ctttatacaa tgaccacatc ctgaaaaggg tgttgctaag 1590
 ctgtaaccga tatgcacttg aatgatgggt aagttaattt tgattcagaa 1640
 tgtgttattt gtcacaaata aacataataa aaggagttca gatgtttttc 1690
 ttcattaacc aaaaaaaaaa aaaaa 1715
 <210> 9
 <211> 420
 <212> PRT
 <213> Homo sapiens
 <400> 9
 Met Ser Glu Arg Lys Glu Gly Arg Gly Lys Gly Lys Gly Lys Lys
 1 5 10 15
 Lys Glu Arg Gly Ser Gly Lys Lys Pro Glu Ser Ala Ala Gly Ser
 20 25 30
 Gln Ser Pro Ala Leu Pro Pro Gln Leu Lys Glu Met Lys Ser Gln
 35 40 45
 Glu Ser Ala Ala Gly Ser Lys Leu Val Leu Arg Cys Glu Thr Ser
 50 55 60
 Ser Glu Tyr Ser Ser Leu Arg Phe Lys Trp Phe Lys Asn Gly Asn
 65 70 75
 Glu Leu Asn Arg Lys Asn Lys Pro Gln Asn Ile Lys Ile Gln Lys
 80 85 90
 Lys Pro Gly Lys Ser Glu Leu Arg Ile Asn Lys Ala Ser Leu Ala
 95 100 105

	Asp Ser Gly Glu Tyr Met Cys Lys Val Ile Ser Lys Leu Gly Asn	110	115	120
	Asp Ser Ala Ser Ala Asn Ile Thr Ile Val Glu Ser Asn Glu Ile	125	130	135
5	Ile Thr Gly Met Pro Ala Ser Thr Glu Gly Ala Tyr Val Ser Ser	140	145	150
	Glu Ser Pro Ile Arg Ile Ser Val Ser Thr Glu Gly Ala Asn Thr	155	160	165
10	Ser Ser Ser Thr Ser Thr Ser Thr Thr Gly Thr Ser His Leu Val	170	175	180
	Lys Cys Ala Glu Lys Glu Lys Thr Phe Cys Val Asn Gly Gly Glu	185	190	195
	Cys Phe Met Val Lys Asp Leu Ser Asn Pro Ser Arg Tyr Leu Cys	200	205	210
15	Lys Cys Pro Asn Glu Phe Thr Gly Asp Arg Cys Gln Asn Tyr Val	215	220	225
	Met Ala Ser Phe Tyr Lys Ala Glu Glu Leu Tyr Gln Lys Arg Val	230	235	240
20	Leu Thr Ile Thr Gly Ile Cys Ile Ala Leu Leu Val Val Gly Ile	245	250	255
	Met Cys Val Val Ala Tyr Cys Lys Thr Lys Lys Gln Arg Lys Lys	260	265	270
	Leu His Asp Arg Leu Arg Gln Ser Leu Arg Ser Glu Arg Asn Asn	275	280	285
25	Met Met Asn Ile Ala Asn Gly Pro His His Pro Asn Pro Pro Pro	290	295	300
	Glu Asn Val Gln Leu Val Asn Gln Tyr Val Ser Lys Asn Val Ile	305	310	315
30	Ser Ser Glu His Ile Val Glu Arg Glu Ala Glu Thr Ser Phe Ser	320	325	330
	Thr Ser His Tyr Thr Ser Thr Ala His His Ser Thr Thr Val Thr	335	340	345
	Gln Thr Pro Ser His Ser Trp Ser Asn Gly His Thr Glu Ser Ile	350	355	360
35	Leu Ser Glu Ser His Ser Val Ile Val Met Ser Ser Val Glu Asn	365	370	375
	Ser Arg His Ser Ser Pro Thr Gly Gly Pro Arg Gly Arg Leu Asn	380	385	390
40	Gly Thr Gly Gly Pro Arg Glu Cys Asn Ser Phe Leu Arg His Ala	395	400	405
	Arg Glu Thr Pro Asp Ser Tyr Arg Asp Ser Pro His Ser Glu Arg	410	415	420

<210> 10

<211> 2431

<212> DNA

<213> Homo sapiens

<400> 10

```

gaggcgctg cctccaacct gcgggcggga ggtgggtggc tgcggggcaa 50
5  ttgaaaaaga gccggcgagg agttccccga aacttggttg aactccgggc 100
   tcgcgcgagg gccaggagct gagcggcggc ggctgccgga cgatgggagc 150
   gtgagcagga cggtgataac ctctccccga tcgggttgcg agggcgcccg 200
   gcagaggcca ggacgcgagc cgccagcggc gggacccatc gacgacttcc 250
   cggggcgaca ggagcagccc cgagagccag ggcgagcgcc cgttccaggt 300
10  ggccggaccg cccgccgct cgcgcgccg ctccctgcag gcaacgggag 350
   acgccccgc gcagcgcgag cgcctcagcg cggccgctcg ctctcccat 400
   cgagggacaa acttttcca aacccgatcc gagcccttgg accaaactcg 450
   cctgcgccga gagccgtccg cgtagagcgc tccgtctccg gcgag  atg 498
                                     Met
15                                     1

   tcc gag cgc aaa gaa ggc aga ggc aaa ggg aag ggc aag 537
   Ser Glu Arg Lys Glu Gly Arg Gly Lys Gly Lys Gly Lys
                                     5          10

20  aag aag gag cga ggc tcc ggc aag aag ccg gag tcc gcg 576
   Lys Lys Glu Arg Gly Ser Gly Lys Lys Pro Glu Ser Ala
   15          20          25

   gcg ggc agc cag agc cca gcc ttg cct ccc caa ttg aaa 615
   Ala Gly Ser Gln Ser Pro Ala Leu Pro Pro Gln Leu Lys
   30          35          40

25  gag atg aaa agc cag gaa tcg gct gca ggt tcc aaa cta 654
   Glu Met Lys Ser Gln Glu Ser Ala Ala Gly Ser Lys Leu
                                     45          50

   gtc ctt cgg tgt gaa acc agt tct gaa tac tcc tct ctc 693
   Val Leu Arg Cys Glu Thr Ser Ser Glu Tyr Ser Ser Leu
30  55          60          65

   aga ttc aag tgg ttc aag aat ggg aat gaa ttg aat cga 732
   Arg Phe Lys Trp Phe Lys Asn Gly Asn Glu Leu Asn Arg
                                     70          75

35  aaa aac aaa cca caa aat atc aag ata caa aaa aag cca 771
   Lys Asn Lys Pro Gln Asn Ile Lys Ile Gln Lys Lys Pro
   80          85          90

   ggg aag tca gaa ctt cgc att aac aaa gca tca ctg gct 810
   Gly Lys Ser Glu Leu Arg Ile Asn Lys Ala Ser Leu Ala
   95          100          105

40  gat tct gga gag tat atg tgc aaa gtg atc agc aaa tta 849
   Asp Ser Gly Glu Tyr Met Cys Lys Val Ile Ser Lys Leu
                                     110          115

   gga aat gac agt gcc tct gcc aat atc acc atc gtg gaa 888
   Gly Asn Asp Ser Ala Ser Ala Asn Ile Thr Ile Val Glu
45  120          125          130

```

tca aac gag atc atc act ggt atg cca gcc tca act gaa 927
 Ser Asn Glu Ile Ile Thr Gly Met Pro Ala Ser Thr Glu
 135 140

5 gga gca tat gtg tct tca gag tct ccc att aga ata tca 966
 Gly Ala Tyr Val Ser Ser Glu Ser Pro Ile Arg Ile Ser
 145 150 155

gta tcc aca gaa gga gca aat act tct tca tct aca tct 1005
 Val Ser Thr Glu Gly Ala Asn Thr Ser Ser Ser Thr Ser
 160 165 170

10 aca tcc acc act ggg aca agc cat ctt gta aaa tgt gcg 1044
 Thr Ser Thr Thr Thr Ser His Leu Val Lys Cys Ala
 175 180

gag aag gag aaa act ttc tgt gtg aat gga ggg gag tgc 1083
 15 Glu Lys Glu Lys Thr Phe Cys Val Asn Gly Gly Glu Cys
 185 190 195

ttc atg gtg aaa gac ctt tca aac ccc tcg aga tac ttg 1122
 Phe Met Val Lys Asp Leu Ser Asn Pro Ser Arg Tyr Leu
 200 205

20 tgc aag tgt cca aat gag ttt act ggt gat cgc tgc caa 1161
 Cys Lys Cys Pro Asn Glu Phe Thr Gly Asp Arg Cys Gln
 210 215 220

aac tac gta atg gcc agc ttc tac aag gcg gag gag ctg 1200
 Asn Tyr Val Met Ala Ser Phe Tyr Lys Ala Glu Glu Leu
 225 230 235

25 tac cag aag aga gtg ctg acc ata acc ggc atc tgc atc 1239
 Tyr Gln Lys Arg Val Leu Thr Ile Thr Gly Ile Cys Ile
 240 245

gcc ctc ctt gtg gtc ggc atc atg tgt gtg gtg gcc tac 1278
 30 Ala Leu Leu Val Val Gly Ile Met Cys Val Val Ala Tyr
 250 255 260

tgc aaa acc aag aaa cag cgg aaa aag ctg cat gac cgt 1317
 Cys Lys Thr Lys Lys Gln Arg Lys Lys Leu His Asp Arg
 265 270

35 ctt cgg cag agc ctt cgg tct gaa cga aac aat atg atg 1356
 Leu Arg Gln Ser Leu Arg Ser Glu Arg Asn Asn Met Met
 275 280 285

aac att gcc aat ggg cct cac cat cct aac cca ccc ccc 1395
 Asn Ile Ala Asn Gly Pro His His Pro Asn Pro Pro Pro
 290 295 300

40 gag aat gtc cag ctg gtg aat caa tac gta tct aaa aac 1434
 Glu Asn Val Gln Leu Val Asn Gln Tyr Val Ser Lys Asn
 305 310

gtc atc tcc agt gag cat att gtt gag aga gaa gca gag 1473
 45 Val Ile Ser Ser Glu His Ile Val Glu Arg Glu Ala Glu
 315 320 325

aca tcc ttt tcc acc agt cac tat act tcc aca gcc cat 1512
 Thr Ser Phe Ser Thr Ser His Tyr Thr Ser Thr Ala His
 330 335

cac tcc act act gtc acc cag act cct agc cac agc tgg 1551

His Ser Thr Thr Val Thr Gln Thr Pro Ser His Ser Trp
 340 345 350
 agc aac gga cac act gaa agc atc ctt tcc gaa agc cac 1590
 Ser Asn Gly His Thr Glu Ser Ile Leu Ser Glu Ser His
 5 355 360 365
 tct gta atc gtg atg tca tcc gta gaa aac agt agg cac 1629
 Ser Val Ile Val Met Ser Ser Val Glu Asn Ser Arg His
 370 375
 agc agc cca act ggg ggc cca aga gga cgt ctt aat ggc 1668
 10 Ser Ser Pro Thr Gly Gly Pro Arg Gly Arg Leu Asn Gly
 380 385 390
 aca gga ggc cct cgt gaa tgt aac agc ttc ctc agg cat 1707
 Thr Gly Gly Pro Arg Glu Cys Asn Ser Phe Leu Arg His
 395 400
 gcc aga gaa acc cct gat tcc tac cga gac tct cct cat 1746
 15 Ala Arg Glu Thr Pro Asp Ser Tyr Arg Asp Ser Pro His
 405 410 415
 agt gaa agg taaaa ccgaaggcaa agctactgca gaggagaaac 1790
 Ser Glu Arg
 20 420
 tcagtcagag aatccctgtg agcacctgcy gtctcacctc aggaaatcta 1840
 ctctaatacag aataaggggc ggcagttacc tgttctagga gtgctcctag 1890
 ttgatgaagt catctctttg tttgacggaa cttatttctt ctgagcttct 1940
 ctcgtcgtcc cagtgactga caggcaacag actcttaaag agctgggatg 1990
 25 ctttgatgcy gaagggtgcag cacatggagt ttccagctct ggccatgggc 2040
 tcagaccac tcggggtctc agtgcctca gttgtaacat tagagagatg 2090
 gcatcaatgc ttgataagga ccttctata attccaattg ccagttatcc 2140
 aaactctgat tcgggtggtc agctggcctc gtgttcttat ctgctaacc 2190
 tgtcttacct tccagcctca gttaagtcaa atcaagggt atgtcattgc 2240
 30 tgaatgtcat ggggggcaac tgcttgccct ccaccctata gtatctattt 2290
 tatgaaattc caagaaggga tgaataaata aatctcttgg atgctgcgtc 2340
 tggcagtcct caggggtggt tttcaaagca gaaaaaaaaa aaaaaaaaaa 2390
 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa a 2431
 <210> 11
 35 <211> 768
 <212> PRT
 <213> Homo sapiens
 <400> 11
 Met Asp Val Lys Glu Arg Lys Pro Tyr Arg Ser Leu Thr Arg Arg
 40 1 5 10 15
 Arg Asp Ala Glu Arg Arg Tyr Thr Ser Ser Ser Ala Asp Ser Glu
 20 25 30

	Glu Gly Lys Ala Pro Gln Lys Ser Tyr Ser Ser Ser Glu Thr Leu	35	40	45
	Lys Ala Tyr Asp Gln Asp Ala Arg Leu Ala Tyr Gly Ser Arg Val	50	55	60
5	Lys Asp Ile Val Pro Gln Glu Ala Glu Glu Phe Cys Arg Thr Gly	65	70	75
	Ala Asn Phe Thr Leu Arg Glu Leu Gly Leu Glu Glu Val Thr Pro	80	85	90
10	Pro His Gly Thr Leu Tyr Arg Thr Asp Ile Gly Leu Pro His Cys	95	100	105
	Gly Tyr Ser Met Gly Ala Gly Ser Asp Ala Asp Met Glu Ala Asp	110	115	120
	Thr Val Leu Ser Pro Glu His Pro Val Arg Leu Trp Gly Arg Ser	125	130	135
15	Thr Arg Ser Gly Arg Ser Ser Cys Leu Ser Ser Arg Ala Asn Ser	140	145	150
	Asn Leu Thr Leu Thr Asp Thr Glu His Glu Asn Thr Glu Thr Asp	155	160	165
20	His Pro Gly Gly Leu Gln Asn His Ala Arg Leu Arg Thr Pro Pro	170	175	180
	Pro Pro Leu Ser His Ala His Thr Pro Asn Gln His His Ala Ala	185	190	195
	Ser Ile Asn Ser Leu Asn Arg Gly Asn Phe Thr Pro Arg Ser Asn	200	205	210
25	Pro Ser Pro Ala Pro Thr Asp His Ser Leu Ser Gly Glu Pro Pro	215	220	225
	Ala Gly Gly Ala Gln Glu Pro Ala His Ala Gln Glu Asn Trp Leu	230	235	240
30	Leu Asn Ser Asn Ile Pro Leu Glu Thr Arg Asn Leu Gly Lys Gln	245	250	255
	Pro Phe Leu Gly Thr Leu Gln Asp Asn Leu Ile Glu Met Asp Ile	260	265	270
	Leu Gly Ala Ser Arg His Asp Gly Ala Tyr Ser Asp Gly His Phe	275	280	285
35	Leu Phe Lys Pro Gly Gly Thr Ser Pro Leu Phe Cys Thr Thr Ser	290	295	300
	Pro Gly Tyr Pro Leu Thr Ser Ser Thr Val Tyr Ser Pro Pro Pro	305	310	315
40	Arg Pro Leu Pro Arg Ser Thr Phe Ala Arg Pro Ala Phe Asn Leu	320	325	330
	Lys Lys Pro Ser Lys Tyr Cys Asn Trp Lys Cys Ala Ala Leu Ser	335	340	345
	Ala Ile Val Ile Ser Ala Thr Leu Val Ile Leu Leu Ala Tyr Phe	350	355	360

	Val Ala Met His Leu Phe Gly Leu Asn Trp His Leu Gln Pro Met	365	370	375
	Glu Gly Gln Met Tyr Glu Ile Thr Glu Asp Thr Ala Ser Ser Trp	380	385	390
5	Pro Val Pro Thr Asp Val Ser Leu Tyr Pro Ser Gly Gly Thr Gly	395	400	405
	Leu Glu Thr Pro Asp Arg Lys Gly Lys Gly Thr Thr Glu Gly Lys	410	415	420
10	Pro Ser Ser Phe Phe Pro Glu Asp Ser Phe Ile Asp Ser Gly Glu	425	430	435
	Ile Asp Val Gly Arg Arg Ala Ser Gln Lys Ile Pro Pro Gly Thr	440	445	450
	Phe Trp Arg Ser Gln Val Phe Ile Asp His Pro Val His Leu Lys	455	460	465
15	Phe Asn Val Ser Leu Gly Lys Ala Ala Leu Val Gly Ile Tyr Gly	470	475	480
	Arg Lys Gly Leu Pro Pro Ser His Thr Gln Phe Asp Phe Val Glu	485	490	495
20	Leu Leu Asp Gly Arg Arg Leu Leu Thr Gln Glu Ala Arg Ser Leu	500	505	510
	Glu Gly Thr Pro Arg Gln Ser Arg Gly Thr Val Pro Pro Ser Ser	515	520	525
	His Glu Thr Gly Phe Ile Gln Tyr Leu Asp Ser Gly Ile Trp His	530	535	540
25	Leu Ala Phe Tyr Asn Asp Gly Lys Glu Ser Glu Val Val Ser Phe	545	550	555
	Leu Thr Thr Ala Ile Ala Leu Pro Pro Arg Leu Lys Glu Met Lys	560	565	570
30	Ser Gln Glu Ser Ala Ala Gly Ser Lys Leu Val Leu Arg Cys Glu	575	580	585
	Thr Ser Ser Glu Tyr Ser Ser Leu Arg Phe Lys Trp Phe Lys Asn	590	595	600
	Gly Asn Glu Leu Asn Arg Lys Asn Lys Pro Gln Asn Ile Lys Ile	605	610	615
35	Gln Lys Lys Pro Gly Lys Ser Glu Leu Arg Ile Asn Lys Ala Ser	620	625	630
	Leu Ala Asp Ser Gly Glu Tyr Met Cys Lys Val Ile Ser Lys Leu	635	640	645
40	Gly Asn Asp Ser Ala Ser Ala Asn Ile Thr Ile Val Glu Ser Asn	650	655	660
	Glu Ile Ile Thr Gly Met Pro Ala Ser Thr Glu Gly Ala Tyr Val	665	670	675
	Ser Ser Glu Ser Pro Ile Arg Ile Ser Val Ser Thr Glu Gly Ala	680	685	690

-27-

Glu Leu Gly Leu Glu Glu Val Thr Pro Pro His Gly Thr
 85 90
 ctg tac cgg aca gac att ggc ctc ccc cac tgc ggc tac 654
 Leu Tyr Arg Thr Asp Ile Gly Leu Pro His Cys Gly Tyr
 5 95 100 105
 tcc atg ggg gct ggc tct gat gcc gac atg gag gct gac 693
 Ser Met Gly Ala Gly Ser Asp Ala Asp Met Glu Ala Asp
 110 115 120
 acg gtg ctg tcc cct gag cac ccc gtg cgt ctg tgg ggc 732
 10 Thr Val Leu Ser Pro Glu His Pro Val Arg Leu Trp Gly
 125 130
 cgg agc aca cgg tca ggg cgc agc tcc tgc ctg tcc agc 771
 Arg Ser Thr Arg Ser Gly Arg Ser Ser Cys Leu Ser Ser
 135 140 145
 15 cgg gcc aat tcc aat ctc aca ctc acc gac acc gag cat 810
 Arg Ala Asn Ser Asn Leu Thr Leu Thr Asp Thr Glu His
 150 155
 gaa aac act gag act gat cat ccg ggc ggc ctg cag aac 849
 20 Glu Asn Thr Glu Thr Asp His Pro Gly Gly Leu Gln Asn
 160 165 170
 cac gcg cgg ctc cgg acg ccg ccg ccg ctc tcg cac 888
 His Ala Arg Leu Arg Thr Pro Pro Pro Pro Leu Ser His
 175 180 185
 gcc cac acc ccc aac cag cac cac gcg gcc tcc att aac 927
 25 Ala His Thr Pro Asn Gln His His Ala Ala Ser Ile Asn
 190 195
 tcc ctg aac cgg ggc aac ttc acg ccg agg agc aac ccc 966
 Ser Leu Asn Arg Gly Asn Phe Thr Pro Arg Ser Asn Pro
 200 205 210
 30 agc ccg gcc ccc acg gac cac tcg ctc tcc gga gag ccc 1005
 Ser Pro Ala Pro Thr Asp His Ser Leu Ser Gly Glu Pro
 215 220
 cct gcc ggc ggc gcc cag gag cct gcc cac gcc cag gag 1044
 35 Pro Ala Gly Gly Ala Gln Glu Pro Ala His Ala Gln Glu
 225 230 235
 aac tgg ctg ctc aac agc aac atc ccc ctg gag acc aga 1083
 Asn Trp Leu Leu Asn Ser Asn Ile Pro Leu Glu Thr Arg
 240 245 250
 aac cta ggc aag cag cca ttc cta ggg aca ttg cag gac 1122
 40 Asn Leu Gly Lys Gln Pro Phe Leu Gly Thr Leu Gln Asp
 255 260
 aac ctc att gag atg gac att ctc ggc gcc tcc cgc cat 1161
 Asn Leu Ile Glu Met Asp Ile Leu Gly Ala Ser Arg His
 265 270 275
 45 gat ggg gct tac agt gac ggg cac ttc ctc ttc aag cct 1200
 Asp Gly Ala Tyr Ser Asp Gly His Phe Leu Phe Lys Pro
 280 285
 gga ggc acc tcc ccg ctc ttc tgc acc aca tca cca ggg 1239
 Gly Gly Thr Ser Pro Leu Phe Cys Thr Thr Ser Pro Gly

	290		295		300	
	tac cca ctg acg tcc agc aca gtg tac tct cct ccg ccc	1278				
	Tyr Pro Leu Thr Ser Ser Thr Val Tyr Ser Pro Pro Pro					
	305		310		315	
5	cga ccc ctg ccc cgc agc acc ttc gcc cgg ccg gcc ttt	1317				
	Arg Pro Leu Pro Arg Ser Thr Phe Ala Arg Pro Ala Phe					
	320		325			
	aac ctc aag aag ccc tcc aag tac tgt aac tgg aag tgc	1356				
10	Asn Leu Lys Lys Pro Ser Lys Tyr Cys Asn Trp Lys Cys					
	330		335		340	
	gca gcc ctg agc gcc atc gtc atc tca gcc act ctg gtc	1395				
	Ala Ala Leu Ser Ala Ile Val Ile Ser Ala Thr Leu Val					
	345		350			
15	atc ctg ctg gca tac ttt gtg gcc atg cac ctg ttt ggc	1434				
	Ile Leu Leu Ala Tyr Phe Val Ala Met His Leu Phe Gly					
	355		360		365	
	cta aac tgg cac ctg cag ccg atg gag ggg cag atg tat	1473				
	Leu Asn Trp His Leu Gln Pro Met Glu Gly Gln Met Tyr					
	370		375		380	
20	gag atc acg gag gac aca gcc agc agt tgg cct gtg cca	1512				
	Glu Ile Thr Glu Asp Thr Ala Ser Ser Trp Pro Val Pro					
	385		390			
	acc gac gtc tcc cta tac ccc tca ggg ggc act ggc tta	1551				
25	Thr Asp Val Ser Leu Tyr Pro Ser Gly Gly Thr Gly Leu					
	395		400		405	
	gag acc cct gac agg aaa ggc aaa gga acc aca gaa gga	1590				
	Glu Thr Pro Asp Arg Lys Gly Lys Gly Thr Thr Glu Gly					
	410		415			
	aag ccc agt agt ttc ttt cca gag gac agt ttc ata gat	1629				
30	Lys Pro Ser Ser Phe Phe Pro Glu Asp Ser Phe Ile Asp					
	420		425		430	
	tct gga gaa att gat gtg gga agg cga gct tcc cag aag	1668				
	Ser Gly Glu Ile Asp Val Gly Arg Arg Ala Ser Gln Lys					
	435		440		445	
35	att cct cct ggc act ttc tgg aga tct caa gtg ttc ata	1707				
	Ile Pro Pro Gly Thr Phe Trp Arg Ser Gln Val Phe Ile					
	450		455			
	gac cat cct gtg cat ctg aaa ttc aat gtg tct ctg gga	1746				
40	Asp His Pro Val His Leu Lys Phe Asn Val Ser Leu Gly					
	460		465		470	
	aag gca gcc ctg gtt ggc att tat ggc aga aaa ggc ctc	1785				
	Lys Ala Ala Leu Val Gly Ile Tyr Gly Arg Lys Gly Leu					
	475		480			
	cct cct tca cat aca cag ttt gac ttt gtg gag ctg ctg	1824				
45	Pro Pro Ser His Thr Gln Phe Asp Phe Val Glu Leu Leu					
	485		490		495	
	gat ggc agg agg ctc cta acc cag gag gcg cgg agc cta	1863				
	Asp Gly Arg Arg Leu Leu Thr Gln Glu Ala Arg Ser Leu					
	500		505		510	

gag ggg acc ccg cgc cag tct cgg gga act gtg ccc ccc 1902
 Glu Gly Thr Pro Arg Gln Ser Arg Gly Thr Val Pro Pro
 515 520

5 tcc agc cat gag aca ggc ttc atc cag tat ttg gat tca 1941
 Ser Ser His Glu Thr Gly Phe Ile Gln Tyr Leu Asp Ser
 525 530 535

gga atc tgg cac ttg gct ttt tac aat gac gga aag gag 1980
 Gly Ile Trp His Leu Ala Phe Tyr Asn Asp Gly Lys Glu
 540 545

10 tca gaa gtg gtt tcc ttt ctc acc act gcc att gcc ttg 2019
 Ser Glu Val Val Ser Phe Leu Thr Thr Ala Ile Ala Leu
 550 555 560

cct ccc cga ttg aaa gag atg aaa agc cag gaa tcg gct 2058
 Pro Pro Arg Leu Lys Glu Met Lys Ser Gln Glu Ser Ala
 15 565 570 575

gca ggt tcc aaa cta gtc ctt cgg tgt gaa acc agt tct 2097
 Ala Gly Ser Lys Leu Val Leu Arg Cys Glu Thr Ser Ser
 580 585

20 gaa tac tcc tct ctc aga ttc aag tgg ttc aag aat ggg 2136
 Glu Tyr Ser Ser Leu Arg Phe Lys Trp Phe Lys Asn Gly
 590 595 600

aat gaa ttg aat cga aaa aac aaa cca caa aat atc aag 2175
 Asn Glu Leu Asn Arg Lys Asn Lys Pro Gln Asn Ile Lys
 605 610

25 ata caa aaa aag cca ggg aag tca gaa ctt cgc att aac 2214
 Ile Gln Lys Lys Pro Gly Lys Ser Glu Leu Arg Ile Asn
 615 620 625

aaa gca tca ctg gct gat tct gga gag tat atg tgc aaa 2253
 Lys Ala Ser Leu Ala Asp Ser Gly Glu Tyr Met Cys Lys
 30 630 635 640

gtg atc agc aaa tta gga aat gac agt gcc tct gcc aat 2292
 Val Ile Ser Lys Leu Gly Asn Asp Ser Ala Ser Ala Asn
 645 650

atc acc atc gtg gaa tca aac gag atc atc act ggt atg 2331
 Ile Thr Ile Val Glu Ser Asn Glu Ile Ile Thr Gly Met
 35 655 660 665

cca gcc tca act gaa gga gca tat gtg tct tca gag tct 2370
 Pro Ala Ser Thr Glu Gly Ala Tyr Val Ser Ser Glu Ser
 670 675

40 ccc att aga ata tca gta tcc aca gaa gga gca aat act 2409
 Pro Ile Arg Ile Ser Val Ser Thr Glu Gly Ala Asn Thr
 680 685 690

tct tca tct aca tct aca tcc acc act ggg aca agc cat 2448
 Ser Ser Ser Thr Ser Thr Ser Thr Thr Gly Thr Ser His
 45 695 700 705

ctt gta aaa tgt gcg gag aag gag aaa act ttc tgt gtg 2487
 Leu Val Lys Cys Ala Glu Lys Glu Lys Thr Phe Cys Val
 710 715

aat gga ggg gag tgc ttc atg gtg aaa gac ctt tca aac 2526

```

Asn Gly Gly Glu Cys Phe Met Val Lys Asp Leu Ser Asn
 720                      725                      730

ccc tcg aga tac ttg tgc aag tgc cca aat gag ttt act 2565
Pro Ser Arg Tyr Leu Cys Lys Cys Pro Asn Glu Phe Thr
5                      735                      740

ggt gat cgc tgc caa aac tac gta atg gcc agc ttc tac 2604
Gly Asp Arg Cys Gln Asn Tyr Val Met Ala Ser Phe Tyr
745                      750                      755

agt acg tcc act ccc ttt ctg tct ctg cct gaa tag 2640
10 Ser Thr Ser Thr Pro Phe Leu Ser Leu Pro Glu
    760                      765                      768

gagcatgctc agttggtgct gctttcttgt tgctgcatct cccctcagat 2690
tccacctaga gctagatgtg tcttaccaga tctaattattg actgcctctg 2740
cctgtcgcat gagaacatta acaaaagcaa ttgtattact tcctctgttc 2790
15 gcgactagtt ggctctgaga tactaatagg tgtgtgaggc tccggatggt 2840
tctggaattg atattgaatg atgtgataca aattgatagt caatatcaag 2890
cagtgaataa tgataataaa ggcatttcaa agtctcactt ttattgataa 2940
aataaaaaatc attctactga acagtccatc ttctttatac aatgaccaca 2990
tcctgaaaag ggtgttgcta agctgtaacc gatatgcact tgaaatgatg 3040
20 gtaagttaat tttgattcag aatgtgttat ttgtcacaaa taaacataat 3090
aaaaggaaaa aaaaaaaaaa a 3111

<210> 13
<211> 1872
<212> DNA
25 <213> Homo sapiens

<400> 13
gaattcgga cagcctctcc tgccgccgct gctgctgccg ccgccgccac 50
cgccggctgg tcctccttct gcttttactt ctctgcatg acagttgttt 100
tcttcatctg agcagacacc agcttcagat gctcgagggtg agaaacatgc 150
30 ctttcagttt gggctactgg ttacttaat taatcagccg gcagctccgt 200
cgatctatct tcgtccctgt cctcttgacg agcccgggat ggtttgaggt 250
agcatttaaa agaactagaa aagtggccca gaaacagcag cttaaagaat 300
tattacgata tactttgatt ttgtagttgc taggagcttt tcttcccccc 350
ttgcatcttt ctgaactctt cttgatttta ataatggcct tggacttgga 400
35 cgatttatcg atttccccct gtaagatgct gtatcatttg gttggggggg 450
cctctgcgtg gtaatggacc gtgagagcgg ccaggccttc ttctggaggt 500

gagccg atg gag att tat tcc cca gac atg tct gag gtc 539
Met Glu Ile Tyr Ser Pro Asp Met Ser Glu Val
    1                      5                      10

```

gcc gcc gag agg tcc tcc agc ccc tcc act cag ctg agt 578
 Ala Ala Glu Arg Ser Ser Ser Pro Ser Thr Gln Leu Ser
 15 20

5 gca gac cca tct ctt gat ggg ctt ccg gca gca gaa gac 617
 Ala Asp Pro Ser Leu Asp Gly Leu Pro Ala Ala Glu Asp
 25 30 35

atg cca gag ccc cag act gaa gat ggg aga acc cct gga 656
 Met Pro Glu Pro Gln Thr Glu Asp Gly Arg Thr Pro Gly
 40 45 50

10 ctc gtg ggc ctg gcc gtg ccc tgc tgt gcg tgc cta gaa 695
 Leu Val Gly Leu Ala Val Pro Cys Cys Ala Cys Leu Glu
 55 60

15 gct gag cgc ctg aga ggt tgc ctc aac tca gag aaa atc 734
 Ala Glu Arg Leu Arg Gly Cys Leu Asn Ser Glu Lys Ile
 65 70 75

tgc att gtc ccc atc ctg gct tgc ctg gtc agc ctc tgc 773
 Cys Ile Val Pro Ile Leu Ala Cys Leu Val Ser Leu Cys
 80 85

20 ctc tgc atc gcc ggc ctc aag tgg gta ttt gtg gac aag 812
 Leu Cys Ile Ala Gly Leu Lys Trp Val Phe Val Asp Lys
 90 95 100

atc ttt gaa tat gac tct cct act cac ctt gac cct ggg 851
 Ile Phe Glu Tyr Asp Ser Pro Thr His Leu Asp Pro Gly
 105 110 115

25 ggg tta ggc cag gac cct att att tct ctg gac gca act 890
 Gly Leu Gly Gln Asp Pro Ile Ile Ser Leu Asp Ala Thr
 120 125

30 gct gcc tca gct gtg tgg gtg tgc tct gag gca tac act 929
 Ala Ala Ser Ala Val Trp Val Ser Ser Glu Ala Tyr Thr
 130 135 140

tca cct gtc tct agg gct caa tct gaa agt gag gtt caa 968
 Ser Pro Val Ser Arg Ala Gln Ser Glu Ser Glu Val Gln
 145 150

35 gtt aca gtg caa ggt gac aag gct gtt gtc tcc ttt gaa 1007
 Val Thr Val Gln Gly Asp Lys Ala Val Val Ser Phe Glu
 155 160 165

cca tca gcg gca ccg aca ccg aag aat cgt att ttt gcc 1046
 Pro Ser Ala Ala Pro Thr Pro Lys Asn Arg Ile Phe Ala
 170 175 180

40 ttt tct ttc ttg ccg tcc act gcg cca tcc ttc cct tca 1085
 Phe Ser Phe Leu Pro Ser Thr Ala Pro Ser Phe Pro Ser
 185 190

45 ccc acc cgg aac cct gag gtg aga acg ccc aag tca gca 1124
 Pro Thr Arg Asn Pro Glu Val Arg Thr Pro Lys Ser Ala
 195 200 205

act cag cca caa aca aca gaa act aat ctc caa act gct 1163
 Thr Gln Pro Gln Thr Thr Glu Thr Asn Leu Gln Thr Ala
 210 215

cct aaa ctt tct aca tct aca tcc acc act ggg aca agc 1202

Pro Lys Leu Ser Thr Ser Thr Ser Thr Thr Gly Thr Ser
 220 225 230

cat ctt gta aaa tgt gcg gag aag gag aaa act ttc tgt 1241
 His Leu Val Lys Cys Ala Glu Lys Glu Lys Thr Phe Cys
 5 235 240 245

gtg aat gga ggg gag tgc ttc atg gtg aaa gac ctt tca 1280
 Val Asn Gly Gly Glu Cys Phe Met Val Lys Asp Leu Ser
 250 255

aac ccc tcg aga tac ttg tgc aag tgc cca aat gag ttt 1319
 10 Asn Pro Ser Arg Tyr Leu Cys Lys Cys Pro Asn Glu Phe
 260 265 270

act ggt gat cgc tgc caa aac tac gta atg gcc agc ttc 1358
 Thr Gly Asp Arg Cys Gln Asn Tyr Val Met Ala Ser Phe
 275 280

tac agt acg tcc act ccc ttt ctg tct ctg cct gaa taggag 1400
 Tyr Ser Thr Ser Thr Pro Phe Leu Ser Leu Pro Glu
 15 285 290 295 296

catgctcagt tgggtgctgct ttcttgttgc tgcattctccc ctcagattcc 1450
 acctagagct agatgtgtct taccagatct aatattgact gcctctgcct 1500

gtcgcattgag aacattaaca aaagcaattg tattacttcc tctgttcgcg 1550
 actagttggc tctgagatac taataggtgt gtgaggctcc ggatgtttct 1600
 ggaattgata ttgaatgatg tgatacaaat tgatagtcaa tatcaagcag 1650
 tgaaatatga taataaaggc atttcaaagt ctacttttta ttgataaaat 1700
 aaaaatcatt ctactgaaca gtccatcttc tttatacaat gaccacatcc 1750

tgaaaagggt gttgctaagc tgtaaccgat atgcacttga aatgatggta 1800
 25 agttaatttt gattcagaat gtgttatttg tcacaaataa acataataaa 1850
 aggaaaaaaaa aaacccgaat tc 1872

<210> 14
 <211> 296
 30 <212> PRT
 <213> Homo sapiens

<400> 14
 Met Glu Ile Tyr Ser Pro Asp Met Ser Glu Val Ala Ala Glu Arg
 1 5 10 15

Ser Ser Ser Pro Ser Thr Gln Leu Ser Ala Asp Pro Ser Leu Asp
 35 20 25 30

Gly Leu Pro Ala Ala Glu Asp Met Pro Glu Pro Gln Thr Glu Asp
 35 40 45

Gly Arg Thr Pro Gly Leu Val Gly Leu Ala Val Pro Cys Cys Ala
 40 50 55 60

Cys Leu Glu Ala Glu Arg Leu Arg Gly Cys Leu Asn Ser Glu Lys
 65 70 75

Ile Cys Ile Val Pro Ile Leu Ala Cys Leu Val Ser Leu Cys Leu

	80	85	90
	Cys Ile Ala Gly Leu Lys Trp Val Phe	Val Asp Lys Ile Phe Glu	
	95	100	105
5	Tyr Asp Ser Pro Thr His Leu Asp Pro	Gly Gly Leu Gly Gln Asp	
	110	115	120
	Pro Ile Ile Ser Leu Asp Ala Thr Ala	Ala Ser Ala Val Trp Val	
	125	130	135
	Ser Ser Glu Ala Tyr Thr Ser Pro Val	Ser Arg Ala Gln Ser Glu	
	140	145	150
10	Ser Glu Val Gln Val Thr Val Gln Gly	Asp Lys Ala Val Val Ser	
	155	160	165
	Phe Glu Pro Ser Ala Ala Pro Thr Pro	Lys Asn Arg Ile Phe Ala	
	170	175	180
15	Phe Ser Phe Leu Pro Ser Thr Ala Pro	Ser Phe Pro Ser Pro Thr	
	185	190	195
	Arg Asn Pro Glu Val Arg Thr Pro Lys	Ser Ala Thr Gln Pro Gln	
	200	205	210
	Thr Thr Glu Thr Asn Leu Gln Thr Ala	Pro Lys Leu Ser Thr Ser	
	215	220	225
20	Thr Ser Thr Thr Gly Thr Ser His Leu	Val Lys Cys Ala Glu Lys	
	230	235	240
	Glu Lys Thr Phe Cys Val Asn Gly Gly	Glu Cys Phe Met Val Lys	
	245	250	255
25	Asp Leu Ser Asn Pro Ser Arg Tyr Leu	Cys Lys Cys Pro Asn Glu	
	260	265	270
	Phe Thr Gly Asp Arg Cys Gln Asn Tyr	Val Met Ala Ser Phe Tyr	
	275	280	285
	Ser Thr Ser Thr Pro Phe Leu Ser Leu	Pro Glu	
	290	295 296	

International Publication No
PCT/US 99/25744

IPC 7 A61K39/00 A61K39/395 A61K38/18 C07K14/475

B. FIELDS SEARCHED

IPC 7 A61K C07K

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>WO 92 20798 A (GENENTECH INC) 26 November 1992 (1992-11-26) cited in the application page 3, line 24 -page 5, line 33 page 8, line 19 -page 13, line 6 claims 1-27</p> <p style="text-align: center;">---</p>	1-18
Y	<p>DAVIS J G ET AL: "Use of the teleost sacculle to identify genes involved in inner ear function." DNA AND CELL BIOLOGY, (1995 OCT) 14 (10) 833-9. , XP000882867 abstract page 838, column 1, line 8-35</p> <p style="text-align: center;">---</p> <p style="text-align: center;">-/--</p>	1-18

☒ Patent family members are listed in annex.

'&' document member of the same patent family

14 April 2000

Muller-Thomalla, K

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 99/25744

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	ZHENG J L ET AL: "Induction of cell proliferation by fibroblast and insulin-like growth factors in pure rat inner ear epithelial cell cultures" JOURNAL OF NEUROSCIENCE,US,NEW YORK, NY, vol. 17, no. 1, 1 January 1997 (1997-01-01), page 216 XP002060020 ISSN: 0270-6474 abstract page 216, column 1, line 1 -page 217, column 1, paragraph 2 ----	1-18
Y	US 5 670 342 A (CARNAHAN JOSETTE FRANCOISE ET AL) 23 September 1997 (1997-09-23) figure 1 column 1, line 11 -column 2, line 44 claims 1-9 ----	1-18
Y	US 5 686 415 A (CARNAHAN JOSETTE FRANÇOISE ET AL) 11 November 1997 (1997-11-11) column 1, line 17 -column 3, line 31 column 8, line 18 -column 10, line 9; claims 1-5 ----	1-18
Y	DANILENKO, DIMITRY M. ET AL: "Neu differentiation factor upregulates epidermal migration and integrin expression in excisional wounds" J. CLIN. INVEST. (1995), 95(2), 842-51 , XP000882322 abstract page 842, column 2, line 1 -page 845, column 1, paragraph 2 page 846, column 2, paragraph 3 -page 850, column 2, line 4 ----	1-18
Y	ZHANG D ET AL: "Neuregulin-3 (NRG3): a novel neural tissue-enriched protein that binds and activates ErbB4." PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, (1997 SEP 2) 94 (18) 9562-7. , XP002910612 abstract column 1, line 1 -column 2, line 13 page 9565, column 1, paragraph 3 -page 9567, column 1, paragraph 1 ----	1-18
E	US 6 017 886 A (CARNAHAN JOSETTE F) 25 January 2000 (2000-01-25) the whole document -----	1-18

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 99/25744

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 1-18 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/US 99/25744

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9220798 A	26-11-1992	US 5367060 A	22-11-1994
		AU 659863 B	01-06-1995
		AU 2347492 A	30-12-1992
		EP 0586607 A	16-03-1994
		JP 6508031 T	14-09-1994
		NZ 242857 A	26-08-1993
		US 5834229 A	10-11-1998
		US 5859206 A	12-01-1999
		US 5856110 A	05-01-1999
		US 5641869 A	24-06-1997
		US 5840525 A	24-11-1994
US 5670342 A	23-09-1997	AU 5377196 A	23-10-1996
		CA 2216165 A	10-10-1996
		EP 0820507 A	28-01-1998
		JP 11503321 T	26-03-1999
		WO 9631599 A	10-10-1996
		US 5686415 A	11-11-1997
		US 5929032 A	27-07-1999
		US 5849705 A	15-12-1998
US 5686415 A	11-11-1997	US 5670342 A	23-09-1997
		AU 5377196 A	23-10-1996
		CA 2216165 A	10-10-1996
		EP 0820507 A	28-01-1998
		JP 11503321 T	26-03-1999
		WO 9631599 A	10-10-1996
		US 5929032 A	27-07-1999
US 6017886 A	25-01-2000	US 5849705 A	15-12-1998
		NONE	